Qiagen (QGEN) 20-F5 Mar 212020 FY Annual report (foreign)Financial data

Company Profile

Cover Page

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2020shares
Entity Addresses [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-38332
Entity Registrant Name	QIAGEN N.V.
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	Hulsterweg 82
Entity Address, Postal Zip Code	5912 PL
Entity Address, City or Town	Venlo
Entity Address, Country	NL
Title of 12(b) Security	Common Shares, par value EUR 0.01 per share
Trading Symbol	QGEN
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding	227,985,334
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Entity Central Index Key	0001015820
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Business Contact
Entity Addresses [Line Items]
Entity Address, Address Line One	Hulsterweg 82
Entity Address, Postal Zip Code	5912 PL
Entity Address, City or Town	Venlo
Entity Address, Country	NL
Contact Personnel Name	Roland Sackers
Contact Personnel Fax Number	011-31-77-355-6658

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 597,984	$ 623,647
Restricted cash	0	5,743
Short-term investments	117,249	129,586
Accounts receivable, net of allowance for credit losses of $27,052 in 2020 and allowance for doubtful accounts of $12,115 in 2019	380,519	385,117
Income taxes receivable	59,335	42,119
Inventories, net	291,181	170,704
Prepaid expenses and other current assets (of which $25,429 and $13,697 in 2020 and 2019 due from related parties, respectively)	206,921	105,464
Fair value of derivative instruments - current	14,127	107,868
Total current assets	1,667,316	1,570,248
Long-term assets:
Property, plant and equipment, net of accumulated depreciation of $630,443 and $699,130 in 2020 and 2019, respectively	559,372	455,243
Goodwill	2,364,031	2,140,503
Intangible assets, net of accumulated amortization of $809,724 and $776,520 in 2020 and 2019, respectively	726,194	632,434
Deferred income tax assets	54,879	56,542
Fair value of derivative instruments - long-term	379,080	192,266
Other long-term assets (of which $9,594 and $16,830 in 2020 and 2019 due from related parties, respectively)	161,658	188,380
Total long-term assets	4,245,214	3,665,368
Total assets	5,912,530	5,235,616
Current liabilities:
Current portion of long-term debt	42,539	285,244
Accounts payable	118,153	84,767
Fair value of derivative instruments - current	51,464	103,175
Accrued and other current liabilities (of which $1,380 and $15,404 due to related parties in 2020 and 2019, respectively)	345,665	444,303
Income taxes payable	57,265	33,856
Total current liabilities	615,086	951,345
Long-term liabilities:
Long-term debt, net of current portion	1,880,210	1,421,108
Deferred income tax liabilities	39,216	23,442
Fair value of derivative instruments - long-term	393,455	196,929
Other long-term liabilities	186,724	106,201
Total long-term liabilities	2,499,605	1,747,680
Commitments and contingencies
Equity:
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding	0	0
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding	0	0
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued—230,829 shares in 2020 and 2019, respectively	2,702	2,702
Additional paid-in capital	1,834,169	1,777,017
Retained earnings	1,323,091	1,178,457
Accumulated other comprehensive loss	(243,822)	(309,619)
Less treasury shares, at cost—2,844 and 3,077 shares in 2020 and 2019, respectively	(118,301)	(111,966)
Total equity	2,797,839	2,536,591
Total liabilities and equity	$ 5,912,530	$ 5,235,616

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Thousands	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Current assets:
Accounts receivable - allowance for doubtful accounts \| $	$ 27,052	$ 12,115
Prepaid expenses and other current assets - due from related parties \| $	25,429	13,697
Long-term assets:
Property, plant and equipment - accumulated depreciation \| $	630,443	699,130
Intangible assets - accumulated amortization \| $	809,724	776,520
Other long-term assets - due from related parties \| $	9,594	16,830
Current liabilities:
Accrued and other current liabilities - due to related parties \| $	$ 1,380	$ 15,404
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding
Preference shares - shares authorized (in shares)	450,000,000	450,000,000
Preference shares - shares issued (in shares)	0	0
Preference shares - shares outstanding (in shares)	0	0
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding
Financing preference shares - shares authorized (in shares)	40,000,000	40,000,000
Financing preference shares - shares issued (in shares)	0	0
Financing preference shares - shares outstanding (in shares)	0	0
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued—230,829 shares in 2020 and 2019, respectively
Common shares - shares authorized (in shares)	410,000,000	410,000,000
Common stock - shares issued (in shares)	230,829,000	230,829,000
Less treasury shares, at cost—2,844 and 3,077 shares in 2020 and 2019, respectively
Treasury shares (in shares)	(2,844,000)	(3,077,000)

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net sales	$ 1,870,346	$ 1,526,424	$ 1,501,848
Cost of sales:
Cost of sales	574,467	449,651	444,165
Acquisition-related intangible amortization	63,164	71,511	56,723
Total cost of sales	637,631	521,162	500,888
Gross profit	1,232,715	1,005,262	1,000,960
Operating expenses:
Research and development	149,072	157,448	161,852
Sales and marketing	413,684	391,906	392,281
General and administrative	111,678	112,262	104,568
Acquisition-related intangible amortization	20,811	29,973	39,032
Restructuring, acquisition, integration and other, net	150,005	199,778	28,659
Long-lived asset impairments	1,034	140,031	7,987
Total operating expenses	846,284	1,031,398	734,379
Income (loss) from operations	386,431	(26,136)	266,581
Other income (expense):
Interest income	10,032	22,113	20,851
Interest expense	(71,317)	(74,185)	(67,293)
Other income, net	114,326	432	5,598
Total other income (expense), net	53,041	(51,640)	(40,844)
Income (loss) before income tax (benefit) expense	439,472	(77,776)	225,737
Income tax expense (benefit)	80,284	(36,321)	35,357
Net income (loss)	$ 359,188	$ (41,455)	$ 190,380
Basic (loss) earnings per common share (in USD per share)	$ 1.57	$ (0.18)	$ 0.84
Diluted (loss) earnings per common share (in USD per share)	$ 1.53	$ (0.18)	$ 0.82
Weighted-average common shares outstanding
Basic (in shares)	228,427	226,777	226,640
Diluted (in shares)	234,214	226,777	233,456

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 359,188	$ (41,455)	$ 190,380
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:
(Losses) gains on cash flow hedges, net of tax benefit of $2.8 million in 2020, tax expense of $0 in 2019 and tax expense of $2.8 million in 2018	(8,536)	11,547	8,526
Reclassification adjustments on cash flow hedges, net of tax expense of $4.7 million in 2020, tax expense of $0 in 2019 and tax benefit of $2.4 million in 2018	13,999	(3,888)	(7,331)
Cash flow hedges, net of tax	5,463	7,659	1,195
Net investment hedge	(26,442)	5,505	13,839
Gain on pension, net of tax expense of $0 in 2020, tax expense of $0.4 million in 2019 and tax benefit of $0.6 million in 2018	(38)	(437)	754
Foreign currency translation adjustments, net of tax expense of $0.9 million in 2020, tax benefit of $0.5 million in 2019 and tax benefit of $1.4 million in 2018	86,814	(11,702)	(106,615)
Total other comprehensive income (loss)	65,797	1,025	(90,827)
Comprehensive income (loss)	$ 424,985	$ (40,430)	$ 99,553

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
(Losses) gains on cash flow hedges - tax expense (benefit)	$ (2.8)	$ 0	$ 2.8
Reclassification adjustments on cash flow hedges - tax expense (benefit)	4.7	0	(2.4)
Gain on pension - tax expense (benefit)	0	0.4	(0.6)
Foreign currency translation adjustments - tax expense (benefit)	$ 0.9	$ (0.5)	$ (1.4)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Impact of Change in Accounting Policy	Common Shares	Additional Paid-In Capital	Retained Earnings	Retained EarningsImpact of Change in Accounting Policy	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)Impact of Change in Accounting Policy	Treasury Shares
Balance (in shares) at Dec. 31, 2017			230,829,000						4,272,000
Balance at Dec. 31, 2017	$ 2,540,996		$ 2,702	$ 1,630,095	$ 1,247,945		$ (220,759)		$ (118,987)
Balance (ASU 2016-01) at Dec. 31, 2017		$ 0				$ (942)		$ 942
Balance (ASU 2016-16) at Dec. 31, 2017		(16,096)				(16,096)
Balance (ASC 606) at Dec. 31, 2017		(1,306)				(1,306)
Increase (Decrease) in Stockholders' Equity
Issuance of warrants	71,983			71,983
Net income (loss)	190,380				190,380
Unrealized gain (loss), net on pension	754						754
Unrealized gain (loss), net on hedging contracts	22,365						22,365
Realized gain (loss), net on hedging contracts	(7,331)						(7,331)
Foreign currency translation adjustments, net of tax expense of $0.9 million in 2020, tax benefit of $0.5 million in 2019 and tax benefit of $1.4 million in 2018	(106,615)						(106,615)
Purchase of treasury shares (in shares)									(2,871,000)
Purchase of treasury shares	(104,685)								$ (104,685)
Issuance of common shares in connection with stock plan (in shares)									1,823,000
Issuance of common shares in connection with stock plan	4,412				(40,357)				$ 44,769
Share-based compensation	40,113			40,113
Balance (in shares) at Dec. 31, 2018			230,829,000						5,320,000
Balance at Dec. 31, 2018	$ 2,634,970	(316)	$ 2,702	1,742,191	1,379,624	(316)	(310,644)		$ (178,903)
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member
Net income (loss)	$ (41,455)				(41,455)
Conversion of warrants (in shares)									2,056,000
Conversion of warrants	(4)			(31,067)	(37,698)				$ 68,761
Unrealized gain (loss), net on pension	(437)						(437)
Unrealized gain (loss), net on hedging contracts	17,052						17,052
Realized gain (loss), net on hedging contracts	(3,888)						(3,888)
Foreign currency translation adjustments, net of tax expense of $0.9 million in 2020, tax benefit of $0.5 million in 2019 and tax benefit of $1.4 million in 2018	(11,702)						(11,702)
Purchase of treasury shares (in shares)									(1,987,000)
Purchase of treasury shares	(74,450)								$ (74,450)
Issuance of common shares in connection with stock plan (in shares)									3,622,000
Issuance of common shares in connection with stock plan	2,075				(121,698)				$ 123,773
Tax withholding related to vesting of stock awards (in shares)									(1,448,000)
Tax withholding related to vesting of stock awards	(51,147)								$ (51,147)
Share-based compensation	$ 65,893			65,893
Balance (in shares) at Dec. 31, 2019	230,829,000		230,829,000						3,077,000
Balance at Dec. 31, 2019	$ 2,536,591	$ (15,074)	$ 2,702	1,777,017	1,178,457	$ (15,074)	(309,619)		$ (111,966)
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Net income (loss)	$ 359,188				359,188
Conversion of warrants (in shares)									807,000
Conversion of warrants	0			(7,547)	(22,725)				$ 30,272
Termination of warrants	(174,626)			(30,289)	(144,337)
Equity component of convertible debt, net	54,052			54,052
Unrealized gain (loss), net on pension	(38)						(38)
Unrealized gain (loss), net on hedging contracts	(34,978)						(34,978)
Realized gain (loss), net on hedging contracts	13,999						13,999
Foreign currency translation adjustments, net of tax expense of $0.9 million in 2020, tax benefit of $0.5 million in 2019 and tax benefit of $1.4 million in 2018	$ 86,814						86,814
Purchase of treasury shares (in shares)	(1,300,000)								(1,346,000)
Purchase of treasury shares	$ (63,995)								$ (63,995)
Issuance of common shares in connection with stock plan (in shares)									1,085,000
Issuance of common shares in connection with stock plan	7,661				(32,418)				$ 40,079
Tax withholding related to vesting of stock awards (in shares)									(313,000)
Tax withholding related to vesting of stock awards	(12,691)								$ (12,691)
Share-based compensation	$ 40,936			40,936
Balance (in shares) at Dec. 31, 2020	230,829,000		230,829,000						2,844,000
Balance at Dec. 31, 2020	$ 2,797,839		$ 2,702	$ 1,834,169	$ 1,323,091		$ (243,822)		$ (118,301)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ 359,188	$ (41,455)	$ 190,380
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:
Depreciation and amortization	205,014	231,458	206,436
Long-lived asset impairments	1,432	144,830	17,020
Amortization of debt discount and issuance costs	42,318	40,763	35,537
Share-based compensation expense	40,936	65,893	40,113
Deferred income tax benefit	(6,706)	(55,362)	(23,272)
(Gain) loss on marketable securities	(1,992)	2,867	(2,725)
Gain on sale of investment	(121,813)	0	0
Reversals of contingent consideration	0	(10,433)	0
Other items, net including fair value changes in derivatives	11,696	(3,394)	(8,834)
Net changes in operating assets and liabilities:
Accounts receivable	(14,711)	(39,578)	(41,813)
Inventories	(107,573)	(30,028)	(36,918)
Prepaid expenses and other current assets	1,061	18,626	(9,942)
Other long-term assets	316	(1,406)	(30,312)
Accounts payable	8,442	9,252	6,993
Accrued and other current liabilities	(22,141)	19,913	(13,317)
Income taxes	4,682	(6,782)	14,239
Other long-term liabilities	57,657	(14,321)	15,911
Net cash provided by operating activities	457,806	330,843	359,496
Cash flows from investing activities:
Purchases of property, plant and equipment	(132,787)	(117,950)	(109,773)
Purchases of intangible assets	(171,450)	(156,934)	(40,990)
Proceeds from (purchases of) investments, net	25,638
Proceeds from (purchases of) investments, net		(5,170)	(9,398)
Cash paid for acquisitions, net of cash acquired	(239,572)	(68,058)	(172,832)
Purchases of short-term investments	(49,770)	(293,959)	(568,002)
Proceeds from redemptions of short-term investments	181,223	396,098	691,765
Proceeds from divestiture	1,845	1,000	16,394
Cash (paid) received for collateral asset	(53,417)	22,685	(3,461)
Other investing activities	(4,991)	10	(15,059)
Net cash used in investing activities	(443,281)	(222,278)	(211,356)
Cash flows from financing activities:
Proceeds from short-term debt	59,345	0	0
Repayment of short-term debt	(58,705)	0	0
Proceeds from long-term debt, net of issuance costs	497,646	0	0
Repayment of long-term debt	(296,400)	(506,400)	0
Payment for termination of warrants	(174,627)	0	0
Payment of intrinsic value of cash convertible notes	(237,438)	(133,763)	0
Proceeds from exercise of call option related to cash convertible notes	239,836	134,737	0
Purchase of treasury shares	(63,995)	(74,450)	(104,685)
Proceeds from issuance of common shares	7,662	2,075	4,412
Tax withholding related to vesting of stock awards	(13,841)	(49,998)	0
Other financing activities	(9,610)	(11,281)	(8,019)
Proceeds from issuance of cash convertible notes, net of issuance costs	0	0	494,879
Purchase of call option related to cash convertible notes	0	0	(97,277)
Proceeds from issuance of warrants, net of issuance costs	0	0	72,406
Principal payments on capital leases	0	0
Principal payments on capital leases			(1,308)
Net cash (used in) provided by financing activities	(50,127)	(639,080)	360,408
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4,196	826	(7,183)
Net (decrease) increase in cash, cash equivalents and restricted cash	(31,406)	(529,689)	501,365
Cash, cash equivalents and restricted cash, beginning of period	629,390	1,159,079	657,714
Cash, cash equivalents and restricted cash, end of period	597,984	629,390	1,159,079
Supplemental cash flow disclosures:
Cash paid for interest	25,351	29,721	25,902
Cash paid for income taxes	$ 42,572	$ 41,474	$ 29,317

Corporate Information and Basis

Corporate Information and Basis of Presentation	12 Months Ended
Corporate Information and Basis of Presentation	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Corporate Information and Basis of Presentation	Corporate Information and Basis of Presentation Corporate Information QIAGEN N.V. is a public limited liability company ('naamloze vennootschap') under Dutch law with registered office at Hulsterweg 82, 5912 PL Venlo, The Netherlands. QIAGEN N.V., a Netherlands holding company, and subsidiaries (we, our or the Company) is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. We provide solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, we employed more than 5,600 people in over 35 locations worldwide. Announced Merger with Thermo Fisher Scientific Inc. On March 3, 2020, QIAGEN and Thermo Fisher Scientific Inc. (NYSE: TMO) announced that their boards of directors, as well as the Managing Board of QIAGEN N.V., unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39.00 per share in cash. On July 16, 2020, Thermo Fisher and QIAGEN entered into an amendment to the Business Combination Agreement dated as of March 3, 2020 whereby Quebec B.V., the wholly-owned subsidiary of Thermo Fisher making the public tender offer, increased the cash consideration offered per QIAGEN share from €39.00 to €43.00. The amendment also provided for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a $95.0 million expense reimbursement payable by QIAGEN to Thermo Fisher if the minimum acceptance threshold is not met. On August 13, 2020, QIAGEN announced that Thermo Fisher did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. For the year ended December 31, 2020, we incurred related expenses of $125.5 million, which includes the $95.0 million expense reimbursement which was paid when the minimum acceptance threshold was not met. These costs are recorded within restructuring, acquisition, integration and other expenses, net in the accompanying consolidated statement of income. Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and all amounts are presented in U.S. dollars rounded to the nearest thousand, unless otherwise indicated. The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments, contingent consideration and available-for-sale financial instruments that have been measured at fair value. We undertake acquisitions to complement our own internal product development activities. In September 2020, we completed the acquisition of the remaining shares in NeuMoDx Molecular, Inc ("NeuMoDx"), a privately-held U.S. company that designs and develops molecular diagnostics solutions for hospital and clinical reference laboratories. In 2019, we completed three immaterial acquisitions, including the January 2019 acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. In April 2018, we acquired all shares in STAT-Dx Life, S.L. ("STAT-Dx"), a privately-held company located in Barcelona, Spain and also completed the acquisition of the remaining shares of a privately held entity in which we held a minority interest. Accordingly, at their respective acquisition dates, all the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include the operating results from the acquired companies from the acquisition date. Certain prior year amounts have been reclassified to conform to the current year presentation.

Effects of New Accounting Prono

Effects of New Accounting Pronouncements	12 Months Ended
Effects of New Accounting Pronouncements	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Effects of New Accounting Pronouncements	Effects of New Accounting Pronouncements The following new Financial Accounting Standards Board (FASB) Accounting Standards Updates (ASU) were adopted in 2020, 2019 and 2018: Adoption of New Accounting Standards in 2020 ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in ASU 2016-13 replace the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The measurement of expected credit losses under Topic 326 is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. In addition, Topic 326 made changes to the accounting for available-for-sale debt securities. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell or believes is more likely than not they will be required to sell. We adopted Topic 326 on January 1, 2020 using the modified retrospective approach by recognizing the effect of initially applying Topic 326 as an after-tax $15.1 million ($19.6 million pre-tax) adjustment to the opening balance of retained earnings at January 1, 2020 for credit losses on loans, notes and accounts receivable. The adoption did not have an impact on our consolidated statements of income or cash flows. ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer of that transaction. The guidance amends ASC 808 to refer to unit-of-account guidance in ASC 606 and requires it to be used only when assessing whether a transaction is in the scope of ASC 606. ASU 2018-18 is effective for us for annual periods beginning on January 1, 2020. Entities are required to apply the amendments retrospectively to the date they initially applied ASC 606. We adopted ASU 2018-18 on January 1, 2020 without any cumulative effect. ASU 2020-03, Codification Improvements to Financial Instruments, was issued to improve and clarify various financial instrument topics, including Topic 326 issued in 2016. The ASU includes seven issues that describe areas of improvement and the related amendments to GAAP. They are intended to make the standards easier to understand and apply and to eliminate inconsistencies. They are narrow in scope and are not expected to significantly change practice for most entities. The amendments have different effective dates with early adoption permitted. We adopted ASU 2020-03 on January 1, 2020 without any effect. ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 , addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. The ASU is effective on January 1, 2021. Early adoption is permitted, including early adoption in an interim period. We adopted ASU 2020-01 on June 30, 2020 without any impact. Adoption of New Accounting Standards in 2019 The FASB issued guidance codified in Accounting Standards Codification (ASC) Topic 842, Leases (Topic 842), which supersedes the lease requirements in ASC Topic 840 and aims to increase transparency and comparability among organizations and requires disclosure of key information about leasing arrangements. The main principle of ASC 842 requires lessees to recognize the assets and liabilities that arise from nearly all leases on the consolidated balance sheet. Lessor accounting remains mainly consistent with the former guidance, with the majority of changes allowing for better alignment with the new lessee model and ASC Topic 606. We adopted these standards as per the effective date of January 1, 2019, using the modified retrospective approach and did not restate comparative periods. Under this approach, the cumulative effect of initially applying the standard was recognized as an adjustment to the opening balance of retained earnings on the date of initial application. As a lessee, the classification of our leases did not change, but we recognized a lease liability and corresponding right-of-use asset on our consolidated balance sheets for all our operating leases. We have elected the package of practical expedients which allows us to not reassess (1) whether existing contracts contain leases, (2) the lease classification for existing leases, and (3) whether existing initial direct costs meet the new definition. We also elected the hindsight practical expedient which permits entities to use hindsight in determining the lease term when transitioning to ASC 842. Our initial lease liabilities and right-of-use assets totaled $57.7 million and $57.4 million, respectively, as recorded in our consolidated balance sheet as of January 1, 2019, primarily relating to leased office space. The difference between the additional lease assets and lease liabilities was recorded as a $0.3 million adjustment to retained earnings. Further disclosure is found in Note 12 "Leases". ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new guidance became effective for public entities beginning on January 1, 2019 by applying a modified retrospective approach to existing hedging relationships as of the adoption date. Under the modified retrospective approach, entities with cash flow or net investment hedges will make (1) a cumulative-effect adjustment to accumulated other comprehensive income so that the adjusted amount represents the cumulative change in the hedging instruments’ fair value since hedge inception (less any amounts that should have been recognized in earnings under the new accounting model) and (2) a corresponding adjustment to opening retained earnings as of the most recent period presented on the date of adoption. We adopted ASU 2017-12 on January 1, 2019 without any cumulative effect. ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , removes Step 2 of the goodwill impairment test. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for public entities for annual periods beginning January 1, 2020 and early adoption is permitted. The new guidance is required to be applied on a prospective basis. We adopted ASU 2017-04 on January 1, 2019 and applied the new guidance prospectively as required. ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework, provides guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements . ASU 2018-13 is effective for public entities for annual periods beginning January 1, 2020. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We adopted ASU 2018-13 on January 1, 2019 and applied the entire standard to disclosures as required beginning in 2019. ASU 2018-15, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, provides guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor, i.e. a service contract. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for public entities for annual periods beginning January 1, 2020, and early adoption is permitted and should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted ASU 2018-15 on January 1, 2019 and applied the guidance to all implementation costs prospectively. ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities, amends how a decision maker or service provider determines whether its fee is a variable interest entity (VIE) when a related party under common control also has an interest in the VIE. We adopted ASU 2018-17 on January 1, 2019, on a prospective basis. Adoption of New Accounting Standards in 2018 ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and additional related accounting standard updates to clarify and provide implementation guidance were adopted with a date of initial application of January 1, 2018. The comparative information for 2017 has not been adjusted and continues to be reported under ASC Topic 605 Revenue Recognition. As a result, we changed our accounting policy for revenue recognition. We applied the Topic 606 using the "modified retrospective method" by recognizing the effect of initially applying Topic 606 as an $1.3 million decrease to the opening balance of retained earnings at January 1, 2018, for all contracts not completed at January 1, 2018. ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities as well as an additional clarifying accounting standard update became effective for our financial statements beginning in the first quarter of 2018. This ASU makes targeted improvements to existing U.S. GAAP for both the recognition and measurement of financial assets and financial liabilities. Changes in accounting to our equity investments as a result of this standard are further discussed in Notes below. As required, we adopted using a cumulative-effect adjustment to the balance sheet as of the beginning of 2018 and recorded an adjustment to decrease opening retained earnings at January 1, 2018 by $0.9 million (pre-tax $1.1 million) as required for our equity investments recorded at fair value. ASU 2016-05, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments and ASU 2016-18, Statement of Cash Flows (Topic 320): Restricted Cash, addresses classification issues and presentation related to the statement of cash flows and was adopted on January 1, 2018 without any impact from the adoption. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, aims to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. This standard was adopted on a modified retrospective basis resulting in a decrease to opening retained earnings of $16.1 million at January 1, 2018. ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , clarifies and provides a more robust framework to use in determining when a set of assets and activities is a business. We adopted this update beginning January 1, 2018, without impact. ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , clarifies when to account for a change to the terms and conditions of a share-based payment award as a modification. This guidance is effective prospectively and was adopted as of January 1, 2018. ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, permits reclassification of stranded tax effects of the U.S. Tax Cuts and Jobs Act (Tax Act). We adopted this standard as of April 1, 2018 with no impact as we had no stranded tax effects. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, we reclassify the tax effects to the consolidated statement of income (loss) on an item-by-item basis when the pre-tax item in accumulated other comprehensive income (loss) is reclassified to income. ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , aligns most of the accounting for share-based payment awards issued to employees and non-employees. We early adopted this standard as of July 1, 2018, without material impact. New Accounting Standards Not Yet Adopted The following new FASB Accounting Standards Updates, which are not yet adopted as of December 31, 2020, have been grouped by their required effective dates or early adoption date: First Quarter of 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod tax allocations and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating income taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods beginning on January 1, 2021, with earlier adoption permitted. We adopted the ASU on the effective date of January 1, 2021 and the adoption of this guidance did not have an impact on our consolidated financial statements on the date of adoption. Ultimately, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , reduces the number of accounting models for convertible instruments. The ASU also amends diluted earnings per share (EPS) calculations for convertible instruments, which will result in more dilutive EPS results. The ASU also amends the requirements for a contract (or embedded derivative) that is potentially settled in an entity’s own shares to be classified in equity. ASU 2020-06 is effective for annual periods beginning on January 1, 2022, with earlier adoption on January 1, 2021 permitted. We early adopted ASU 2020-06 on January 1, 2021 and as a result reclassified $54.1 million from equity for the conversion feature to the liability for our 2027 Convertible Notes further discussed in Note 16 "Debt". Through December 31, 2022 ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and ASU 2021-01 Reference Rate Reform (Topic 848): Scope, provide companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. Companies can apply the ASU immediately. However, the guidance will only be available for a limited time, generally through December 31, 2022. We continue to evaluate the guidance.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of QIAGEN N.V. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Investments in either common stock or in-substance common stock of companies where we exercise significant influence over the operations but do not have control, and where we are not the primary beneficiary, are accounted for using the equity method. All other investments are accounted for as discussed under "Non-marketable Investments" below. When there is a portion of equity in an acquired subsidiary not attributable, directly or indirectly, to the Company, we record the fair value of the noncontrolling interests at the acquisition date and classify the amounts attributable to noncontrolling interests separately in equity in the consolidated financial statements. Any subsequent changes in the Company's ownership interest while the Company retains its controlling financial interest in its subsidiary are accounted for as equity transactions. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentrations of Risk We buy materials for products from many suppliers, and are not dependent on any one supplier or group of suppliers for the business as a whole. However, key components of certain products, including certain instrumentation components and chemicals, are available only from a single source. If supplies from these vendors were delayed or interrupted for any reason, we may not be able to obtain these materials timely or in sufficient quantities in order to produce certain products and sales levels could be negatively affected. Additionally, our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories. Fluctuations in the research and development budgets of these researchers and their organizations for applications in which our products are used could have a significant effect on the demand for our products. The financial instruments used in managing our foreign currency, equity and interest rate exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated international financial institutions. The carrying values of our financial instruments incorporate the non-performance risk by using market pricing for credit risk. However, we have no reason to believe that any counterparties will default on their obligations. In order to minimize our exposure with any single counterparty, we have entered into master agreements which allow us to manage the exposure with the respective counterparty on a net basis. Other financial instruments that potentially subject us to concentrations of credit risk are cash and cash equivalents, short-term investments, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and short-term investments by dealing with highly-rated financial institutions and investing in a broad and diverse range of financial instruments. We have established guidelines related to credit quality and maturities of investments intended to maintain safety and liquidity. Concentration of credit risk with respect to accounts receivable is limited due to a large and diverse customer base, which is dispersed over different geographic areas. Allowances are maintained for potential credit losses and such losses have historically been within expected ranges. Foreign Currency Translation Our reporting currency is the U.S. dollar and the functional currencies of our subsidiaries are generally the local currency of the respective countries in which they are headquartered. All amounts in the financial statements of entities whose functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows: (1) assets and liabilities at period-end rates, (2) income statement accounts at average exchange rates for the period, and (3) components of equity at historical rates. Translation gains or losses are recorded in equity, and transaction gains and losses are reflected in net income (loss) as a component of other income, net. Realized gains or losses on the value of derivative contracts entered into to hedge the exchange rate exposure of receivables and payables are also included in net income (loss) as a component of other income, net. The net loss on foreign currency transactions was $4.1 million, $5.7 million, and $12.3 million in 2020, 2019 and 2018, respectively, and is included in other income, net. The exchange rates of key currencies were as follows: Closing rate at December 31, Annual average rate (US$ equivalent for one) 2020 2019 2020 2019 2018 Euro (EUR) 1.2271 1.1234 1.1411 1.1196 1.1813 Pound Sterling (GBP) 1.3649 1.3204 1.2836 1.2768 1.3356 Swiss Franc (CHF) 1.1360 1.0350 1.0659 1.0062 1.0228 Australian Dollar (AUD) 0.7720 0.7023 0.6905 0.6954 0.7478 Canadian Dollar (CAD) 0.7849 0.7696 0.7463 0.7535 0.7719 Japanese Yen (JPY) 0.0097 0.0092 0.0094 0.0092 0.0091 Chinese Yuan (CNY) 0.1530 0.1437 0.1450 0.1448 0.1514 Segment Information We determined that we operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting . Our chief operating decision maker (CODM) makes decisions based on the Company as a whole. In addition, we have a common basis of organization and types of products and services which derive revenues and consistent product margins. Accordingly, we operate and make decisions as one reporting unit. Revenue Recognition We recognize revenue when control of promised goods or services transfers to our customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The majority of our sales revenue is recognized when products are shipped to the customers at which point control transfers. Warranty We provide warranties on our products against defects in materials and workmanship for a period of one year. A provision for estimated future warranty costs is recorded in cost of sales at the time product revenue is recognized. Product warranty obligations are included in accrued and other current liabilities in the accompanying consolidated balance sheets. Research and Development Research and product development costs are expensed as incurred. Research and development expenses consist primarily of salaries and related expenses, facility costs, and amounts paid to contract research organizations and laboratories for the provision of services and materials as well as costs for internal use or clinical trials. Government Grants We recognize government grants when there is reasonable assurance that all conditions will be complied with and the grant will be received. Our government grants generally represent subsidies for specified activities and are therefore recognized when earned as a reduction of the expenses recorded for the activity that the grants are intended to compensate. Thus, when the grant relates to research and development expense, the grant is recognized over the same period that the related costs are incurred. Otherwise, amounts received under government grants are recorded as liabilities in the balance sheet. When the grant relates to an asset, the nominal amount of the grant is deducted from the carrying amount of the asset and recognized over the same period that the related asset is depreciated. Borrowing Costs Borrowing costs directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets (qualifying asset) when such borrowing costs are significant. All other borrowing costs are expensed in the period they occur. Shipping and Handling Income and Costs Shipping and handling costs charged to customers are recorded as revenue in the period that the related product sale revenue is recorded. Associated costs of shipping and handling are included in sales and marketing expenses. For the years ended December 31, 2020, 2019 and 2018, shipping and handling costs totaled $32.1 million, $27.9 million and $28.4 million, respectively. Advertising Costs The costs of advertising are expensed as incurred and are included as a component of sales and marketing expense. Advertising costs for the years ended December 31, 2020, 2019 and 2018 were $9.5 million, $8.1 million and $8.1 million, respectively. General and Administrative General and administrative expenses primarily represent the costs required to support administrative infrastructure. These costs include licensing costs in connection with continued investments in information technology improvements, including cyber security, across the organization as well as personnel in administrative functions. Restructuring, Acquisition, Integration and Other We incur indirect acquisition and business integration costs in connection with business combinations which are expensed when incurred. These costs represent incremental costs that we believe would not have been incurred absent the business combinations. Major components of these costs include consulting and related fees incurred to integrate or restructure the acquired operations, payroll and related costs for employees remaining with the Company on a transitional basis and public relations, advertising and media costs for re-branding of the combined organization. Restructuring costs include personnel costs (principally termination benefits) as well as contract and other costs, primarily contract termination costs. Termination benefits are accounted for in accordance with FASB ASC Topic 712, Compensation - Nonretirement Postemployment Benefits, and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits, the similarity of benefits under the current plan and prior plans, and the existence of statutory required minimum benefits. Contract and other costs are accounted for in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations and are recorded when the liability is incurred. The specific restructuring measures and associated estimated costs are based on management's best business judgment under the existing circumstances at the time the estimates are made. If future events require changes to these estimates, such adjustments will be reflected in the period of the revised estimate. Income Taxes We account for income taxes under the liability method. Under this method, total income tax expense is the amount of income taxes expected to be payable for the current year plus the change from the beginning of the year for deferred income tax assets and liabilities established for the expected future tax consequences resulting from differences in the financial statement carrying amount and the tax basis of assets and liabilities. Deferred tax assets and/or liabilities are determined by multiplying the differences between the financial statement carrying amount and the tax reporting bases for assets and liabilities by the enacted tax rates expected to be in effect when such differences are recovered or settled. Deferred tax assets are reduced by a valuation allowance to the amount more likely than not to be realized. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Tax benefits are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement with the taxing authority using the cumulative probability method, assuming the tax authority has full knowledge of the position and all relevant facts. Our policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties within the income tax expense. Derivative Instruments We enter into derivative financial instrument contracts to minimize the variability of cash flows or income statement impact associated with the anticipated transactions being hedged or to hedge fluctuating interest rates. As changes in foreign currency or interest rate impact the value of anticipated transactions, the fair value of the forward or swap contracts also changes, offsetting foreign currency or interest rate fluctuations. Derivative instruments are recorded on the balance sheet at fair value. Changes in fair value of derivatives are recorded in current earnings or other comprehensive income, depending on whether a derivative is designated as part of a hedge transaction. Share-Based Payments Compensation cost for all share-based payments is recorded based on the grant date fair value, less an estimate for pre-vesting forfeitures, recognized in expense over the service period using an accelerated method. Forfeiture Rate— This is the estimated percentage of grants that are expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimated the forfeiture rate based on historical forfeiture experience. Restricted Stock Units and Performance Stock Units: Restricted stock units and performance stock units represent rights to receive Common Shares at a future date. The fair market value of restricted and performance stock units is determined based on the number of stock units granted and the fair market value of our shares on the grant date. The fair market value at the time of the grant, less an estimate for pre-vesting forfeitures, is recognized in expense over the vesting period. At each reporting period, the estimated performance achievement of the performance stock units is assessed and any change in the estimated achievement is recorded on a cumulative basis in the period of adjustment. Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit in banks and other cash invested temporarily in various instruments that are short-term and highly liquid, and having an original maturity of less than 90 days at the date of purchase. Cash and cash equivalents as of December 31, 2020 and 2019 consist of the following: (in thousands) 2020 2019 Cash at bank and on hand $ 245,373 $ 189,569 Short-term bank deposits 352,611 434,078 Cash and cash equivalents $ 597,984 $ 623,647 Restricted Cash Restricted cash includes cash that is subject to legal restriction in connection with a tender offer and not available for general operating purposes. As of December 31, 2019, we had $5.7 million of restricted cash. Short-Term Investments Short-term investments consisting of marketable equity securities are reported at fair value with gains and losses recorded in earnings. Short-term investments consisting of cash investments are classified as “available for sale” and stated at fair value, which is equivalent to the amortized cost, in the accompanying consolidated balance sheet. Interest income is accrued when earned and changes in fair market values are reflected in other income, net. The amortization of premiums and accretion of discounts to maturity arising from acquisition is included in interest income. A decline in fair value that is judged to be other-than-temporary is accounted for as a realized loss and the write-down is included in the consolidated statements of income. Realized gains and losses, determined on a specific identification basis on the sale of short-term investments, are included in income. Fair Value of Financial Instruments The carrying amount of cash and cash equivalents, notes receivable, accounts receivable, accounts payable and accrued liabilities approximate their fair values because of the short maturities of those instruments. The carrying value of our variable rate debt and leases approximates their fair values because of the short maturities and/or interest rates which are comparable to those available to us on similar terms. The fair values of the zero coupon convertible debt and the Cash Convertible Notes are based on an estimation using available over-the-counter market information. The fair values of the Private Placement Senior Notes were estimated using the changes in the U.S. Treasury rates and the fair value of the German Private Placement is based on an estimation using changes in the euro swap rates. Accounts Receivable and Allowance for Credit Losses Our accounts receivable consist of unsecured customer obligations and we are at risk to the extent such amounts become uncollectible. Accounts receivable are carried at face value less an allowance for doubtful accounts as of December 31, 2019, and following the adoption of ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, less an allowance for expected credit losses. We continually monitor accounts receivable balances, and until December 31, 2019, provided for an allowance for doubtful accounts at the time collection became questionable based on payment history or age of the receivable. Since January 1, 2020, we maintain allowances for credit losses resulting from the expected failure or inability of our customers to make required payments. We recognize the allowance for expected credit losses at inception and reassess regularly considering historical experience with bad debts, the aging of the receivables, credit quality of the customer base, current economic conditions and other reasonable and supportable expectations for future conditions, if applicable. Once a receivable is determined to be uncollectible, the balance is charged against the allowance. We sell our products worldwide through sales subsidiaries and distributors. There is no concentration of credit risk with respect to trade accounts receivable as we have a large number of internationally dispersed customers. Trade accounts receivable are non-interest bearing and mostly have payment terms of 30-90 days. For all years presented, no single customer represented more than ten percent of accounts receivable or consolidated net sales. The changes in the allowance for credit losses on accounts receivable for the year ended December 31, 2020 and in the allowance for doubtful accounts for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2020 2019 2018 Balance at beginning of year $ 12,115 $ 9,270 $ 8,008 ASC 326 adoption impact 8,089 — — Additions charged to expense 16,439 8,701 4,448 Deductions from allowance (9,868) (5,777) (2,827) Currency translation adjustments and other 277 (79) (359) Balance at end of year $ 27,052 $ 12,115 $ 9,270 For the year ended December 31, 2020, additions charged to expense of $16.4 million include the forward-looking expected impact of the global economic uncertainty caused by COVID-19. Loans and Other Receivables and Allowance for Credit Losses Prepaid expenses and other current assets include other short-term receivables and other long-term assets include long-term loan receivables. Following the adoption of Topic 326, we are required to use the new forward-looking expected credit loss model that replaced the previous incurred credit loss model. The new model generally results in earlier recognition of allowances for credit losses and requires consideration of a broader range of information to estimate expected credit losses over the entire lifetime of the assets. Accordingly, with the adoption of Topic 326, we recorded allowances for credit losses of $10.2 million for other receivables and $1.3 million for loan receivables. As of December 31, 2020, allowances for credit losses of $7.9 million for other receivables are included in prepaid expenses and other current assets and $1.2 million for loan receivables are included in other long-term assets in the accompanying consolidated balance sheet. The allowances reflect the forward-looking expected impact of non-payment of the contractual amounts due. Inventories Inventories are stated at the lower of cost or net realizable value, determined on either a weighted average cost basis or a standard cost basis which is regularly adjusted to actual. Inventories include material, direct labor and overhead costs and are reduced for estimated obsolescence. Inventories consisted of the following as of December 31, 2020 and 2019: (in thousands) 2020 2019 Raw materials $ 65,449 $ 26,077 Work in process 74,398 45,729 Finished goods 151,334 98,898 Total inventories, net $ 291,181 $ 170,704 Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated amortization. Capitalized internal-use software costs include only those direct costs associated with the actual development or acquisition of computer software solely to meet internal needs and cloud-based applications to deliver our service and comprise costs associated with the design, coding, installation and testing of the system. Costs associated with preliminary development, such as the evaluation and selection of alternatives, as well as training, maintenance and support are expensed as incurred. Costs for software to be sold, leased or otherwise marketed that are related to the conceptual formulation and design are expensed as incurred. Costs incurred to produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established are capitalized and amortized in accordance with the accounting standards for the costs of software to be sold, leased, or otherwise marketed. All other depreciation is computed using the straight-line method over the estimated useful lives of the assets (3 to 40 years). Amortization of leasehold improvements is computed on a straight-line basis over the lesser of the remaining life of the lease or the estimated useful life of the improvement asset. We have a policy of capitalizing expenditures that materially increase assets’ useful lives and charging ordinary maintenance and repairs to operations as incurred. When property or equipment is disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in earnings. Business Combinations We include the results of operations of the businesses that we acquire as of the acquisition date. The purchase price of an acquired business is allocated to the individual assets acquired and liabilities assumed based on their fair values at the date of acquisition. Those fair values are determined using income, cost and market approaches, most of which depend upon significant inputs that are not observable in the market, or level 3 measurements. The excess of purchase price over the fair value of identifiable assets acquired and liabilities assumed is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. The purchase price for some business combinations includes consideration that is contingent on the achievement of net sales or earnings targets by the acquired business. Contingent consideration is measured initially and on a recurring basis at fair value. Payments to settle the acquisition-date fair value of contingent consideration are presented as financing activities on the statement of cash flows; any payments in excess of the acquisition-date fair value are presented as operating activities. Acquired Intangibles and Goodwill Acquired intangibles with alternative future uses are carried at cost less accumulated amortization and consist of licenses to technology held by third parties and other acquired intangible assets. Amortization is computed over the estimated useful life of the underlying patents, which has historically ranged from 1 to 20 years. Purchased intangible assets acquired in business combinations, other than goodwill, are amortized over their estimated useful lives unless these lives are determined to be indefinite. Intangibles are assessed for recoverability considering the contract life and the period of time over which the intangible will contribute to future cash flow. The unamortized cost of intangible assets, where cash flows are independent and identifiable from other assets, is evaluated periodically and adjusted, if necessary, if events and circumstances indicate that a decline in value below the carrying amount has occurred. Intangible asset impairments recorded during the year ended December 31, 2020, 2019 and 2018 are further discussed in Note 6 "Restructuring and Impairments". Amortization expense related to developed technology and patent and license rights which have been acquired in a business combination is included in cost of sales. Amortization of trademarks, customer base and non-compete agreements which have been acquired in a business combination is recorded in operating expense under the caption 'acquisition-related intangible amortization'. Amortization expenses of intangible assets not acquired in a business combination are recorded within either the cost of sales, research and development or sales and marketing line items based on the use of the asset. We dispose the gross carrying amount and accumulated amortization of fully amortized intangible assets from historic business combinations once they are considered fully integrated into our business. The fair value of in-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when any event or circumstance indicates that the fair value may be below the carrying value. If and when research and development is complete, the associated asset is amortized over the estimated useful life. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired arising from business combinations. Goodwill is subject to impairment tests annually or earlier if indicators of potential impairment exist, using a fair-value-based approach. We have elected to perform our annual test for indications of impairment as of October 1 st of each year. Following the annual impairment tests for the years ended December 31, 2020, 2019 and 2018, goodwill has not been impaired. Non-Marketable Investments We have investments in non-marketable equity securities issued by privately held companies. These investments are included in other long-term assets in the accompanying consolidated balance sheets. Non-marketable investments through which we exercise significant influence but do not have control are accounted for using the equity method. We monitor for changes in circumstances that may require a reassessment of the level of influence. Following the adoption of ASU 2016-01 on January 1, 2018, our non-marketable equity securities not accounted for under the equity method are either carried at fair value or under the measurement alternative. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Investments are evaluated periodically, or when impairment indicators are noted, to determine if declines in value are other-than-temporary. In making that determination, we consider all available evidence relating to the realizable value of a security. This evidence includes, but is not limited to, the following: • adverse financial conditions of a specific issuer, segment, industry, region or other variables; • the length of time and the extent to which the fair value has been less than cost; and • the financial condition and near-term prospects of the issuer. We consider whether the fair values of any of our non-marketable investments have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If any such decline is considered to be other than temporary (based on various factors, including historical financial results, product development activities and the overall health of the affiliate’s industry), then a write-down of the investment would be recorded in operating expense to its estimated fair value. Investment impairments recorded during the year ended December 31, 2020 are discussed in Note 10 "Investments." Variable Interest Entities We evaluate at the inception of each arrangement whether we have made an investment in an entity that is considered a variable interest entity (VIE) or if we hold other variable interests in an arrangement that is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE as an investment in a non-marketable investment or in accordance with other applicable GAAP. Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. We consider, amongst other indicators, a history of operating losses or a change in expected sales levels to be indicators of potential impairment. Assets are grouped and evaluated for impairment at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying amount of the asset exceeds fair value which is determined by applicable market prices, when available. When market prices are not available, we generally measure fair value by discounting projected future cash flows of the asset. Considerable judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could differ from such estimates.

Revenue

Revenue	12 Months Ended
Revenue	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Nature of Goods and Services Our revenues are reported net of sales and value added taxes and accruals for estimated rebates and returns and are derived primarily from the sale of consumable and instrumentation products, and to a much lesser extent, from the sale of services, intellectual property and technology. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to performance obligations based on their relative stand-alone selling prices. We offer warranties on our products. Certain of our warranties are assurance-type in nature and do not cover anything beyond ensuring that the product is functioning as intended. Based on the guidance in Topic 606, assurance-type warranties do not represent separate performance obligations. The Company also sells separately-priced service contracts which qualify as service-type warranties and represent separate performance obligations. We sell our products and services both directly to customers and through distributors generally under agreements with payment terms typically less than 90 days and in most cases not exceeding one year and therefore contracts do not contain a significant financing component. Consumable and Related Revenue Consumable Products: In the last three years, revenue from consumable product sales has accounted for approximately 78-80% of our net sales and revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of our contracts have a single performance obligation to transfer a product or multiple performance obligations to transfer multiple products concurrently. Accordingly, we recognize revenue when control of the products has transferred to the customer, which is generally at the time of shipment of products as this is when title and risk of loss have been transferred. In addition, invoicing typically occurs at this time so this is when we have a present right to payment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products and is generally based upon a negotiated formula, list or fixed price. Related Revenue: Revenues from related products include software-as-a-service (SaaS), licenses, intellectual property and patent sales, royalties and milestone payments and over the last three years has accounted for approximately 6-10% of our net sales. SaaS arrangements: Revenue from SaaS arrangements, which allow customers to use hosted software over the contract period without taking possession of the software, is recognized over the duration of the agreement unless the terms of the agreement indicate that revenue should be recognized in a different pattern, for example based on usage. Licenses : Licenses for on-site software, which allow customers to use the software as it exists when made available, are sold as perpetual licenses or term licenses. Revenue from on-site licenses are recognized upfront at the point in time at the later of when the software is made available to the customer and the beginning of the license term. When a portion of the transaction price is allocated to a performance obligation to provide support and/or updates, revenue is recognized as the updates/support are provided, generally over the life of the license. Fees from research collaborations include payments for technology transfer and access rights. Royalties from licensees of intellectual property are based on sales of licensed products and revenues are recognized at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Milestone Payments: At the inception of each companion diagnostic co-development arrangement that includes development milestone payments, which represent variable consideration, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control, such as milestones which are achieved through regulatory approvals, are considered to be constrained and excluded from the transaction price until those approvals are received. Revenue is recognized following the input method as this is considered to best depict the timing of the transfer of control. This involves measuring actual hours incurred to date as a proportion of the total budgeted hours of the project. At the end of each subsequent reporting period, the proportion of completion is trued-up. We also re-evaluate the probability of achievement of development milestones and any related constraint on a periodic basis, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Instruments Revenue from instrumentation includes the instrumentation equipment, installation, training and other instrumentation services, such as extended warranty services or product maintenance contracts and over the last three years has accounted for approximately 11-14% of net sales. Revenue from instrumentation equipment is recognized when the customer obtains control of the instrument which is predominantly at the time of delivery or when title has transferred to the customer. Service revenue is recognized over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. Contract Estimates The majority of our revenue is derived from contracts (i) with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount in which we have the right to invoice as product is delivered. We have elected the practical expedient not to disclose the value of remaining performance obligations associated with these types of contracts. However, we have certain companion diagnostic co-development contracts to provide research and development activities in which our performance obligations extend over multiple years. As of December 31, 2020, we had $23.7 million of remaining performance obligations for which the transaction price is not constrained related to these contracts which we expect to recognize over the next 12 to 18 months. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. Contract Balances The timing of revenue recognition, billings and cash collections can result in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) in the consolidated balance sheet. Contract assets as of December 31, 2020 and 2019 totaled $8.5 million and $5.5 million, respectively, and are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets and relate to the companion diagnostic co-development contracts discussed above. Contract liabilities primarily relate to non-cancellable advances or deposits received from customers before revenue is recognized and is primarily related to instrument service and SaaS arrangements. As of December 31, 2020 and 2019, contract liabilities totaled $68.9 million and $56.2 million, respectively, of which $57.1 million and $48.5 million is included in accrued and other current liabilities, respectively, and $11.8 million and $7.7 million in included in other long-term liabilities, respectively. During the twelve months ended December 31, 2020 and 2019, we satisfied the associated performance obligations and recognized revenue of $48.1 million and $48.3 million, respectively, related to advance customer payments previously received. Disaggregation of Revenue We disaggregate our revenue based on product type and customer class as shown in the tables below for the years ended December 31, 2020, 2019 and 2018: (in thousands) 2020 2019 2018 Consumables and related revenues $ 774,234 $ 665,866 $ 649,602 Instruments 129,742 71,266 82,197 Molecular Diagnostics 903,976 737,132 731,799 Consumables and related revenues 841,201 688,281 665,857 Instruments 125,169 101,011 104,192 Life Sciences 966,370 789,292 770,049 Total $ 1,870,346 $ 1,526,424 $ 1,501,848 Additionally, we disaggregate our revenue based on product category as shown in the tables below for the years ended December 31, 2020, 2019 and 2018: (in thousands) 2020 2019 2018 Sample technologies $ 803,867 $ 548,365 $ 546,636 Diagnostic solutions 460,757 465,503 461,064 PCR / Nucleic acid amplification 363,552 224,685 236,952 Genomics / NGS 165,570 183,768 163,383 Other 76,600 104,103 93,813 Total $ 1,870,346 $ 1,526,424 $ 1,501,848 Refer to Note 21 "Segment Information" for disclosure of revenue by geographic region.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Dec. 31, 2020
Asset Acquisitions, Business Combinations And Divestitures [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures Business Combinations and Asset Acquisitions For acquisitions which have been accounted for as business combinations, the acquired companies’ results have been included in the accompanying consolidated statements of income (loss) from their respective dates of acquisition. Our acquisitions have historically been made at prices above the fair value of the acquired net assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing infrastructure, such as sales force, shared service centers, distribution channels and customer relations, to expand sales of an acquired business' products; use of the infrastructure of the acquired businesses to cost-effectively expand sales of our products; and elimination of duplicative facilities, functions and staffing. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired in-process research and development with no alternative future use is charged to expense at the acquisition date. 2020 Business Combinations In September 2020, we completed the acquisition of the remaining 80.1% of NeuMoDx Molecular, Inc. ("NeuMoDx") shares, a privately-held U.S. company in which we held a minority interest. NeuMoDx designs and develops molecular diagnostics solutions for hospital and clinical reference laboratories. Prior to acquisition, we held a 19.9% investment in NeuMoDx with a carrying value of $41.0 million. The cash consideration, net of cash acquired totaled $239.4 million for the remaining shares. Of this amount, $8.5 million was retained in an escrow account as of December 31, 2020 which is expected to be fully utilized to cover claims for breach of any representations, warranties or indemnities. The acquisition date fair value of the minority interest investment was $52.7 million and a gain of $11.7 million was recorded in restructuring, acquisition, integration and other, net in the accompanying consolidated statement of income. The fair value of the minority interest investment was determined using an implied purchase price reduced by a 20% control premium. We incurred $2.5 million acquisition related costs to effect the business combination, of which $1.8 million was incurred during the year ended December 31, 2020, and are included in restructuring, acquisition, integration and other, net. Revenue and earnings in the reporting period since the acquisition date have not been significant. The allocation of the purchase price is preliminary and not yet finalized. The preliminary allocation of the purchase price is based upon preliminary estimates which used information that was available to management at the time the consolidated financial statements were prepared and these estimates and assumptions are subject to change within the measurement period, up to one year from the acquisition date. Accordingly, the allocation may change. We continue to gather information about the fair value of all assets and liabilities, including intangible assets acquired, and the related deferred taxes. The preliminary purchase price allocation for NeuMoDx as of December 31, 2020 and the difference to September 30, 2020 is as follows: (in thousands) As of December 31, 2020 As of September 30, 2020 Difference Purchase Price: Cash consideration $ 251,730 $ 251,730 $ — Fair value of minority interest 52,727 52,727 — $ 304,457 $ 304,457 $ — Preliminary Allocation: Cash and cash equivalents $ 12,291 $ 12,291 $ — Accounts receivable 5,691 5,691 — Inventories 20,666 18,866 1,800 Prepaid expenses and other current assets 5,961 5,943 18 Accounts payable (12,450) (11,168) (1,282) Accruals and other current liabilities (18,929) (18,770) (159) Other long-term liabilities (4,101) (4,101) — Fixed and other long-term assets 7,076 6,698 378 Developed technology 101,000 119,100 (18,100) In-process research and development 55,000 64,800 (9,800) Patents and license rights 770 770 — Customer backlog 400 900 (500) Goodwill 157,627 149,877 7,750 Deferred tax asset 12,457 — 12,457 Deferred tax liability on fair value of identifiable intangible assets acquired (39,002) (46,440) 7,438 Total $ 304,457 $ 304,457 $ — The in-process research and development recognized relates to technologies that remain in development and have not yet obtained regulatory approvals. The technologies within in-process research and development are expected to be completed within the next three years. The weighted average amortization period for the acquired intangibles is 10 years. The goodwill acquired is not deductible for tax purposes. Pro forma results The following unaudited pro forma information assumes that the above acquisition occurred at the beginning of the periods presented. For the year ended December 31, 2020, pro forma net sales would have been $1.90 billion, pro forma net income would have been $347.0 million, and pro forma diluted net income per common share would have been $1.48. For the year ended December 31, 2019, pro forma net sales would have been $1.53 billion, pro forma net loss would have been $69.1 million and pro forma diluted net loss per common share would have been $0.30. These unaudited pro forma results are intended for informational purposes only and are not necessarily indicative of the results of operations that would have occurred had the acquisition been in effect at the beginning of the periods presented, or of future results of the combined operations. 2019 Business Combinations In January 2019, we completed the acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. The cash consideration, net of cash acquired, was $24.5 million. This acquisition was not significant to the overall consolidated financial statements and as of December 31, 2019, the allocation of the purchase price was final. The acquisition did not have a material impact to net sales, net income or earnings per share and therefore no pro forma information has been provided herein. In the third quarter of 2019, we acquired two additional companies for total cash consideration, net of cash acquired, of $43.5 million. The purchase price allocations for these acquisitions were final as of March 31, 2020. These acquisitions were not significant to the overall consolidated financial statements and the acquisitions did not have a material impact to net sales, net income or earnings per share. Thus, no pro forma information has been provided herein. Other 2018 Business Combination In April 2018, we acquired all remaining shares of a privately held entity in which we held a minority interest. The value of the minority interest investment was revalued in connection with the acquisition by $4.8 million and a corresponding gain was recorded in restructuring, acquisition, integration and other, net in the accompanying consolidated statement of income for the year ended December 31, 2018. This acquisition was not significant to the overall consolidated financial statements. The acquisition did not have a material impact to net sales, net income or earnings per share and therefore no pro forma information has been provided herein. 2019 Asset Acquisition On January 31, 2019, we acquired the digital PCR asset of Formulatrix, Inc., a developer of laboratory automation solutions. We paid Formulatrix $125.0 million in cash upon closing. During 2020, we paid the remaining $135.9 million of milestone payments. Divestitures In 2019, we sold a portfolio of protein catalysation products for $1.0 million. An immaterial gain was recorded on the sale. In 2018, we sold a portfolio of veterinary testing products for a total of €15.1 million ($18.5 million), of which €13.4 million ($16.4 million) was received during 2018 and the remaining €1.7 million ($1.8 million) was collected in 2020. An $8.0 million gain was recorded on the sale to other income, net in the accompanying consolidated statement of income for the year-ended December 31, 2018.

Restructuring and Impairments

Restructuring and Impairments	12 Months Ended
Restructuring and Impairments	Dec. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Restructuring and Impairments As part of our restructuring activities, we incur expenses that qualify as exit and disposal costs under U.S. GAAP including severance and employee costs as well as contract and other costs, primarily contract termination costs, as well as inventory write-offs and other implementation costs primarily related to consulting fees. Personnel related costs primarily relate to cash severance and other termination benefits including accelerated share-based compensation. We also incur expenses that are an integral component of, and are directly attributable to, our restructuring activities which do not qualify as exit and disposal costs under U.S. GAAP, which consist of asset-related costs such as intangible asset impairments and other asset related write-offs. Personnel costs are primarily determined based on established benefit arrangements, local statutory requirements, or historical benefit practices. We recognize these benefits when payment is probable and estimable. Other benefits which require future service and are associated to non-recurring benefits are recognized ratably over the future service period. Other assets, including inventory, are impaired or written-off if the carrying value exceeds the fair value. All other costs are recognized as incurred. 2019 Restructuring In the second half of 2019, we decided to suspend development of NGS-related instrument systems and entered into a new strategic partnership with Illumina to commercialize IVD kits worldwide on Illumina's diagnostic sequencers. In order to align our business with this new strategy, we began restructuring initiatives to target resource allocation to growth opportunities in our Sample to Insight portfolio. Impairments to property, plant and equipment primarily impacted computer software and machinery and equipment. Costs incurred to either purchase software or produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established were previously capitalized during the development of certain NGS-related instrument systems. These long-lived assets were fully impaired due to the decision to suspend further development. In addition to computer software, certain machinery and equipment assets were fully impaired given that these assets had no alternative use following the changes announced for this program and it was estimated that no value was recoverable in a market disposal. Due to the suspended development, intangible assets were also assessed for recoverability. The abandoned assets include developed technology related to the suspended projects as well as the termination of licenses which were used exclusively in connection with this program. As a result, we recorded intangible asset impairment charges due to the conclusion that the identified assets have no alternative use outside of the suspended program and thus are fully impaired. We also conducted an impairment review of inventory and prepaid and other assets and recorded the charges noted in the table below. As these charges, including inventory, are a direct result of the decision to suspend further development of NGS-related instrument systems and are not related to external market factors, the impairment charges were recorded in the line item restructuring, acquisition, integration and other, net in the consolidated statements of income (loss) due to the assets being deemed excess and no longer utilized due to the discontinued development and related actions discussed above. In addition, we implemented measures to: • shift Commercial Operations activities into Business Areas; • transition manufacturing activities into a regional structure; and • expand the scope of activities at QIAGEN Business Services (QBS) centers in Wroclaw, Poland and Manila, Philippines During 2020, certain of the planned measures were delayed during the acquisition attempt by Thermo Fisher or changed as a result of business needs during the pandemic. The following is a summary of the charges recorded in the consolidated statements of income (loss) during the years ended December 31, 2020 and 2019 and total program charges through December 31, 2020. Classification and Type of Charge (in thousands) Note 2020 2019 Total program charges through 2020 Restructuring, acquisition, integration and other, net Personnel related (1) (22) $ 904 $ 70,578 $ 71,482 Contract termination expense (1) 682 42,099 42,781 Consulting fees 1,153 10,150 11,303 Accounts receivable (2) (622) 10,825 10,203 Inventories 1,014 12,336 13,350 Prepaid expenses and other assets (2) 127 17,012 17,139 3,258 163,000 166,258 Long-lived asset impairments Property, plant and equipment (9) 1,034 98,472 99,506 Intangible assets (11) — 40,301 40,301 1,034 138,773 139,807 Other income, net Equity method investment impairment (10) — 4,799 4,799 Total $ 4,292 $ 306,572 $ 310,864 (1) During the year ended December 31, 2019, personnel related and contract termination costs include $2,956 and $15,676, respectively, due to related parties. (2) During the year ended December 31, 2019, accounts receivable and prepaid expenses and other assets includes $5,984 and $2,270, respectively due from related parties. Of the total costs incurred, $11.2 million and $60.2 million are accrued as of December 31, 2020 and 2019, respectively, in accrued and other current liabilities in the accompanying consolidated balance sheets as summarized in the following table that includes the cash components of the restructuring activity. (in thousands) Personnel Related Contract Termination Consulting Fees Total Costs incurred in 2019 $ 44,640 $ 42,099 $ 10,150 $ 96,889 Payments (17,272) (18,294) (2,162) (37,728) Foreign currency translation adjustment 631 493 (53) 1,071 Liability at December 31, 2019 27,999 24,298 7,935 60,232 Additional costs incurred in 2020 4,542 1,639 1,661 7,842 Release of excess accrual (3,638) (957) (508) (5,103) Payments (24,355) (18,319) (9,028) (51,702) Foreign currency translation adjustment 139 (230) (12) (103) Liability at December 31, 2020 $ 4,687 $ 6,431 $ 48 $ 11,166 Future pre-tax costs between $5 - $10 million are expected to be incurred, primarily related to personnel and consulting, in the first half of 2021. 2017 Restructuring We initiated restructuring initiatives in 2017 to mitigate the negative impacts stemming from the U.S. tax reform. Total pre-tax costs for the initiatives, which concluded in 2018, were $24.4 million. Cumulative costs for this program were as follows: (in thousands) Personnel Related Contract and Other Costs Inventory Write-offs & Asset Impairments Total Cost of sales $ — $ — $ 3,039 $ 3,039 Restructuring, acquisition, integration and other, net 6,174 4,583 — 10,757 Total 2017 costs 6,174 4,583 3,039 13,796 Cost of sales 424 1,193 — 1,617 Restructuring, acquisition, integration and other, net 4,207 4,232 1,610 10,049 Total 2018 costs 4,631 5,425 1,610 11,666 Restructuring, acquisition, integration and other, net (1,100) — — (1,100) Total 2019 releases (1,100) — — (1,100) Total cumulative costs $ 9,705 $ 10,008 $ 4,649 $ 24,362 During 2018, fixed asset impairments of $1.6 million were recorded in connection with this initiative and are included within long-lived asset impairments in the accompanying consolidated statement of income.

Short-Term Investments

Short-Term Investments	12 Months Ended
Short-Term Investments	Dec. 31, 2020
Short-term Investments [Abstract]
Short-Term Investments	Short-Term Investments As of December 31, 2020 and 2019, short-term investments consisted of the following: (in thousands) 2020 2019 Marketable equity securities $ 117,249 $ — Money market deposits — 87,468 Commercial paper — 22,459 Loans receivable — 19,659 Total $ 117,249 $ 129,586 At December 31, 2020, short-term investments include the fair value of our marketable equity securities totaling $117.2 million. These investments, further discussed in Note 10 "Investments", are reported at fair value with gains and losses recorded in earnings. At December 31, 2019 we had $129.6 million ($65.0 million and €57.5 million) of money market deposits, commercial paper and loan receivables due from financial and nonfinancial institutions. These instruments are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are carried at fair market value, which is equal to the

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2020
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are summarized as follows as of December 31, 2020 and 2019: (in thousands) Note 2020 2019 Prepaid expenses $ 61,159 $ 39,930 Cash collateral (14) 56,100 2,683 Other receivables 32,901 29,486 Value added tax 31,128 20,347 Loan receivables 17,094 7,539 Contract assets (4) 8,539 5,479 Total prepaid expenses and other current assets $ 206,921 $ 105,464

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment of December 31, 2020 and 2019 were as follows: (in thousands) Estimated useful life (in years) 2020 2019 Land — $ 18,903 $ 17,684 Buildings and improvements 5-40 362,902 341,032 Machinery and equipment 3-10 322,379 292,294 Computer software 3-7 260,730 301,604 Furniture and office equipment 3-10 108,339 102,901 Construction in progress — 116,562 98,858 1,189,815 1,154,373 Less: Accumulated depreciation and amortization (630,443) (699,130) Property, plant and equipment, net $ 559,372 $ 455,243 In 2019, we began restructuring initiatives to target resource allocation to growth opportunities in our Sample to Insight portfolio and in connection therewith, we recorded impairments. Asset impairment charges for the years ended December 31, 2020, 2019 and 2018 were as follows: (in thousands) 2020 2019 2018 Machinery and equipment $ 77 $ 9,177 $ — Computer software — 44,649 2,911 Furniture and office equipment 315 4,030 — Construction in progress 642 41,870 4,979 Total impairment in property, plant and equipment $ 1,034 $ 99,726 $ 7,890 During the year ended December 31, 2020, $1.0 million of impairments were related to the 2019 Restructuring program discussed in Note 6 "Restructuring and Impairments". In 2019, $98.5 million of impairments were related to the 2019 Restructuring program while the remaining $1.2 million were related to other identified impairments during the year. In 2018, we recorded asset impairment charges of $7.9 million of internal-use software of which $1.6 million were related to the 2017 Restructuring program discussed in Note 6 and $6.3 million were related to strategic shifts in our business. For the years ended December 31, 2020, 2019 and 2018 depreciation and amortization expense totaled $78.6 million, $86.0 million and $87.9 million, respectively. For the years ended December 31, 2020, 2019 and 2018 amortization related to computer software to be sold, leased or marketed totaled $7.4 million, $18.3 million and $17.2 million, respectively. Impairment charges related to computer software to be sold, leased or marketed are included in computer software and construction in progress in the table above and totaled $65.9 million for the year ended December 31, 2019. As of December 31, 2020 and 2019, the unamortized balance of computer software to be sold, leased or marketed was $50.5 million and $36.6 million, respectively. Repairs and maintenance expense was $13.8 million, $10.7 million and $12.1 million in 2020, 2019 and 2018, respectively. For the year ended December 31, 2020, construction in progress primarily includes amounts related to projects to expand production lines as well as increase capacity of manufacturing as well as ongoing software development projects. For the years ended December 31, 2020, 2019 and 2018, interest capitalized in connection with construction projects was not significant.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Marketable Equity Securities We hold investments in marketable equity securities that have readily determinable fair values. Since January 1, 2018, these investments are reported at fair value with gains and losses recorded in earnings. As of December 31, 2020, our investments in marketable equity securities totaled $117.5 million, of which $117.2 million are included in short-term investments and $0.3 million are included in other long-term assets in the accompanying consolidated balance sheet, as follows: Short-Term Long-Term (in thousands, except shares held) Invitae Corporation OncoCyte Oncimmune Holdings plc HTG Molecular Diagnostics, Inc Shares held 2,769,189 88,101 560,416 55,556 Cost basis $ — $ — $ — $ 2,000 Fair value $ 115,780 $ 211 $ 1,258 $ 266 Total cumulative unrealized gain (loss) $ 115,780 $ 211 $ 1,258 $ (1,734) In 2020, HTGM completed a 15:1 reverse stock split. In 2020, we received 2.4 million shares of Invitae as part of the initial consideration for the sale of our ArcherDX shares, followed by an earn-out of an additional 0.4 million Invitae shares. Additionally in 2020, we received 0.1 million shares in OncoCyte. These transactions are discussed further below. In February 2021, we sold 2.4 million shares of Invitae for $101.5 million. During the year ended December 31, 2020, unrealized losses recognized for the change in fair market value of all marketable equity securities totaled $5.7 million of which $5.4 million is attributable to short-term investments and $0.3 million to long-term investments. As of December 31, 2019, these marketable securities are included in other long-term assets in the accompanying consolidated balance sheet as follows: Long-Term (in thousands, except shares held) Oncimmune HTGM Shares held 560,416 833,333 Cost basis $ — $ 2,000 Fair value $ 285 $ 585 Total cumulative unrealized gain (loss) $ 285 $ (1,415) During 2019, we received 0.6 million shares in Oncimmune in settlement of a zero-book value financial instrument held with a third party. On the date of receipt, these shares held a fair value of $0.7 million which was recorded as a gain in other income, net for the year ended December 31, 2019. During the years ended December 31, 2019 and 2018 unrealized losses recognized for the change in fair market value of all marketable equity securities totaled $2.1 million and $0.1 million, respectively. Non-Marketable Investments We have made strategic investments in certain privately-held companies without readily determinable market values. Non-Marketable Investments Accounted for Under the Equity Method A summary of our non-marketable investments accounted for as equity method investments is as follows: Ownership Equity investments Share of income (loss) ($ in thousands) 2020 2019 2020 2019 2018 PreAnalytiX GmbH 50.00 % $ 4,761 $ 5,452 $ 3,070 $ 3,971 $ 4,062 Suzhou Fuda Business Management and Consulting Partnership 33.67 % 3,301 3,100 — — — Apis Assay Technologies Ltd 19.00 % 1,940 719 1,221 (51) — TVM Life Science Ventures III 3.10 % 1,545 1,219 630 (330) — Hombrechtikon Systems Engineering AG 19.00 % (530) (761) 97 (1,124) (668) MAQGEN Biotechnology Co., Ltd 40.00 % — — — (383) (579) Biotype Innovation GmbH 0.00 % — — — — (123) Pyrobett 0.00 % — — — — (100) $ 11,017 $ 9,729 $ 5,018 $ 2,083 $ 2,592 TVM Life Science Ventures III is a limited partnership and we account for our 3.1% investment under the equity method as we have the ability to exercise significant influence over the limited partnership. Of the $11.0 million of non-marketable investments accounted for as equity method investments, $11.5 million is included in other long-term assets and $0.5 million, where we are committed to fund losses, is included in other long-ter m liabilities in the accompanying consolidated balance sheet as of December 31, 2020. During the year ended December 31, 2019, we recorded an impairment of $4.8 million in other income, net in the accompanying consolidated statements of income, following changes in circumstances of MAQGEN Biotechnology Co., Ltd that indicated the carrying value was no longer recoverable. Accordingly, the investment was fully impaired. In 2018, we recorded impairments totaling $6.1 million in other income, net in the accompanying consolidated statements of income, following changes in the investees' circumstances that indicated the carrying value was no longer recoverable. Three of our equity method investments are variable interest entities and we are not the primary beneficiary as we do not hold the power to direct the activities that most significantly impact the economic performance. Therefore, these investments are not consolidated. As of December 31, 2020, these investments had a total net carrying value of $3.0 million, of which $3.5 million is included in other long-term assets and $0.5 million is included in other long-term liabilities in the accompanying consolidated balance sheet. As of December 31, 2019, these investments held a balance of $1.2 million, of which $1.9 million is included in other long-term assets and $0.8 million is included in other long-term liabilities in the accompanying consolidated balance sheet. These balances represent our maximum exposure to loss. Non-Marketable Investments Not Accounted for Under the Equity Method At December 31, 2020 and 2019, we had investments in non-publicly traded companies that do not have readily determinable fair values with carrying amounts that totaled $4.1 million and $70.8 million, respectively. The changes in these investments which are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 70,849 $ 59,484 Full acquisition of equity securities (41,001) — Sale of equity securities (23,812) — Loss on sale of equity securities (2,250) — Impairments (398) — Cash investments in equity securities, net 173 3,619 Net increases due to observable price changes — 7,760 Foreign currency translation adjustments 581 (14) Balance at end of year $ 4,142 $ 70,849 2020 Changes in Non-Marketable Investments Not Accounted for Under the Equity Method During 2020, we acquired the remaining shares of NeuMoDx as further discussed in Note 5 "Acquisitions and Divestitures". In 2020, Invitae Corporation ("Invitae"), a publicly traded company (NVTA), completed the acquisition of ArcherDX, Inc. ("ArcherDX"), a company in which we held an approximate 8% investment. In exchange for our shares in ArcherDX, we initially received cash of $21.1 million and 2.4 million shares in Invitae followed by an additional 0.4 million shares for milestone achievement. For the year ended December 31, 2020, we recognized a total gain of $123.3 million in other income, net in the accompanying consolidated statement of income as a result of this transaction. We are entitled to up to 1.7 million additional Invitae shares subject to milestone achievement. We sold an investment with a carrying value of $2.5 million in exchange for cash of $0.3 million including the shares in OncoCyte, as discussed above. A loss of $2.3 million was recognized in other income, net in the accompanying consolidated statement of income on the sale of this investment. We sold another investment for its book value and received $3.7 million in cash. In 2020, we recorded a $0.4 million impairment in other income, net in the accompanying consolidated statement of income due following indications that the carrying value was no longer recoverable. Accordingly, the investment was fully impaired.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
Goodwill and Intangible Assets	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The following sets forth the intangible assets by major asset class as of December 31, 2020 and 2019: Weighted Average Life 2020 2019 (in thousands) Gross Carrying Amount Accumulated Gross Carrying Accumulated Amortized Intangible Assets: Patent and license rights 10.50 $ 298,395 $ (197,038) $ 320,406 $ (216,554) Developed technology 10.74 860,129 (378,705) 766,966 (346,085) Customer base, trademarks, and non-compete agreements 12.02 314,876 (233,981) 314,638 (213,881) 10.86 $ 1,473,400 $ (809,724) $ 1,402,010 $ (776,520) Unamortized Intangible Assets: In-process research and development $ 62,518 $ 6,944 Goodwill 2,364,031 2,140,503 $ 2,426,549 $ 2,147,447 The in-process research and development as of December 31, 2020 is associated to the acquisitions of NeuMoDx in 2020 and STAT-Dx in 2018. The estimated fair value of acquired in-process research and development projects which have not reached technological feasibility at the date of acquisition are capitalized and subsequently tested for impairment through completion of the development process, at which point the capitalized amounts are amortized over their estimated useful life. If a project is abandoned rather than completed, all capitalized amounts are written-off immediately. Developed technology includes the acquired intangibles from NeuMoDx and the digital PCR asset from Formulatrix as discussed in Note 5 "Acquisitions and Divestitures" which are both being amortized over 10 years. The changes in intangible assets for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 632,434 $ 475,043 Additions 24,007 286,159 Additions from acquisitions 157,170 36,458 Amortization (103,230) (122,560) Disposals (537) — Impairments — (40,301) Foreign currency translation adjustments 16,350 (2,365) Balance at end of year $ 726,194 $ 632,434 Cash paid for purchases of intangible assets during the twelve months ended December 31, 2020 totaled $171.5 million, of which $146.1 million is related to current year payments for assets that were accrued as of December 31, 2019, $24.0 million of current year additions and $1.4 million for prepayments recorded in other long-term assets in the accompanying consolidated balance sheet. Cash paid for intangible assets during the year ended December 31, 2019 totaled $156.9 million of which $11.5 million is related to current year payments for licenses that were accrued as of December 31, 2018 and $0.5 million is related to prepayments recorded in other long-term assets in accompanying consolidated balance sheet. Intangible asset additions of $286.2 million includes $144.9 million of cash paid during the year ended December 31, 2019, together with $137.8 million of additions that were accrued as of December 31, 2019 and $3.5 million of additions which were previously recorded as prepayments. Amortization expense on intangible assets totaled approximately $103.2 million, $122.6 million and $118.6 million, respectively, for the years ended December 31, 2020, 2019 and 2018. During the year ended December 31, 2019, we recorded an impairment charge of $40.3 million related to the restructuring activities discussed further in Note 6 "Restructuring and Impairments" of which $28.1 million is related to patent and license rights and $12.1 million is related to developed technology. Amortization of intangibles for the next five years is expected to be approximately: Years ended December 31, (in thousands) 2021 $ 103,485 2022 $ 89,734 2023 $ 87,355 2024 $ 83,520 2025 $ 71,130 The changes in goodwill for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 2,140,503 $ 2,108,536 Business combinations 157,627 34,807 Purchase adjustments 3,382 (236) Disposals — (225) Foreign currency translation adjustments 62,519 (2,379) Balance at end of year $ 2,364,031 $ 2,140,503 The changes in the carrying amount of goodwill during the year ended December 31, 2020 resulted primarily from the acquisition of NeuMoDx discussed in Note 5 "Acquisitions and Divestitures" and changes in foreign currency translation. The changes in goodwill during the year ended December 31, 2019 resulted primarily from the acquisition of N-of-One, Inc. and other acquisitions and divestitures also discussed in Note 5 "Acquisitions and Divestitures" and changes in foreign currency translation.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2020
Leases [Abstract]
Leases	Leases We have operating leases primarily for real estate. The leases generally have terms which range from one year to 15 years, some include options to extend or renew, and some include options to early terminate the leases. As of December 31, 2020 and 2019, no such options have been recognized as part of the right-of-use assets and lease liabilities. Operating leases can contain variable lease charges based on an index like consumer prices or rates. During the year ended December 31, 2020 and 2019, amounts recorded as variable lease payments not included in the operating lease liability were not material. When the interest rate implicit in each lease is not readily determinable, we apply our incremental borrowing rate in determining the present value of lease payments. All operating lease expense is recognized on a straight-line basis over the lease term. For the years ended December 31, 2020 and 2019, we recognized $25.0 million and $24.4 million in total lease costs, respectively. Supplemental balance sheet and other information related to operating leases as of December 31, 2020 and 2019 are as follows: (in thousands, except lease term and discount rate) Location in balance sheet 2020 2019 Operating lease right-of-use assets Other long-term assets $ 102,522 $ 57,305 Current operating lease liabilities Accrued and other current liabilities $ 23,450 $ 18,739 Long-term operating lease liabilities Other long-term liabilities $ 85,585 $ 39,631 Weighted average remaining lease term 7.04 years 3.71 years Weighted average discount rate 1.89 % 2.39 % Supplemental cash flow information related to operating leases for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Cash paid for operating leases included in operating cash flows $ 24,193 $ 26,113 Operating lease right-of-use assets obtained in exchange for lease obligations $ 58,992 $ 24,670 Future maturities of operating lease liabilities as of December 31, 2020 are as follows: Years ending December 31, (in thousands) 2021 $ 25,353 2022 20,993 2023 16,280 2024 10,790 2025 6,707 Thereafter 36,878 Total lease payments 117,001 Less: imputed interest (7,966) Total $ 109,035 As of December 31, 2020, we do not have any material operating leases that have not yet commenced. We did not hold any material finance leases as of December 31, 2020 and 2019.

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	12 Months Ended
Accrued and Other Current Liabilities	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Accrued and Other Current Liabilities	Accrued and Other Current Liabilities Accrued and other current liabilities at December 31, 2020 and 2019 consist of the following: (in thousands) Note 2020 2019 Payroll and related accruals $ 99,085 $ 66,866 Other liabilities 67,244 54,241 Deferred revenue (4) 57,066 48,525 Accrued expenses 51,026 38,963 Accrued contingent consideration and milestone payments (15) 23,593 142,604 Operating lease liabilities (12) 23,450 18,739 Restructuring (6) 11,599 62,227 Accrued royalties (20) 7,427 5,481 Accrued interest on long-term debt (16) 4,575 5,257 Cash collateral (14) 600 1,400 Total accrued and other current liabilities $ 345,665 $ 444,303

Derivatives and Hedging

Derivatives and Hedging	12 Months Ended
Derivatives and Hedging	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging	Derivatives and Hedging Objective and Strategy In the ordinary course of business, we use derivative instruments, including swaps, forwards and/or options, to manage potential losses from foreign currency exposures and interest bearing assets or liabilities. The principal objective of such derivative instruments is to minimize the risks and/or costs associated with our global financial and operating activities. We do not utilize derivative or other financial instruments for trading or other speculative purposes. We recognize all derivatives as either assets or liabilities on the balance sheet on a gross basis, measure those instruments at fair value and recognize the change in fair value in earnings in the period of change, unless the derivative qualifies as an effective hedge that offsets certain exposures. We have agreed with almost all of our counterparties with whom we had entered into cross-currency swaps, interest rate swaps or foreign exchange contracts, to enter into bilateral collateralization contracts under which we will receive or provide cash collateral, as the case may be, for the net position with each of these counterparties . As of December 31, 2020, cash collateral positions consisted of $0.6 million recorded in accrued and other current liabilities and $56.1 million recorded in prepaid expenses and other current assets. As of December 31, 2019, we had cash collateral positions consisting of $1.4 million recorded in accrued and other current liabilities and $2.7 million recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheets. Non-Derivative Hedging Instrument Net Investment Hedge In 2017, we entered into a foreign currency non-derivative hedging instrument that is designated and qualifies as net investment hedge. The objective of the hedge is to protect part of the net investment in foreign operations against adverse changes in the exchange rate between the Euro and the functional currency of the U.S. dollar. The non-derivative hedging instrument is the German private corporate bond ("Schuldschein") which was issued in the total amount of $331.1 million as described in Note 16 "Debt". Of the $331.1 million, which is held in both U.S. dollars and Euros, €255.0 million is designated as the hedging instrument against a portion of our Euro net investments in our foreign operations. The relative changes in both the hedged item and hedging instrument are calculated by applying the change in spot rate between two assessment dates against the respective notional amount. The effective portion of the hedge is recorded in the cumulative translation adjustment account within other accumulated comprehensive loss. Based on the spot rate method, the unrealized loss recorded in equity as of December 31, 2020 and 2019 is $26.9 million and $0.4 million, respectively. Since we are using the debt as the hedging instrument, which is also remeasured based on the spot rate method, there is no hedge ineffectiveness related to the net investment hedge as of December 31, 2020 and 2019. Derivatives Designated as Hedging Instruments Cash Flow Hedges As of December 31, 2020 and 2019, we held derivative instruments that are designated and qualify as cash flow hedges, where the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive loss and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. To date, we have not recorded any hedge ineffectiveness related to any cash-flow hedges in earnings. Based on their valuation as of December 31, 2020, we expect approximately $3.6 million of derivative losses included in accumulated other comprehensive loss will be reclassified into income during the next 12 months. The cash flows derived from derivatives are classified in the consolidated statements of cash flows in the same category as the consolidated balance sheets account of the underlying item. We use interest rate derivative contracts to align our portfolio of interest bearing assets and liabilities with our risk management objectives. During 2015, we entered into five cross currency interest rate swaps through 2025 for a total notional amount of €180.0 million which qualify for hedge accounting as cash flow hedges. We determined that no ineffectiveness exists related to these swaps. As of December 31, 2020 and 2019, interest receivables of $1.1 million and $1.5 million, respectively are recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheets. Fair Value Hedges As of December 31, 2020 and 2019, we held derivative instruments that qualify for hedge accounting as fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the effective portion of the gain or loss on the derivative is reflected in earnings. This effect on earnings is offset by the change in the fair value of the hedged item attributable to the risk being hedged that is also recorded in earnings. To date, there has been no ineffectiveness. The cash flows derived from derivatives are classified in the consolidated statements of cash flows in the same category as the consolidated balance sheets account of the underlying item. We hold interest rate swaps which effectively fix the fair value of a portion of our fixed rate private placement debt and qualify for hedge accounting as fair value hedges. We determined that no ineffectiveness exists related to these swaps. As of December 31, 2020 and 2019, interest receivables of $0.6 million and $0.1 million, respectively, are recorded in prepaid and other current assets in the accompanying consolidated balance sheets. Derivatives Not Designated as Hedging Instruments Call Options We entered into Call Options which, along with the sale of the Warrants, represent the Call Spread Overlay entered into in connection with the Cash Convertible Notes and which are more fully described in Note 16 "Debt". In these transactions, the Call Options are intended to address the equity price risk inherent in the cash conversion feature of each instrument by offsetting cash payments in excess of the principal amount due upon any conversion of the Cash Convertible Notes. Aside from the initial payment of premiums for the Call Options, we will not be required to make any cash payments under the Call Options. We will, however, be entitled to receive under the terms of the Call Options, an amount of cash generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is equal to the conversion price of the Cash Convertible Notes. The Call Options, for which our common stock is the underlying security, are derivative assets that requires mark-to-market accounting treatment due to the cash settlement features until the Call Options settle or expire. The Call Options are measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the Call Options, refer to Note 15 "Financial Instruments and Fair Value Measurements". The Call Options do not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of income (loss) in other income, net. Because the terms of the Call Options are substantially similar to those of the Cash Convertible Notes' embedded cash conversion option, discussed below, we expect the effect on earnings from the two derivative instruments to mostly offset each other. Cash Convertible Notes Embedded Cash Conversion Option The embedded cash conversion option within the Cash Convertible Notes discussed in Note 16 "Debt" is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income (loss) in other income, net until the cash conversion option settles or expires. The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 15 "Financial Instruments and Fair Value Measurements". Embedded Conversion Option During 2017, we purchased a convertible note for $3.0 million from a publicly listed company considered a related party. The embedded conversion option within the convertible note was required to be separated from the convertible note and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income (loss) in other income, net. The embedded cash conversion option was measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. During 2020, $3.2 million was collected including the principal including accrued interest. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 15 "Financial Instruments and Fair Value Measurements". Foreign Exchange Contracts As a globally active enterprise, we are subject to risks associated with fluctuations in foreign currencies in our ordinary operations. This includes foreign currency-denominated receivables, payables, debt, and other balance sheet positions including intercompany items. We manage balance sheet exposure on a group-wide basis using foreign exchange forward contracts, foreign exchange options and cross-currency swaps. We are party to various foreign exchange forward, option and swap arrangements which had, at December 31, 2020 and 2019, aggregate notional values of $1.3 billion and $701.4 million, respectively which expire at various dates through March 2021. The transactions have been entered into to offset the effects from short-term balance sheet exposure to foreign currency exchange risk. Changes in the fair value of these arrangements have been recognized in other income, net. Fair Values of Derivative Instruments The following table summarizes the fair value amounts of derivative instruments reported in the consolidated balance sheets as of December 31, 2020 and 2019: 2020 2019 (in thousands) Current Asset Long-Term Asset Current Asset Long-Term Asset Assets: Derivative instruments designated as hedges Interest rate contracts - fair value hedge (1) $ — $ 5,042 $ — $ 2,474 Total derivative instruments designated as hedges $ — $ 5,042 $ — $ 2,474 Undesignated derivative instruments Equity options $ 2,415 $ 374,038 $ 101,179 $ 189,792 Foreign exchange forwards and options 11,712 — 6,689 — Total undesignated derivative instruments $ 14,127 $ 374,038 $ 107,868 $ 189,792 Total Derivative Assets $ 14,127 $ 379,080 $ 107,868 $ 192,266 2020 2019 (in thousands) Current Liability Long-Term Liability Current Liability Long-Term Liability Liabilities: Derivative instruments designated as hedges Interest rate contracts - cash flow hedge (1) $ — $ (17,409) $ — $ (6,027) Total derivative instruments designated as hedges $ — $ (17,409) $ — $ (6,027) Undesignated derivative instruments Equity options $ (5,966) $ (376,046) $ (101,361) $ (190,902) Foreign exchange forwards and options (45,498) — (1,814) — Total undesignated derivative instruments $ (51,464) $ (376,046) $ (103,175) $ (190,902) Total Derivative Liabilities $ (51,464) $ (393,455) $ (103,175) $ (196,929) _________________ (1) The fair value amounts for the interest rate contracts do not include accrued interest. Gains and Losses on Derivative Instruments The following tables summarize the gains and losses on derivative instruments for the years ended December 31, 2020, 2019 and 2018: 2020 2019 2018 (in thousands) Other income, net Other income, net Other income, net Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded $ 114,326 $ 432 $ 5,598 Gains (Losses) on Derivatives in Cash Flow Hedges Interest rate contracts Amount of gain (loss) reclassified from accumulated other comprehensive loss $ 18,666 $ (3,888) $ (9,774) Amounts excluded from effectiveness testing — — — Gains (Losses) on Derivatives in Fair Value Hedges Interest rate contracts Hedged item (2,568) (3,668) 2,051 Derivatives designated as hedging instruments 2,568 3,668 (2,051) Gains (Losses) Derivatives Not Designated as Hedging Instruments Embedded conversion option — (349) 131 Equity options 322,580 (104,125) 74,682 Cash convertible notes embedded cash conversion option (321,213) 106,998 (76,500) Foreign exchange forwards and options (12,429) 1,835 (19,857) Total gains (losses) $ 7,604 $ 471 $ (31,318) Balance Sheet Line Items in which the Hedged Item is Included The following tables summarizes the balance sheet line items in which the hedged item is included as of December 31, 2020 and 2019: Carrying Amount of the Hedged Assets (Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities) (in thousands) 2020 2019 2020 2019 Long-term debt $ (131,923) $ (129,290) $ 5,042 $ 2,474

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
Financial Instruments and Fair Value Measurements	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements Assets and liabilities are measured at fair value according to a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1. Observable inputs, such as quoted prices in active markets; Level 2. Inputs, other than the quoted price in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Our assets and liabilities measured at fair value on a recurring basis consist of marketable securities discussed in Note 10 "Investments", which are classified in Level 1, short-term investments, which are classified in Level 2 of the fair value hierarchy, derivative contracts used to hedge currency and interest rate risk and derivative financial instruments entered into in connection with the Cash Convertible Notes discussed in Note 16 "Debt", which are classified in Level 2 of the fair value hierarchy, contingent consideration accruals which are classified in Level 3 of the fair value hierarchy, and are shown in the tables below and non-marketable equity securities remeasured during the year ended December 31, 2020 and 2019 are classified within Level 3 in the fair value hierarchy. There were no transfers between levels for the year ended December 31, 2020. In determining fair value for Level 2 instruments, we apply a market approach, using quoted active market prices relevant to the particular instrument under valuation, giving consideration to the credit risk of both the respective counterparty to the contract and the Company. To determine our credit risk, we estimated our credit rating by benchmarking the price of outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, our credit risk was quantified by reference to publicly-traded debt with a corresponding rating. The Level 2 derivative financial instruments include the Call Options asset and the embedded conversion option liability. See Note 16 "Debt", and Note 14 "Derivatives and Hedging", for further information. The derivatives are not actively traded and are valued based on an option pricing model that uses observable market data for inputs. Significant market data inputs used to determine fair values included our common stock price, the risk-free interest rate, and the implied volatility of our common stock. The Call Options asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated. Our Level 3 instruments include non-marketable equity security investments. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Our Level 3 instruments also include contingent consideration liabilities. We value contingent consideration liabilities using unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. Contingent consideration arrangements obligate us to pay the sellers of an acquired entity if specified future events occur or conditions are met such as the achievement of technological or revenue milestones. We use various key assumptions, such as the probability of achievement of the milestones (0% to 100%) and the discount rate (between 6.5% and 6.9%), to represent the non-performing risk factors and time value when applying the income approach. We regularly review the fair value of the contingent consideration, and reflect any change in the accrual in the consolidated statements of income (loss) in the line items commensurate with the underlying nature of milestone arrangements. The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019: 2020 2019 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ — $ — $ — $ — $ 129,586 $ — $ 129,586 Marketable equity securities 117,515 — — 117,515 870 — — 870 Non-marketable equity securities — — 4,142 4,142 — — 70,849 70,849 Equity options — 376,453 — 376,453 — 290,971 — 290,971 Foreign exchange forwards and options — 11,712 — 11,712 — 6,689 — 6,689 Interest rate contracts — 5,042 — 5,042 — 2,474 — 2,474 $ 117,515 $ 393,207 $ 4,142 $ 514,864 $ 870 $ 429,720 $ 70,849 $ 501,439 Liabilities: Foreign exchange forwards and options $ — $ (45,498) $ — $ (45,498) $ — $ (1,814) $ — $ (1,814) Interest rate contracts — (17,409) — (17,409) — (6,027) — (6,027) Equity options — (382,012) — (382,012) — (292,263) — (292,263) Contingent consideration — — (23,593) (23,593) — — (162,160) (162,160) $ — $ (444,919) $ (23,593) $ (468,512) $ — $ (300,104) $ (162,160) $ (462,264) Refer to Note 10 "Investments" for the change in non-marketable equity securities with Level 3 inputs during the year ended December 31, 2020 and 2019. For contingent consideration liabilities with Level 3 inputs, the following table summarizes the activity for the years ended December 31, 2020 and 2019: (in thousands) 2020 2019 Balance at beginning of year $ (162,160) $ (48,971) Additions from acquisitions (3,223) (132,422) Payments 141,790 11,800 Gain included in earnings — 7,433 Balance at end of year $ (23,593) $ (162,160) As of December 31, 2020, we had $23.6 million accrued for contingent consideration which is included in accrued and other current liabilities in the accompanying consolidated balance sheet. As of December 31, 2020, the $3.2 million of additions is related to the time value increases of existing contingent consideration liabilities related to both the 2019 asset acquisition of Formulatrix discussed in Note 5 "Acquisitions and Divestitures" as well as the 2018 acquisition of STAT-Dx. During 2019, a gain for the reduction in the fair value of contingent consideration related to unmet milestones of $7.4 million was recognized in restructuring, acquisition, integration and other, net in the accompanying consolidated statements of income (loss) and additions of $132.4 million primarily related to the asset acquisition of Formulatrix as discussed in Note 5. The carrying values of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities, approximate their fair values due to their short-term maturities. The estimated fair value of long-term debt as disclosed in Note 16 "Debt" was based on current interest rates for similar types of borrowings. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. There were no fair value differences in the years ended December 31, 2020 and 2019 for nonfinancial assets or liabilities required to be measured at fair value on a nonrecurring basis other than the impairments of non-marketable investments not accounted for under the equity method as discussed in Note 10. The table below presents the carrying values and the estimated fair values of financial instruments not presented in the tables above as of December 31, 2020 and 2019. 2020 2019 (in thousands) Carrying Amount Level 1 Level 2 Carrying Amount Level 1 Level 2 Long-term debt including current portion: Cash convertible notes $ 791,000 $ 1,167,201 $ — $ 1,046,511 $ 1,296,334 $ — Convertible notes 442,481 510,930 — — — — U.S. Private placement 331,717 — 337,747 328,984 — 329,157 German private placement 357,551 — 361,957 330,857 — 334,371 $ 1,922,749 $ 1,678,131 $ 699,704 $ 1,706,352 $ 1,296,334 $ 663,528 The fair values of the financial instruments presented in the tables above were determined as follows: Cash Convertible Notes and Convertible Notes: Fair value is based on an estimation using available over-the-counter market information on the Cash Convertible Notes due in 2021, 2023 and 2024 as well as the Convertible Notes due in 2027. U.S. Private Placement: Fair value of the outstanding bonds is based on an estimation using the changes in the U.S. Treasury rates. German Private Placement: Fair value is based on an estimation using changes in the euro swap rates.

Debt

Debt	12 Months Ended
Debt	Dec. 31, 2020
Debt Instruments [Abstract]
Debt	Debt At December 31, 2020 and 2019, total current long-term debt, net of debt issuance costs of $10.7 million and $10.8 million, respectively, consists of the following: (in thousands) 2020 2019 0.875% Senior Unsecured Cash Convertible Notes due 2021 $ 200 $ 285,244 0.500% Senior Unsecured Cash Convertible Notes due 2023 361,304 347,995 1.000% Senior Unsecured Cash Convertible Notes due 2024 429,496 413,272 0.000% Senior Unsecured Convertible Notes due 2027 442,481 — 3.75% Series B Senior Notes due October 16, 2022 304,761 302,040 3.90% Series C Senior Notes due October 16, 2024 26,956 26,944 German Private Placement (Schuldschein) 357,551 330,857 Total long-term debt 1,922,749 1,706,352 Less current portion 42,539 285,244 Long-term portion $ 1,880,210 $ 1,421,108 The notes are all unsecured obligations that rank pari passu. Interest expense on long-term debt was $63.5 million, $68.0 million and $61.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. In 2020, we repaid $296.4 million of the 2021 Notes, leaving $0.2 million outstanding as of December 31, 2020, which will be repaid at the original maturity on March 19, 2021. In 2019, we repaid $506.4 million of long-term debt including $430.0 million for the amount due for the 2019 Cash Convertible Notes, $73.0 million for amounts due for the U.S. Private Placement and $3.4 million for a portion of the 2021 Cash Convertible Notes which was converted during the contingent conversion period as discussed further below. Future maturities (stated at the carrying values) of long-term debt as of December 31, 2020, are as follows: Years ending December 31, (in thousands) 2021 $ 42,539 2022 485,795 2023 361,304 2024 572,870 2025 — thereafter 460,241 $ 1,922,749 Convertible Notes due 2027 On December 17, 2020, we issued zero coupon convertible notes in an aggregate principal amount of $500.0 million with a maturity date of December 17, 2027 (2027 Notes). The 2027 Notes carry no coupon interest. The net proceeds of the 2027 Notes totaled $497.6 million, after debt issuance costs of $3.7 million, of which $1.3 million was accrued as of December 31, 2020. In accounting for the issuance of the 2027 Notes, we separated the 2027 Notes into liability and equity components. We allocated $445.9 million of the 2027 Notes to the liability component, representing the fair value of a similar debt instrument that does not have an associated convertible feature; and $54.1 million to the equity component, representing the conversion option, which does not meet the criteria for separate accounting as a derivative as it is indexed to our own stock. The effective interest rate of the 2027 Notes is 1.65%, which is imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the 2027 Note. We incurred issuance costs of $3.7 million related to the 2027 Notes. Issuance costs were allocated to the liability and equity components based on the same proportion used to allocate the proceeds. Issuance costs attributable to the liability component of $3.3 million are amortized to interest expense over the term of the 2027 Notes, and issuance costs attributable to the equity component of $0.5 million are included along with the equity component in equity. The 2027 Notes are convertible into common shares based on an initial conversion rate, subject to adjustment, of 2,477.65 shares per $200,000 principal amount of notes (which represents an initial conversion price of $80.7218 per share, or 6.2 million underlying shares). At conversion, we will settle the 2027 Notes by repaying the principal portion in cash and any excess of the conversion value over the principal amount in shares of common stock. The notes may be redeemed at the option of each noteholder at their principal amount on December 17, 2025 or in connection with a change of control or delisting event. The 2027 Notes are convertible in whole, but not in part, at the option of the noteholders on a net share settlement basis, at the prevailing conversion price in the following circumstances beginning after January 27, 2021 through June 16, 2027: • if the last reported sale price of our common stock for at least 20-consecutive trading days during a period of 30-consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; or • if we undergo certain fundamental changes as defined in the agreement; or • if parity event or trading price unavailability event, as the case maybe occurs during the period of 10 days, including the first business day following the relevant trading price notification date; or • if we distribute assets or property to all or substantially all of the holders of our common stock and those assets or other property have a value of more than 25% of the average daily volume-weighted average trading price of our common stock for the prior 20 consecutive trading days; or • in case of early redemption in respect of the outstanding notes at our option, where the conversion date falls in the period from (and including) the date on which the call notice is published to (and including) the 45th business day prior to the redemption date; or • if we experience certain customary events of default, including defaults under certain other indebtedness, until such event of default has been cured or waived. The noteholders may convert their notes at any time, without condition, on or after June 17, 2027 until the 45th business day prior to December 17, 2027. Cash Convertible Notes due 2019, 2021, 2023, and 2024 On March 19, 2014, we issued $730.0 million aggregate principal amount of Cash Convertible Senior Notes in two tranches consisting of $430.0 million due on March 19, 2019 (2019 Notes) and $300.0 million due on March 19, 2021 (2021 Notes). The aggregate net proceeds of the 2019 and 2021 Convertible Notes were $680.7 million, after payment of the net cost of the Call Spread Overlay described below and transaction costs. During 2019, $430.0 million was paid at maturity (2019 Notes) and $3.4 million of the 2021 Notes was redeemed. In 2020, a total of $296.4 million of the 2021 Notes was repaid, leaving $0.2 million outstanding as of December 31, 2020, which will be repaid at the original maturity on March 19, 2021. On September 13, 2017, we issued $400.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2023 (2023 Notes). The net proceeds of the 2023 Notes were $365.6 million , after payment of the net cost of the Call Spread Overlay described below and transaction costs . On November 13, 2018, we issued $500.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2024 (2024 Notes). The net proceeds of the 2024 Notes were $468.9 million, after payment of the net cost of the Call Spread Overlay described below and transaction costs. We refer to the 2019 Notes, 2021 Notes 2023 Notes, and 2024 Notes, collectively as the “Cash Convertible Notes". Interest on the Cash Convertible Notes is payable semi-annually in arrears and will mature on the maturity date unless repurchased or converted with their terms prior to such date. The interest rate and corresponding maturity of each Note are summarized in the table below. The Cash Convertible Notes are solely convertible into cash in whole, but not in part, at the option of noteholders under the circumstances described below and during the contingent conversion periods as shown in the table below. Cash Convertible Notes Annual Interest Rate Date of Interest Payments Maturity Date Contingent Conversion Period Conversion Rate per $200,000 Principal Amount 2021 Notes 0.875% March 19 and September 19 March 19, 2021 From April 29, 2014 to September 18, 2020 7,063.1647 2023 Notes 0.500% March 13 and September 13 September 13, 2023 From October 24, 2017 to March 13, 2023 4,829.7279 2024 Notes 1.000% May 13 and November 13 November 13, 2024 From December 24, 2018 to August 2, 2024 4,360.3098 Additionally, conversion may occur at any time following a Contingent Conversion Period through the fifth business day immediately preceding the applicable maturity date. Upon conversion, noteholders will receive an amount in cash equal to the Cash Settlement Amount, calculated as described below. The Cash Convertible Notes are not convertible into shares of our common stock or any other securities. Noteholders may convert Cash Convertible Notes into cash at their option at any time during the Contingent Conversion Periods described above only under the following circumstances (Contingent Conversion Conditions): • if the last reported sale price of our common stock for at least 20-consecutive trading days during a period of 30-consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • if we undergo certain fundamental changes as defined in the agreement; • during the five • if parity event or trading price unavailability event, as the case maybe occurs during the period of 10 days, including the first business day following the relevant trading price notification date; • if we elect to distribute assets or property to all or substantially all of the holders of our common stock and those assets or other property have a value of more than 25% of the average daily volume-weighted average trading price of our common stock for the prior 20 consecutive trading days; • if we elect to redeem the Cash Convertible Notes; or • if we experience certain customary events of default, including defaults under certain other indebtedness until such event has been cured or waived or the payment of the Notes have been accelerated. The Contingent Conversion Conditions in the 2021, 2023, and 2024 Notes noted above have been analyzed under ASC 815, Derivatives and Hedging , and, based on our analysis, we determined that each of the embedded features listed above are clearly and closely related to the 2021, 2023 and 2024 Notes (i.e., the host contracts). As a result, pursuant to the accounting provisions of ASC 815, Derivatives and Hedging , the Contingent Conversion Conditions noted above are not required to be bifurcated as separate instruments. No Contingent Conversion Conditions were triggered for the 2023 Notes and 2024 Notes as of December 31, 2020. Upon conversion, holders are entitled to a cash payment (Cash Settlement Amount) equal to the average of the conversion rate multiplied by the daily volume-weighted average trading price for our common stock over a 50-day period. The conversion rate is subject to adjustment in certain instances but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of certain corporate events that may occur prior to the applicable maturity date, we may be required to pay a cash make-whole premium by increasing the conversion rate for any holder who elects to convert Cash Convertible Notes in connection with the occurrence of such a corporate event. We may redeem the Cash Convertible Notes in their entirety at a price equal to 100% of the principal amount of the applicable Cash Convertible Notes plus accrued interest at any time when 20% or less of the aggregate principal amount of the applicable Cash Convertible Notes originally issued remain outstanding. Because the Cash Convertible Notes contain an embedded cash conversion option, we have determined that the embedded cash conversion option is a derivative financial instrument, which is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income (loss) until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash conversion option for the 2019 and 2021 Notes was $51.2 million and $54.0 million, respectively, $74.5 million for the 2023 Notes, and $98.5 million for the 2024 Notes, which simultaneously reduced the carrying value of the Cash Convertible Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the Cash Convertible Notes, refer to Note 14 "Derivatives and Hedging". As noted above, the reduced carrying value on the Cash Convertible Notes resulted in a debt discount that is amortized to the principal amount through the recognition of non-cash interest expense using the effective interest method over the expected life of the debt, which is five seven In connection with the issuance of the 2019 and 2021 Cash Convertible Notes, we incurred approximately $13.1 million in transaction costs. We incurred approximately $6.2 million in transaction costs for the 2023 Cash Convertible Notes. For 2024 Cash Convertible Notes, we incurred $5.7 million transaction costs. Such costs have been allocated to the Cash Convertible Notes and deferred and are being amortized to interest expense over the terms of the Cash Convertible Notes using the effective interest method. Interest expense for the years ended December 31, 2020 and 2019 related to the 2027 Notes and the Cash Convertible Notes was comprised of the following: (in thousands) 2020 2019 Coupon interest $ 9,025 $ 9,954 Amortization of original issuance discount 38,229 36,966 Amortization of debt issuance costs 2,942 3,014 Total interest expense $ 50,196 $ 49,934 Cash Convertible Notes Call Spread Overlay Concurrent with the issuance of the Cash Convertible Notes, we entered into privately negotiated hedge transactions (Call Options) with, and issued warrants to purchase shares of our common stock (Warrants) to, certain financial institutions. We refer to the Call Options and Warrants collectively as the “Call Spread Overlay”. The Call Options are intended to offset any cash payments payable by us in excess of the principal amount due upon any conversion of the Cash Convertible Notes. During 2014, we used $105.2 million of the proceeds from the issuance of the 2019 and 2021 Cash Convertible Notes to pay for the Call Options, and simultaneously received $69.4 million from the sale of the Warrants, for a net cash outlay of $35.8 million for the Call Spread Overlay. During 2017, we used $73.7 million of the proceeds from the from the issuance of the 2023 Cash Convertible Notes to pay for the premium for the Call Option, and simultaneously received $45.3 million from the sale of Warrants, for a net cash outlay of $28.3 million for the Call Spread Overlay. A total of $0.4 million in issuance costs were paid in connection with the Warrant and the Call Option. In November 2018, we used $97.3 million of the proceeds from the from the issuance of the 2024 Cash Convertible Notes to pay for the premium for the Call Option, and simultaneously received $72.4 million from the sale of Warrants, for a net cash outlay of $24.9 million for the Call Spread Overlay. A total of $0.9 million in issuance costs were paid in connection with the Warrant and the Call Option. The Call Options are derivative financial instruments and are discussed further in Note 14 "Derivatives and Hedging". The Warrants are equity instruments and are further discussed in Note 18 "Equity". Aside from the initial payment of a premium of $105.2 million (2019 and 2021 Notes), $73.7 million (2023 Notes), and $97.3 million (2024 Notes) for the Call Option, we will not be required to make any cash payments under the Call Options, and will be entitled to receive an amount of cash, generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is initially equal to the conversion price of the Cash Convertible Notes. During 2019, we received $133.2 million in cash upon the exercise of the call options in connection with the repayment of the 2019 Notes. In the same transaction, we paid $132.7 million for the intrinsic value of the 2019 Notes' embedded cash conversion option. The net effect of the cash paid and received of $0.5 million was recognized as a gain in other income, net. In connection with the early conversion of a portion of 2021 Notes during 2019, we received $1.5 million upon the exercise of the related call options. Also, we paid $1.1 million for the intrinsic value of the 2021 Notes' embedded cash conversion option. As a result of these early conversions, a gain of $0.4 million was recognized in other income, net. During 2020, while the 2021 Notes were contingently convertible, we received conversion notices for $119.4 million of outstanding principal. In December 2020, we initiated a tender offer and repurchased a further $177.0 million of outstanding principal. In connection with these transactions, we received $239.8 million in cash upon the exercise of the call options and we paid $237.4 million for the intrinsic value of the 2021 Notes' embedded cash conversion option. The net effect of the cash paid and received of $2.4 million was recognized as a gain in other income, net. Following the completion of the tender offer, $0.2 million of 2021 Notes will remain outstanding and will be repaid or converted at their stated maturity date on March 19, 2021. The Warrants that were issued with our Cash Convertible Notes, could have a dilutive effect to the extent that the price of our common stock exceeds the applicable strike price of the Warrants. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, plus cash in lieu of any fractional shares. We will not receive any proceeds if the Warrants are exercised. U.S. Private Placement In October 16, 2012, we completed a private placement through the issuance of new senior unsecured notes at a total amount of $400.0 million with a weighted average interest rate of 3.66% (settled on October 16, 2012). The notes were issued in three series: (1) $73.0 million 7-year term due and paid on October 16, 2019 (3.19%); (2) $300.0 million 10-year term due on October 16, 2022 (3.75%); and (3) $27.0 million 12-year term due on October 16, 2024 (3.90%). We paid $2.1 million in debt issuance costs which will be amortized through interest expense using the effective interest method over the lifetime of the notes. The note purchase agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on priority indebtedness and the maintenance of certain financial ratios. We were in compliance with these covenants at December 31, 2020. Based on an estimation using the changes in the U.S. Treasury rates, the Level 2 fair value of these senior notes as of December 31, 2020 and 2019 was approximately $337.7 million and $329.2 million, respectively. During 2014, we entered into interest rate swaps, which effectively fixed the fair value of $200.0 million of this debt, which was reduced to $127.0 million following the 2019 $73.0 million repayment. These interest rate swaps qualify for hedge accounting as fair value hedges as described in Note 14 "Derivatives and Hedging". German Private Placement (Schuldschein) In 2017, we completed a German private placement bond ("Schuldschein") which was issued in several tranches totaling $331.1 million due in various periods through 2027. The Schuldschein consists of one U.S. dollar and several Euro denominated tranches. The Euro tranches are designated as a foreign currency non-derivative hedging instrument that qualifies as a net investment hedge as described in Note 14 "Derivatives and Hedging". Based on the spot rate method, the change in the carrying value of the Euro denominated tranches attributed to the net investment hedge as of December 31, 2020 totaled $26.9 million of unrealized loss and is recorded in equity. We paid $1.2 million in debt issuance costs which are being amortized through interest expense over the lifetime of the notes. A summary of the tranches is as follows: Carrying Value (in thousands) as of Currency Notional Amount Interest Rate Maturity December 31, 2020 December 31, 2019 EUR €11.5 million Fixed 0.4% March 2021 $ 14,115 $ 12,905 EUR €23.0 million Floating EURIBOR + 0.4% March 2021 28,224 25,811 EUR €21.5 million Fixed 0.68% October 2022 26,361 24,112 EUR €64.5 million Floating EURIBOR + 0.5% October 2022 79,083 72,335 USD $45.0 million Floating LIBOR + 1.2% October 2022 44,948 44,919 EUR €25.0 million Floating EURIBOR + 0.5% October 2022 30,642 28,026 EUR €64.0 million Fixed 1.09% June 2024 78,429 71,747 EUR €31.0 million Floating EURIBOR + 0.7% June 2024 37,989 34,753 EUR €14.5 million Fixed 1.61% June 2027 17,760 16,249 $ 357,551 $ 330,857 The financial markets regulators in the United Kingdom and the Eurozone have passed regulations that will become effective in 2021 under which LIBOR and EURIBOR in their current form will not be compliant. Market participants and regulators are working on establishing new interest rate benchmarks. While the outcome of this work is not clear yet, the Schuldschein, our syndicated loan facility, and our interest rate swaps continue to make reference to the current LIBOR and EURIBOR benchmark rates. These agreements contain language for the determination of interest rates in case the benchmark rate is not available. However, it appears likely that the agreements will need to be adjusted in line with still to be developed market practice once new benchmark rates become available. Revolving Credit Facility Our credit facilities available and undrawn at December 31, 2020 total €427.0 million (approximately $524.0 million). This includes a €400.0 million syndicated ESG-linked revolving credit facility expiring December 2023 and three other lines of credit amounting to €27.0 million with no expiration date. The €400.0 million facility can be utilized in Euro and bears interest of 0.525% to 1.525% above EURIBOR, and is offered with interest periods of one three

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income (loss) before income taxes for the years ended December 31, 2020, 2019 and 2018 consisted of: (in thousands) 2020 2019 2018 Pretax (loss) income in The Netherlands $ (16,640) $ 17,455 $ (1,675) Pretax income (loss) from foreign operations 456,112 (95,231) 227,412 $ 439,472 $ (77,776) $ 225,737 Income tax expense (benefit) for the years ended December 31, 2020, 2019 and 2018 are as follows: (in thousands) 2020 2019 2018 Current—The Netherlands $ 270 $ 5,670 $ 5,794 —Foreign 86,720 13,371 52,835 86,990 19,041 58,629 Deferred—The Netherlands (6,921) 4,177 2,551 —Foreign 215 (59,539) (25,823) (6,706) (55,362) (23,272) Total income tax expense (benefit) $ 80,284 $ (36,321) $ 35,357 The Netherlands statutory income tax rate was 25% for the years ended December 31, 2020, 2019 and 2018. Income from foreign subsidiaries is generally taxed at the statutory income tax rates applicable in the respective countries of domicile. The principal items comprising the differences between income taxes computed at The Netherlands statutory rate and our effective tax rate for the years ended December 31, 2020, 2019 and 2018 are as follows: 2020 2019 2018 Income taxes at The Netherlands statutory rate 25.0 % 25.0 % 25.0 % Unrecognized tax benefits (1) 8.2 (14.1) 6.0 Valuation allowance (2) (8.1) (26.9) 1.5 Taxation of foreign operations, net (3) (2.1) 33.1 (15.1) Prior year taxes (1.6) (1.4) 0.2 Tax impact from intangible property transfer (0.8) 27.2 — Tax impact from (deductible) nondeductible items (0.8) (10.3) 1.3 Excess tax benefit related to share-based compensation (0.6) 5.1 (2.1) Government incentives and other deductions (4) (0.6) 9.7 (1.2) Changes in tax laws and rates (0.3) (0.4) 0.8 Other items, net 0.0 (0.3) (0.7) Effective tax rate 18.3 % 46.7 % 15.7 % ____________________ (1) During 2020, we analyzed accruals for tax contingencies, primarily related to the potential nondeductibility of the $95.0 million expense reimbursement paid in connection with the unsuccessful acquisition attempt by Thermo Fisher and ongoing income tax audits. (2) Due to increased taxable income and deferred tax liability position in 2020, we released a net $35.6 million valuation allowance primarily related to U.S. disallowed interest. (3) Our effective tax rate reflects the benefit of our global operations where certain income or loss is taxed at rates higher or lower than The Netherlands’ statutory rate of 25% as well as the benefit of some income being partially exempt from income taxes due to various intercompany operating and financing activities. These foreign tax benefits are due to a combination of favorable tax laws, regulations and exemptions in these jurisdictions. Partial tax exemptions exist on foreign income primarily derived from operations in Germany, The Netherlands and Singapore. Further, we have intercompany financing arrangements in which the intercompany income is nontaxable or partially exempt or subject to lower statutory tax rates. During 2020, we had intercompany arrangements through Dubai, and in 2018 through mid-2019 had arrangements through Luxembourg and Ireland. (4) Government incentives include favorable tax regulations in the U.S. relating to research and development expense and other government incentives. We conduct business globally and, as a result, file numerous consolidated and separate income tax returns in The Netherlands, Germany, and the U.S. federal jurisdiction, as well as in various other state and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. Tax years in The Netherlands are potentially open back to 2008 for income tax examinations by tax authorities. The German group is open to audit for the tax years starting in 2014 and in 2019, the German tax authority commenced an audit for the 2014-2016 tax years. The U.S. consolidated group is subject to federal and most state income tax examinations by tax authorities beginning with the year ending December 31, 2017 through the current period. Our other subsidiaries, with few exceptions, are no longer subject to income tax examinations by tax authorities for years before 2016. Changes in the amount of unrecognized tax benefits for the years ended December 31, 2020, 2019, and 2018 are as follows: (in thousands) 2020 2019 2018 Balance at beginning of year $ 58,002 $ 55,780 $ 44,033 Additions based on tax positions related to the current year 31,758 5,770 3,359 Additions for tax positions of prior years 3,560 14,532 11,984 Decrease for tax position of prior years (57) (9,073) — Decrease related to settlements — (7,605) — Decrease due to lapse of statute of limitations (520) (409) (1,238) Increase (decrease) from currency translation 7,349 (993) (2,358) Balance at end of year $ 100,092 $ 58,002 $ 55,780 At December 31, 2020 and 2019, our net unrecognized tax benefits totaled approximately $100.1 million and $58.0 million, respectively, which, if recognized, would favorably affect our effective tax rate in any future period. It is reasonably possible that approximately $38.0 million of the unrecognized tax benefits may be released or utilized during the next 12 months due to lapse of statute of limitations or settlements with tax authorities; however, various events could cause our current expectations to change in the future. The above unrecognized tax benefits, if ever recognized in the financial statements, would be recorded in the statements of income (loss) as part of income tax expense (benefit). Our policy is to recognize interest accrued related to an underpayment of income taxes in interest expense and penalties within income tax expense. For the years ended December 31, 2020, 2019 and 2018, we recognized a net expense for interest and penalties of $1.9 million, $1.6 million and $1.1 million, respectively. At December 31, 2020 and 2019, we have accrued interest of $4.4 million and $2.5 million, respectively, which are not included in the table above. We have recorded net deferred tax assets of $15.7 million and $33.1 million at December 31, 2020 and 2019, respectively. The components of the net deferred tax asset and liability at December 31, 2020 and 2019 are as follows: 2020 2019 (in thousands) Deferred Deferred Deferred Deferred Net operating loss and tax credit carryforward $ 67,856 $ — $ 50,274 $ — Accrued and other liabilities 22,926 — 17,977 — Inventories 3,872 (2,269) 4,726 (1,439) Unrealized gain (loss) on investments — (25,779) — (4,973) Property, plant and equipment 6,099 (23,376) 5,297 (20,332) Intangible assets 2,817 (55,999) 1,078 (26,294) Share-based compensation 18,377 — 13,787 — Disallowed interest carryforwards 42,090 — 73,690 — Convertible notes 6,512 (13,513) 7,104 — Other 9,428 (6,046) 5,998 (6,174) 179,977 (126,982) 179,931 (59,212) Valuation allowance (37,332) — (87,619) — $ 142,645 $ (126,982) $ 92,312 $ (59,212) Net deferred tax assets $ 15,663 $ 33,100 At December 31, 2020, we had $686.3 million in total net operating loss (NOL) carryforwards which included $318.6 million for Germany, $176.4 million for the U.S., $68.5 million for The Netherlands, $49.8 million for Spain, and $73.0 million for other foreign jurisdictions. The NOL carryforwards in Germany and Spain carryforward indefinitely and we expect them to be fully utilized in future years. The entire NOL carryforward in the U.S. is subject to limitations under Section 382 of the U.S. Internal Revenue Code. The NOL carryforwards in the U.S. expire between 2024 and 2034 and in The Netherlands the NOL carryforwards expire between 2026 and 2028. NOL carryforwards of $25.3 million in other foreign jurisdictions expire between 2021 and 2030 while the remainder can be carried forward indefinitely. At December 31, 2020, we had $158.8 million of disallowed interest carryforwards which can be carried forward indefinitely. At December 31, 2020, tax credits total $3.0 million which expire between 2030 and 2039. For the years ended December 31, 2020, 2019 and 2018, the changes in the valuation allowance charged to income tax expense totaled $36.8 million, $19.0 million and $0.8 million, respectively. For the year ended December 31, 2020, the changes in the valuation allowance charged to additional paid in capital totaled $13.5 million. The valuation allowance principally relates to disallowed interest carryforwards and net operating loss carryforwards. The Company can only recognize a deferred tax asset to the extent it is "more likely than not" that these assets will be realized. Judgments around realizability depend on the availability and weight of both positive and negative evidence. As of December 31, 2020, a deferred tax liability has not been recognized for residual income taxes in The Netherlands on the undistributed earnings of the majority of our foreign subsidiaries as these earnings are considered to be either indefinitely reinvested or can be repatriated tax free under the Dutch participation exemption. The indefinitely reinvested earnings retained of our subsidiaries that would be subject to tax if distributed amounted to $538.3 million at December 31, 2020. Estimating the amount of the unrecognized deferred tax liability on indefinitely reinvested foreign earnings is not practicable. Should the earnings be remitted as dividends, we may be subject to taxes including withholding tax. We have $28.1 million of undistributed earnings that we do not consider indefinitely reinvested and have recorded a deferred tax liability at December 31, 2020 and 2019, of $1.6 million and $1.5 million, respectively.

Equity

Equity	12 Months Ended
Equity	Dec. 31, 2020
Equity [Abstract]
Equity	Equity Shares The authorized classes of our shares consist of Common Shares (410 million authorized), Preference Shares (450 million authorized) and Financing Preference Shares (40 million authorized). All classes of shares have a par value of €0.01. No Financing Preference Shares or Preference Shares have been issued. Like all shareholders' equity accounts, common shares are translated to U.S. dollars at the foreign exchange rates in effect when the shares are issued. Issuance and Conversion of Warrants In connection with the issuance of the Cash Convertible Notes as described in Note 16 "Debt", we issued Warrants as summarized in the table below. The number of warrants and exercise prices are subject to customary adjustments under certain circumstances. The proceeds, net of issuance costs, from the sale of the Warrants are included as additional paid in capital in the accompanying consolidated balance sheets. The Warrants are exercisable only upon expiration. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of any fractional shares. The Warrants could separately have a dilutive effect on shares of our common stock to the extent that the market value per share of our common stock exceeds the applicable exercise price of the Warrants (as measured under the terms of the Warrants). Cash convertible notes Issued on Number of share warrants issued Exercise price per share Proceeds from issuance of warrants, net of issuance costs (in millions) Warrants expire over a period of 50 trading days beginning on 2019 March 19, 2014 15.2 $32.0560 $40.6 December 27, 2018 2021 March 19, 2014 10.6 $32.0560 $28.3 December 29, 2020 2023 September 13, 2017 9.7 $50.9664 $45.3 June 26, 2023 2024 November 13, 2018 10.9 $52.1639 $72.4 August 27, 2024 During 2020, 0.8 million common shares were issued in connection with the early conversion of 4.2 million warrants related to the 2021 Notes which resulted in a $7.5 million decrease to additional paid in capital, a $22.7 million decrease in retained earnings, and a decrease of $30.3 million in treasury shares. The remaining warrants related to the 2021 Notes of 6.3 million were terminated in 2020, resulting in a cash payment of $174.6 million, a $30.3 million decrease to additional paid in capital and a $144.3 million decrease in retained earnings. During 2019, 2.1 million common shares were issued in connection with the conversion of the 15.2 million warrants related to the 2019 Notes which resulted in a $31.1 million decrease to additional paid in capital, a $37.7 million decrease in retained earnings, a decrease of $68.8 million in treasury shares and an approximately $4 thousand cash payment for fractional shares. Share Repurchase Programs On May 6, 2019, we announced our sixth share repurchase program of up to $100 million of our common shares. During 2020, we repurchased 1.3 million QIAGEN shares for $64.0 million (including transaction costs). This program ended on December 17, 2020. On January 31, 2018, we announced our fifth share repurchase program of up to $200 million of our common shares. During 2018, we repurchased 2.9 million QIAGEN shares for $104.7 million (including transaction costs). During 2019, we repurchased 2.0 million QIAGEN shares for $74.5 million (including transaction costs), bringing the total shares repurchased under this program to 4.9 million for $179.1 million (including transaction costs). This program ended on June 30, 2019. The cost of repurchased shares is included in treasury stock and reported as a reduction in total equity when a repurchase occurs. Repurchased shares will be held in treasury in order to satisfy various obligations, which include exchangeable debt instruments, warrants and employee share-based remuneration plans. Accumulated Other Comprehensive Loss The following table is a summary of the components of accumulated other comprehensive loss as of December 31, 2020 and 2019: (in thousands) 2020 2019 Net unrealized loss on hedging contracts, net of tax $ (23,268) $ (2,289) Net unrealized loss on pension, net of tax (599) (561) Foreign currency effects from intercompany long-term investment transactions, net of tax of $10.7 million and $9.7 million in 2020 and 2019, respectively (25,717) (22,587) Foreign currency translation adjustments (194,238) (284,182) Accumulated other comprehensive loss $ (243,822) $ (309,619)

Earnings per Common Share

Earnings per Common Share	12 Months Ended
Earnings per Common Share	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share We present basic and diluted earnings per share. Basic earnings per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that would occur if all “in the money” securities to issue common shares were exercised. The following schedule summarizes the information used to compute earnings per common share for the years ended December 31, 2020, 2019 and 2018: (in thousands, except per share data) 2020 2019 2018 Net income (loss) $ 359,188 $ (41,455) $ 190,380 Weighted average number of common shares used to compute basic net income per common share 228,427 226,777 226,640 Dilutive effect of stock options and restrictive stock units 3,350 — 4,613 Dilutive effect of outstanding warrants 2,437 — 2,203 Weighted average number of common shares used to compute diluted net income per common share 234,214 226,777 233,456 Outstanding options and awards having no dilutive effect, not included in above calculation 11 107 272 Outstanding warrants having no dilutive effect, not included in above calculation 26,438 32,938 35,939 Basic earnings (loss) per common share $ 1.57 $ (0.18) $ 0.84 Diluted earnings (loss) per common share $ 1.53 $ (0.18) $ 0.82 For purposes of considering the 2027 Notes in determining diluted earnings (loss) per common share, only an excess of the conversion value over the principal amount would have a dilutive impact using the treasury stock method. Since the 2027 Notes were out of the money and anti-dilutive during the period from December 17, 2020 through December 31, 2020, they were excluded from the diluted earnings (loss) per common share calculation in 2020.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Licensing and Purchase Commitments We have licensing agreements with companies, universities and individuals, some of which require certain up-front payments. Royalty payments are required on net product sales ranging from 0.45 percent to 25 percent of covered products or based on quantities sold. Several of these agreements have minimum royalty requirements. The accompanying consolidated balance sheets include accrued royalties relating to these agreements in the amount of $7.4 million and $5.5 million at December 31, 2020 and 2019, respectively. Royalty expense relating to these agreements amounted to $12.2 million, $13.5 million, and $14.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. Royalty expense is primarily recorded in cost of sales, with a small portion recorded as research and development expense depending on the use of the technology under license. Some of these agreements also have minimum raw material purchase requirements and requirements to perform specific types of research. At December 31, 2020, we had commitments to purchase goods or services, and for future license and royalty payments. They are as follows: Years ending December 31, (in thousands) Purchase License & Royalty 2021 $ 199,843 $ 10,003 2022 42,628 7,217 2023 5,364 4,483 2024 3,000 2,623 2025 — 2,349 Thereafter — 3,364 $ 250,835 $ 30,039 As of December 31, 2020, $28.4 million of the total purchase commitments are with companies in which we hold an interest and are considered related parties. Contingent Consideration Commitments Pursuant to the purchase agreements for certain acquisitions and other contractual arrangements, we could be required to make additional contingent cash payments totaling up to $26.6 million based on the achievement of certain revenue and operating results milestones as follows: Years ending December 31, (in thousands) 2021 $ 8,850 2022 17,700 $ 26,550 Of the $26.6 million total contingent obligation as discussed further in Note 9 "Financial Instruments and Fair Value Measurements," we have assessed the fair value at December 31, 2020 to be $23.6 million which is included in accrued and other current liabilities in the accompanying consolidated balance sheet. Employment Agreements Certain of our employment contracts contain provisions which guarantee the payments of certain amounts in the event of a change in control, as defined in the agreements, or if the executive is terminated for reasons other than cause, as defined in the agreements. At December 31, 2020, the commitment under these agreements totaled $21.2 million. Contingencies In the ordinary course of business, we provide a warranty to customers that our products are free of defects and will conform to published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. We provide for estimated warranty costs at the time of the product sale. The changes in the carrying amount of warranty obligations for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 3,141 $ 2,848 Provision charged to cost of sales 5,645 3,229 Usage (3,978) (2,921) Adjustments to previously provided warranties, net (125) (1) Currency translation 130 (14) Balance at end of year $ 4,813 $ 3,141 Litigation From time to time, we may be party to legal proceedings incidental to our business. As of December 31, 2020, certain claims, suits or legal proceedings arising out of the normal course of business have been filed or were pending against QIAGEN or our subsidiaries. These matters have arisen in the ordinary course and conduct of business, as well as through acquisition. Although it is not possible to predict the outcome of such litigation, we assess the degree of probability and evaluate the reasonably possible losses that we could incur as a result of these matters. We accrue for any estimated loss when it is probable that a liability has been incurred and the amount of probable loss can be estimated.

Segment Information

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2020
Segment Reporting Information, Additional Information [Abstract]
Segment Information	Segment Information We operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting . We have a common basis of organization and our products and services are offered globally. Considering the acquisitions made during 2020 and our continued restructuring and streamlining of the growing organization, our chief operating decision maker (CODM) continues to make decisions with regards to business operations and resource allocation based on evaluations of QIAGEN as a whole. Accordingly, we operate and make decisions as one business segment. Product category and geographic information follows below. Product Category Information Net sales for the product categories are attributed based on those revenues related to sample and assay products and similarly related revenues including bioinformatics solutions, and revenues derived from instrumentation sales. Refer to Note 4 "Revenue" for disaggregation of revenue based on product categories and customer class. Geographical Information Net sales are attributed to countries based on the location of the customer. QIAGEN operates manufacturing facilities in Germany, China, and the United States that supply products to customers as well as QIAGEN subsidiaries in other countries. The intersegment portions of such net sales are excluded to derive consolidated net sales. No single customer represents more than ten percent of consolidated net sales. Our country of domicile is The Netherlands, which reported net sales of $17.8 million, $15.8 million and $15.9 million for the years ended 2020, 2019 and 2018, respectively, and these amounts are included in the line item Europe, Middle East and Africa as shown in the table below. Net sales (in thousands) 2020 2019 2018 Americas: United States $ 728,577 $ 663,869 $ 632,660 Other Americas 96,880 58,121 60,359 Total Americas 825,457 721,990 693,019 Europe, Middle East and Africa 682,289 487,476 490,301 Asia Pacific, Japan and Rest of World 362,600 316,958 318,528 Total $ 1,870,346 $ 1,526,424 $ 1,501,848 Long-lived assets include property, plant and equipment. The Netherlands, which is included in the balances for Europe, reported long-lived assets of $1.5 million and $1.3 million as of December 31, 2020 and 2019, respectively. Long-lived assets (in thousands) 2020 2019 Americas: United States $ 154,843 $ 147,027 Other Americas 2,436 3,507 Total Americas 157,279 150,534 Europe, Middle East and Africa: Germany 304,571 229,225 Other Europe, Middle East and Africa 71,444 49,004 Total Europe, Middle East and Africa 376,015 278,229 Asia Pacific and Japan 26,078 26,480 Total $ 559,372 $ 455,243

Share-Based Compensation

Share-Based Compensation	12 Months Ended
Share-Based Compensation	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Share-Based Compensation	Share-Based Compensation We adopted the QIAGEN N.V. Amended and Restated 2005 Stock Plan (the 2005 Plan) in 2005 and the QIAGEN N.V. 2014 Stock Plan (the 2014 Plan) in 2014. The 2005 Plan expired by its terms in April 2015 and no further awards will be granted under the 2005 Plan. The plans allow for the granting of stock rights and incentive stock options, as well as non-qualified options, stock grants and stock-based awards, generally with terms of up to 5 or 10 years, subject to earlier termination in certain situations. The vesting and exercisability of certain stock rights will be accelerated in the event of a Change of Control, as defined in the plans. All option grants have been at the market value on the grant date or at a premium above the closing market price on the grant date. We issue Treasury Shares to satisfy option exercises and award releases and had approximately 14.4 million Common Shares reserved and available for issuance under the 2005 and 2014 Plans at December 31, 2020. Stock Options We have not granted stock options since 2013. A summary of the status of employee stock options as of December 31, 2020 and changes during the year then ended is presented below: All Employee Options Number of Shares (in thousands) Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding at January 1, 2020 792 $ 20.06 Exercised (365) $ 20.97 Outstanding at December 31, 2020 427 $ 19.28 1.25 $ 14,338 Vested at December 31, 2020 427 $ 19.28 1.25 $ 14,338 Vested and expected to vest at December 31, 2020 427 $ 19.28 1.25 $ 14,338 The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was $6.5 million, $2.0 million and $5.0 million, respectively. The actual tax benefit for the tax deductions from option exercises totaled $1.3 million, $0.5 million, and $0.8 million during the years ended December 31, 2020, 2019 and 2018, respectively. At December 31, 2020, there was no unrecognized share-based compensation expense related to employee stock option awards. At December 31, 2020, 2019 and 2018, 0.4 million, 0.8 million and 0.9 million options were exercisable at a weighted average price of $19.28, $20.06 and $20.04 per share, respectively. The options outstanding at December 31, 2020 expire in various years through 2023. Stock Units Stock units represent rights to receive Common Shares at a future date and include restricted stock units which are subject to time-vesting only and performance stock units which include performance conditions in addition to time-vesting. The final number of performance stock units earned is based on the performance achievement which for some grants can reach up to 200% of the granted shares. There is no exercise price and the fair market value at the time of the grant is recognized over the requisite vesting period, generally up to 5 or 10 years. The fair market value is determined based on the number of stock units granted and the market value of our shares on the grant date. Pre-vesting forfeitures were estimated to be approximately 6.2%. At December 31, 2020, there was $73.1 million remaining in unrecognized compensation cost including estimated forfeitures related to these awards, which is expected to be recognized over a weighted average period of 2.25 years. The weighted average grant date fair value of stock units granted during the years ended December 31, 2020, 2019 and 2018 was $36.92, $37.28 and $35.37, respectively. The total fair value of stock units that vested during the years ended December 31, 2020, 2019 and 2018 was $29.3 million, $123.9 million and $54.3 million, respectively. A summary of stock units as of December 31, 2020 and changes during the year are presented below: Stock Units Stock Units Weighted Average Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2020 5,183 Granted 1,035 Vested (720) Forfeited (365) Outstanding at December 31, 2020 5,133 2.25 $ 261,458 Vested and expected to vest at December 31, 2020 3,881 2.02 $ 205,097 Beginning in 2019, we began net share settlement for the tax withholding upon the vesting of awards. Shares are issued on the vesting dates net of the applicable statutory tax withholding to be paid by us on behalf of our employees. As a result, fewer shares are issued than the number of stock units outstanding. We record a liability for the tax withholding to be paid by us as a reduction to treasury shares. Compensation Expense Share-based compensation expense before taxes for the years ended December 31, 2020, 2019 and 2018 totaled approximately $40.9 million, $65.9 million and $40.1 million, respectively, as shown in the table below. (in thousands) 2020 2019 2018 Cost of sales $ 2,897 $ 2,493 $ 2,879 Research and development 7,014 5,810 6,457 Sales and marketing 15,889 7,947 9,372 General and administrative 15,136 23,705 21,405 Restructuring, acquisition, integration and other, net — 25,938 — Share-based compensation expense 40,936 65,893 40,113 Less: income tax benefit (1) 9,552 12,153 8,277 Net share-based compensation expense $ 31,384 $ 53,740 $ 31,836 (1) Does not include the excess tax benefit realized for the tax deductions of the share-based payment arrangements which totaled $2.5 million, $4.0 million and $4.7 million, respectively, for the years ended December 31, 2020, 2019 and 2018. Share-based compensation expense includes amounts related to the restructuring programs discussed in Note 6 "Restructuring and Impairments", including accelerated expense in 2019. No share-based compensation costs were capitalized for the years ended December 31, 2020, 2019 or 2018 as the amounts were not material.

Employee Benefits

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2020
Retirement Benefits, Description [Abstract]
Employee Benefits	Employee BenefitsWe maintain various benefit plans, including defined contribution and defined benefit plans. Our U.S. defined contribution plan is qualified under Section 401(k) of the Internal Revenue Code, and covers substantially all U.S. employees. Participants may contribute a portion of their compensation not exceeding a limit set annually by the Internal Revenue Service. This plan includes a provision for us to match a portion of employee contributions. Total expense under the 401(k) plans, including the plans acquired via business acquisitions, was $3.6 million, $4.0 million and $4.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. We also have a defined contribution plan which covers certain executives. We make matching contributions up to an established maximum. Matching contributions made to the plan, and expensed, totaled approximately $0.2 million in each of the years ended December 31, 2020, 2019 and 2018. We have five defined benefit, non-contributory retirement or termination plans that cover certain employees in Germany, France, Japan, Italy and the United Arab Emirates. These defined benefit plans provide benefits to covered individuals satisfying certain age and/or service requirements. For certain plans, we calculate the vested benefits to which employees are entitled if they separate immediately. The benefits accrued on a pro-rata basis during the employees’ employment period are based on the individuals’ salaries, adjusted for inflation. The liability under the defined benefit plans was $9.3 million at December 31, 2020 and $8.2 million at December 31, 2019, and is included as a component of other long-term liabilities on the accompanying consolidated balance sheets.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions From time to time, we have transactions with other companies in which we hold an interest, all of which are individually and in the aggregate immaterial, as summarized in the table below. Net sales to related parties for the years ended December 31, 2020, 2019, and 2018 are as follows: (in thousands) 2020 2019 2018 Net sales $ 6,025 $ 20,002 $ 23,358 Net sales with related parties primarily reflects our ventures in China including our partnership to externalize the HPV test franchise for cervical cancer screening in China as well as our joint venture with Sichuan Maccura Biotechnology Co., Ltd which was terminated in conjunction with the 2019 restructuring activities discussed further in Note 6 "Restructuring and Impairments" which also details related party restructuring charges. As of December 31, 2020 and 2019 balances with related parties are as follows: (in thousands) 2020 2019 Accounts receivable $ 3,961 $ 7,589 Prepaid expenses and other current assets $ 25,429 $ 13,697 Other long-term assets $ 9,594 $ 16,830 Accounts payable $ 4,050 $ 1,775 Accrued and other current liabilities $ 1,380 $ 15,404 Prepaid expenses and other current assets include supplier advances from companies with which we have an investment or partnership interest. As of December 31, 2019, this also included short-term loan receivables that were collected during 2020. During 2018, we purchased a convertible note for $15.0 million from a privately held company due in December 2021. During 2020, we purchased an additional convertible note from the same company for $10.0 million due in August 2023. Both notes bear interest at 8%. In the event the company goes public, the notes will convert into common shares in the company ranking pari passu with existing common shares. As of December 31, 2020, $17.1 million is included in prepaid expenses and other current assets and $9.0 million is included in other long-term assets in the accompanying consolidated balance sheets related to the principal, accrued interest and allowance for credit loss upon adoption of ASC 326 on January 1, 2020. As of December 31, 2019, $16.3 million is included in other long-term assets related to the principal and accrued interest due from this company related to the convertible note.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II QIAGEN N.V. AND SUBSIDIARIES SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018 (in thousands) Balance at Charged to Costs and Deductions Foreign Exchange and Other (1) Balance at Year Ended December 31, 2018: Allowance for doubtful accounts $ 8,008 $ 4,448 $ (2,827) $ (359) $ 9,270 Year Ended December 31, 2019: Allowance for doubtful accounts $ 9,270 $ 8,701 $ (5,777) $ (79) $ 12,115 Year Ended December 31, 2020: Allowance for credit losses $ 12,115 $ 17,764 $ (13,784) $ 20,089 $ 36,184 (2) On January 1, 2020, we adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments on a modified retrospective basis. Allowance for credit losses includes allowances for accounts receivable, loans receivable and other receivables for the year ended December 31, 2020 (1) Includes the ASC 326 adoption impact of $19.6 million in the year ended December 31, 2020. (2) Of this amount, $1.2 million in 2020 is classified as long-term.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and all amounts are presented in U.S. dollars rounded to the nearest thousand, unless otherwise indicated. The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments, contingent consideration and available-for-sale financial instruments that have been measured at fair value. We undertake acquisitions to complement our own internal product development activities. In September 2020, we completed the acquisition of the remaining shares in NeuMoDx Molecular, Inc ("NeuMoDx"), a privately-held U.S. company that designs and develops molecular diagnostics solutions for hospital and clinical reference laboratories. In 2019, we completed three immaterial acquisitions, including the January 2019 acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. In April 2018, we acquired all shares in STAT-Dx Life, S.L. ("STAT-Dx"), a privately-held company located in Barcelona, Spain and also completed the acquisition of the remaining shares of a privately held entity in which we held a minority interest. Accordingly, at their respective acquisition dates, all the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include the operating results from the acquired companies from the acquisition date. Certain prior year amounts have been reclassified to conform to the current year presentation.
Adoption of New Accounting Standards and New Accounting Standards Not Yet Adopted	The following new Financial Accounting Standards Board (FASB) Accounting Standards Updates (ASU) were adopted in 2020, 2019 and 2018: Adoption of New Accounting Standards in 2020 ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in ASU 2016-13 replace the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The measurement of expected credit losses under Topic 326 is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. In addition, Topic 326 made changes to the accounting for available-for-sale debt securities. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell or believes is more likely than not they will be required to sell. We adopted Topic 326 on January 1, 2020 using the modified retrospective approach by recognizing the effect of initially applying Topic 326 as an after-tax $15.1 million ($19.6 million pre-tax) adjustment to the opening balance of retained earnings at January 1, 2020 for credit losses on loans, notes and accounts receivable. The adoption did not have an impact on our consolidated statements of income or cash flows. ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer of that transaction. The guidance amends ASC 808 to refer to unit-of-account guidance in ASC 606 and requires it to be used only when assessing whether a transaction is in the scope of ASC 606. ASU 2018-18 is effective for us for annual periods beginning on January 1, 2020. Entities are required to apply the amendments retrospectively to the date they initially applied ASC 606. We adopted ASU 2018-18 on January 1, 2020 without any cumulative effect. ASU 2020-03, Codification Improvements to Financial Instruments, was issued to improve and clarify various financial instrument topics, including Topic 326 issued in 2016. The ASU includes seven issues that describe areas of improvement and the related amendments to GAAP. They are intended to make the standards easier to understand and apply and to eliminate inconsistencies. They are narrow in scope and are not expected to significantly change practice for most entities. The amendments have different effective dates with early adoption permitted. We adopted ASU 2020-03 on January 1, 2020 without any effect. ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 , addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. The ASU is effective on January 1, 2021. Early adoption is permitted, including early adoption in an interim period. We adopted ASU 2020-01 on June 30, 2020 without any impact. Adoption of New Accounting Standards in 2019 The FASB issued guidance codified in Accounting Standards Codification (ASC) Topic 842, Leases (Topic 842), which supersedes the lease requirements in ASC Topic 840 and aims to increase transparency and comparability among organizations and requires disclosure of key information about leasing arrangements. The main principle of ASC 842 requires lessees to recognize the assets and liabilities that arise from nearly all leases on the consolidated balance sheet. Lessor accounting remains mainly consistent with the former guidance, with the majority of changes allowing for better alignment with the new lessee model and ASC Topic 606. We adopted these standards as per the effective date of January 1, 2019, using the modified retrospective approach and did not restate comparative periods. Under this approach, the cumulative effect of initially applying the standard was recognized as an adjustment to the opening balance of retained earnings on the date of initial application. As a lessee, the classification of our leases did not change, but we recognized a lease liability and corresponding right-of-use asset on our consolidated balance sheets for all our operating leases. We have elected the package of practical expedients which allows us to not reassess (1) whether existing contracts contain leases, (2) the lease classification for existing leases, and (3) whether existing initial direct costs meet the new definition. We also elected the hindsight practical expedient which permits entities to use hindsight in determining the lease term when transitioning to ASC 842. Our initial lease liabilities and right-of-use assets totaled $57.7 million and $57.4 million, respectively, as recorded in our consolidated balance sheet as of January 1, 2019, primarily relating to leased office space. The difference between the additional lease assets and lease liabilities was recorded as a $0.3 million adjustment to retained earnings. Further disclosure is found in Note 12 "Leases". ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new guidance became effective for public entities beginning on January 1, 2019 by applying a modified retrospective approach to existing hedging relationships as of the adoption date. Under the modified retrospective approach, entities with cash flow or net investment hedges will make (1) a cumulative-effect adjustment to accumulated other comprehensive income so that the adjusted amount represents the cumulative change in the hedging instruments’ fair value since hedge inception (less any amounts that should have been recognized in earnings under the new accounting model) and (2) a corresponding adjustment to opening retained earnings as of the most recent period presented on the date of adoption. We adopted ASU 2017-12 on January 1, 2019 without any cumulative effect. ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , removes Step 2 of the goodwill impairment test. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for public entities for annual periods beginning January 1, 2020 and early adoption is permitted. The new guidance is required to be applied on a prospective basis. We adopted ASU 2017-04 on January 1, 2019 and applied the new guidance prospectively as required. ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework, provides guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements . ASU 2018-13 is effective for public entities for annual periods beginning January 1, 2020. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We adopted ASU 2018-13 on January 1, 2019 and applied the entire standard to disclosures as required beginning in 2019. ASU 2018-15, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, provides guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor, i.e. a service contract. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for public entities for annual periods beginning January 1, 2020, and early adoption is permitted and should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted ASU 2018-15 on January 1, 2019 and applied the guidance to all implementation costs prospectively. ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities, amends how a decision maker or service provider determines whether its fee is a variable interest entity (VIE) when a related party under common control also has an interest in the VIE. We adopted ASU 2018-17 on January 1, 2019, on a prospective basis. Adoption of New Accounting Standards in 2018 ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and additional related accounting standard updates to clarify and provide implementation guidance were adopted with a date of initial application of January 1, 2018. The comparative information for 2017 has not been adjusted and continues to be reported under ASC Topic 605 Revenue Recognition. As a result, we changed our accounting policy for revenue recognition. We applied the Topic 606 using the "modified retrospective method" by recognizing the effect of initially applying Topic 606 as an $1.3 million decrease to the opening balance of retained earnings at January 1, 2018, for all contracts not completed at January 1, 2018. ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities as well as an additional clarifying accounting standard update became effective for our financial statements beginning in the first quarter of 2018. This ASU makes targeted improvements to existing U.S. GAAP for both the recognition and measurement of financial assets and financial liabilities. Changes in accounting to our equity investments as a result of this standard are further discussed in Notes below. As required, we adopted using a cumulative-effect adjustment to the balance sheet as of the beginning of 2018 and recorded an adjustment to decrease opening retained earnings at January 1, 2018 by $0.9 million (pre-tax $1.1 million) as required for our equity investments recorded at fair value. ASU 2016-05, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments and ASU 2016-18, Statement of Cash Flows (Topic 320): Restricted Cash, addresses classification issues and presentation related to the statement of cash flows and was adopted on January 1, 2018 without any impact from the adoption. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, aims to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. This standard was adopted on a modified retrospective basis resulting in a decrease to opening retained earnings of $16.1 million at January 1, 2018. ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , clarifies and provides a more robust framework to use in determining when a set of assets and activities is a business. We adopted this update beginning January 1, 2018, without impact. ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , clarifies when to account for a change to the terms and conditions of a share-based payment award as a modification. This guidance is effective prospectively and was adopted as of January 1, 2018. ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, permits reclassification of stranded tax effects of the U.S. Tax Cuts and Jobs Act (Tax Act). We adopted this standard as of April 1, 2018 with no impact as we had no stranded tax effects. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, we reclassify the tax effects to the consolidated statement of income (loss) on an item-by-item basis when the pre-tax item in accumulated other comprehensive income (loss) is reclassified to income. ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , aligns most of the accounting for share-based payment awards issued to employees and non-employees. We early adopted this standard as of July 1, 2018, without material impact. New Accounting Standards Not Yet Adopted The following new FASB Accounting Standards Updates, which are not yet adopted as of December 31, 2020, have been grouped by their required effective dates or early adoption date: First Quarter of 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod tax allocations and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating income taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods beginning on January 1, 2021, with earlier adoption permitted. We adopted the ASU on the effective date of January 1, 2021 and the adoption of this guidance did not have an impact on our consolidated financial statements on the date of adoption. Ultimately, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , reduces the number of accounting models for convertible instruments. The ASU also amends diluted earnings per share (EPS) calculations for convertible instruments, which will result in more dilutive EPS results. The ASU also amends the requirements for a contract (or embedded derivative) that is potentially settled in an entity’s own shares to be classified in equity. ASU 2020-06 is effective for annual periods beginning on January 1, 2022, with earlier adoption on January 1, 2021 permitted. We early adopted ASU 2020-06 on January 1, 2021 and as a result reclassified $54.1 million from equity for the conversion feature to the liability for our 2027 Convertible Notes further discussed in Note 16 "Debt". Through December 31, 2022 ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and ASU 2021-01 Reference Rate Reform (Topic 848): Scope, provide companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. Companies can apply the ASU immediately. However, the guidance will only be available for a limited time, generally through December 31, 2022. We continue to evaluate the guidance.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of QIAGEN N.V. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Investments in either common stock or in-substance common stock of companies where we exercise significant influence over the operations but do not have control, and where we are not the primary beneficiary, are accounted for using the equity method. All other investments are accounted for as discussed under
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentrations of Risk	Concentrations of Risk We buy materials for products from many suppliers, and are not dependent on any one supplier or group of suppliers for the business as a whole. However, key components of certain products, including certain instrumentation components and chemicals, are available only from a single source. If supplies from these vendors were delayed or interrupted for any reason, we may not be able to obtain these materials timely or in sufficient quantities in order to produce certain products and sales levels could be negatively affected. Additionally, our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories. Fluctuations in the research and development budgets of these researchers and their organizations for applications in which our products are used could have a significant effect on the demand for our products. The financial instruments used in managing our foreign currency, equity and interest rate exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated international financial institutions. The carrying values of our financial instruments incorporate the non-performance risk by using market pricing for credit risk. However, we have no reason to believe that any counterparties will default on their obligations. In order to minimize our exposure with any single counterparty, we have entered into master agreements which allow us to manage the exposure with the respective counterparty on a net basis. Other financial instruments that potentially subject us to concentrations of credit risk are cash and cash equivalents, short-term investments, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and short-term investments by dealing with highly-rated financial institutions and investing in a broad and diverse range of financial instruments. We have established guidelines related to credit quality and maturities of investments intended to maintain safety and liquidity. Concentration of credit risk with respect to accounts receivable is limited due to a large and diverse customer base, which is dispersed over different geographic areas. Allowances are maintained for potential credit losses and such losses have historically been within expected ranges.
Foreign Currency Translation	Foreign Currency TranslationOur reporting currency is the U.S. dollar and the functional currencies of our subsidiaries are generally the local currency of the respective countries in which they are headquartered. All amounts in the financial statements of entities whose functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows: (1) assets and liabilities at period-end rates, (2) income statement accounts at average exchange rates for the period, and (3) components of equity at historical rates. Translation gains or losses are recorded in equity, and transaction gains and losses are reflected in net income (loss) as a component of other income, net. Realized gains or losses on the value of derivative contracts entered into to hedge the exchange rate exposure of receivables and payables are also included in net income (loss) as a component of other income, net.
Segment Information	Segment Information We determined that we operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting
Warranty	WarrantyWe provide warranties on our products against defects in materials and workmanship for a period of one year. A provision for estimated future warranty costs is recorded in cost of sales at the time product revenue is recognized. Product warranty obligations are included in accrued and other current liabilities in the accompanying consolidated balance sheets.
Research and Development	Research and Development Research and product development costs are expensed as incurred. Research and development expenses consist primarily of salaries and related expenses, facility costs, and amounts paid to contract research organizations and laboratories for the provision of services and materials as well as costs for internal use or clinical trials.
Government Grants	Government Grants We recognize government grants when there is reasonable assurance that all conditions will be complied with and the grant will be received. Our government grants generally represent subsidies for specified activities and are therefore recognized when earned as a reduction of the expenses recorded for the activity that the grants are intended to compensate. Thus, when the grant relates to research and development expense, the grant is recognized over the same period that the related costs are incurred. Otherwise, amounts received under government grants are recorded as liabilities in the balance sheet. When the grant relates to an asset, the nominal amount of the grant is deducted from the carrying amount of the asset and recognized over the same period that the related asset is depreciated.
Borrowing Costs	Borrowing CostsBorrowing costs directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets (qualifying asset) when such borrowing costs are significant. All other borrowing costs are expensed in the period they occur.
Revenue Recognition and Shipping and Handling Income and Costs	Revenue Recognition We recognize revenue when control of promised goods or services transfers to our customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The majority of our sales revenue is recognized when products are shipped to the customers at which point control transfers.
Advertising Costs	Advertising CostsThe costs of advertising are expensed as incurred and are included as a component of sales and marketing expense.
General and Administrative, Restructuring, Integration and Other	General and Administrative General and administrative expenses primarily represent the costs required to support administrative infrastructure. These costs include licensing costs in connection with continued investments in information technology improvements, including cyber security, across the organization as well as personnel in administrative functions. Restructuring, Acquisition, Integration and Other We incur indirect acquisition and business integration costs in connection with business combinations which are expensed when incurred. These costs represent incremental costs that we believe would not have been incurred absent the business combinations. Major components of these costs include consulting and related fees incurred to integrate or restructure the acquired operations, payroll and related costs for employees remaining with the Company on a transitional basis and public relations, advertising and media costs for re-branding of the combined organization. Restructuring costs include personnel costs (principally termination benefits) as well as contract and other costs, primarily contract termination costs. Termination benefits are accounted for in accordance with FASB ASC Topic 712, Compensation - Nonretirement Postemployment Benefits, and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits, the similarity of benefits under the current plan and prior plans, and the existence of statutory required minimum benefits. Contract and other costs are accounted for in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations
Income Taxes	Income Taxes We account for income taxes under the liability method. Under this method, total income tax expense is the amount of income taxes expected to be payable for the current year plus the change from the beginning of the year for deferred income tax assets and liabilities established for the expected future tax consequences resulting from differences in the financial statement carrying amount and the tax basis of assets and liabilities. Deferred tax assets and/or liabilities are determined by multiplying the differences between the financial statement carrying amount and the tax reporting bases for assets and liabilities by the enacted tax rates expected to be in effect when such differences are recovered or settled. Deferred tax assets are reduced by a valuation allowance to the amount more likely than not to be realized. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Tax benefits are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement with the taxing authority using the cumulative probability method, assuming the tax authority has full knowledge of the position and all relevant facts. Our policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties within the income tax expense.
Derivative Instruments	Derivative Instruments We enter into derivative financial instrument contracts to minimize the variability of cash flows or income statement impact associated with the anticipated transactions being hedged or to hedge fluctuating interest rates. As changes in foreign currency or interest rate impact the value of anticipated transactions, the fair value of the forward or swap contracts also changes, offsetting foreign currency or interest rate fluctuations. Derivative instruments are recorded on the balance sheet at fair value. Changes in fair value of derivatives are recorded in current earnings or other comprehensive income, depending on whether a derivative is designated as part of a hedge transaction.
Share-Based Payments	Share-Based Payments Compensation cost for all share-based payments is recorded based on the grant date fair value, less an estimate for pre-vesting forfeitures, recognized in expense over the service period using an accelerated method. Forfeiture Rate— This is the estimated percentage of grants that are expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimated the forfeiture rate based on historical forfeiture experience.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents consist of cash on deposit in banks and other cash invested temporarily in various instruments that are short-term and highly liquid, and having an original maturity of less than 90 days at the date of purchase.
Restricted Cash	Restricted CashRestricted cash includes cash that is subject to legal restriction in connection with a tender offer and not available for general operating purposes.
Short Term Investments	Short-Term Investments Short-term investments consisting of marketable equity securities are reported at fair value with gains and losses recorded in earnings. Short-term investments consisting of cash investments are classified as “available for sale” and stated at fair value, which is equivalent to the amortized cost, in the accompanying consolidated balance sheet. Interest income is accrued when earned and changes in fair market values are reflected in other income, net. The amortization of premiums and accretion of discounts to maturity arising from acquisition is included in interest income. A decline in fair value that is judged to be other-than-temporary is accounted for as a realized loss and the write-down is included in the consolidated statements of income. Realized gains and losses, determined on a specific identification basis on the sale of short-term investments, are included in income.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amount of cash and cash equivalents, notes receivable, accounts receivable, accounts payable and accrued liabilities approximate their fair values because of the short maturities of those instruments. The carrying value of our variable rate debt and leases approximates their fair values because of the short maturities and/or interest rates which are comparable to those available to us on similar terms. The fair values of the zero coupon convertible debt and the Cash Convertible Notes are based on an estimation using available over-the-counter market information. The fair values of the Private Placement Senior Notes were estimated using the changes in the U.S. Treasury rates and the fair value of the German Private Placement is based on an estimation using changes in the euro swap rates. Assets and liabilities are measured at fair value according to a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1. Observable inputs, such as quoted prices in active markets; Level 2. Inputs, other than the quoted price in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Our assets and liabilities measured at fair value on a recurring basis consist of marketable securities discussed in Note 10 "Investments", which are classified in Level 1, short-term investments, which are classified in Level 2 of the fair value hierarchy, derivative contracts used to hedge currency and interest rate risk and derivative financial instruments entered into in connection with the Cash Convertible Notes discussed in Note 16 "Debt", which are classified in Level 2 of the fair value hierarchy, contingent consideration accruals which are classified in Level 3 of the fair value hierarchy, and are shown in the tables below and non-marketable equity securities remeasured during the year ended December 31, 2020 and 2019 are classified within Level 3 in the fair value hierarchy. There were no transfers between levels for the year ended December 31, 2020. In determining fair value for Level 2 instruments, we apply a market approach, using quoted active market prices relevant to the particular instrument under valuation, giving consideration to the credit risk of both the respective counterparty to the contract and the Company. To determine our credit risk, we estimated our credit rating by benchmarking the price of outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, our credit risk was quantified by reference to publicly-traded debt with a corresponding rating. The Level 2 derivative financial instruments include the Call Options asset and the embedded conversion option liability. See Note 16 "Debt", and Note 14 "Derivatives and Hedging", for further information. The derivatives are not actively traded and are valued based on an option pricing model that uses observable market data for inputs. Significant market data inputs used to determine fair values included our common stock price, the risk-free interest rate, and the implied volatility of our common stock. The Call Options asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated. Our Level 3 instruments include non-marketable equity security investments. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Our accounts receivable consist of unsecured customer obligations and we are at risk to the extent such amounts become uncollectible. Accounts receivable are carried at face value less an allowance for doubtful accounts as of December 31, 2019, and following the adoption of ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, less an allowance for expected credit losses. We continually monitor accounts receivable balances, and until December 31, 2019, provided for an allowance for doubtful accounts at the time collection became questionable based on payment history or age of the receivable. Since January 1, 2020, we maintain allowances for credit losses resulting from the expected failure or inability of our customers to make required payments. We recognize the allowance for expected credit losses at inception and reassess regularly considering historical experience with bad debts, the aging of the receivables, credit quality of the customer base, current economic conditions and other reasonable and supportable expectations for future conditions, if applicable. Once a receivable is determined to be uncollectible, the balance is charged against the allowance. We sell our products worldwide through sales subsidiaries and distributors. There is no concentration of credit risk with respect to trade accounts receivable as we have a large number of internationally dispersed customers. Trade accounts receivable are non-interest bearing and mostly have payment terms of 30-90 days. For all years presented, no single customer represented more than ten percent of accounts receivable or consolidated net sales.
Inventories	InventoriesInventories are stated at the lower of cost or net realizable value, determined on either a weighted average cost basis or a standard cost basis which is regularly adjusted to actual. Inventories include material, direct labor and overhead costs and are reduced for estimated obsolescence.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated amortization. Capitalized internal-use software costs include only those direct costs associated with the actual development or acquisition of computer software solely to meet internal needs and cloud-based applications to deliver our service and comprise costs associated with the design, coding, installation and testing of the system. Costs associated with preliminary development, such as the evaluation and selection of alternatives, as well as training, maintenance and support are expensed as incurred. Costs for software to be sold, leased or otherwise marketed that are related to the conceptual formulation and design are expensed as incurred. Costs incurred to produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established are capitalized and amortized in accordance with the accounting standards for the costs of software to be sold, leased, or otherwise marketed. All other depreciation is computed using the straight-line method over the estimated useful lives of the assets (3 to 40 years). Amortization of leasehold improvements is computed on a straight-line basis over the lesser of the remaining life of the lease or the estimated useful life of the improvement asset. We have a policy of capitalizing expenditures that materially increase assets’ useful lives and charging ordinary maintenance and repairs to operations as incurred. When property or equipment is disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in earnings.
Business Combinations	Business Combinations We include the results of operations of the businesses that we acquire as of the acquisition date. The purchase price of an acquired business is allocated to the individual assets acquired and liabilities assumed based on their fair values at the date of acquisition. Those fair values are determined using income, cost and market approaches, most of which depend upon significant inputs that are not observable in the market, or level 3 measurements. The excess of purchase price over the fair value of identifiable assets acquired and liabilities assumed is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. The purchase price for some business combinations includes consideration that is contingent on the achievement of net sales or earnings targets by the acquired business. Contingent consideration is measured initially and on a recurring basis at fair value. Payments to settle the acquisition-date fair value of contingent consideration are presented as financing activities on the statement of cash flows; any payments in excess of the acquisition-date fair value are presented as operating activities.
Acquired Intangibles and Goodwill	Acquired Intangibles and Goodwill Acquired intangibles with alternative future uses are carried at cost less accumulated amortization and consist of licenses to technology held by third parties and other acquired intangible assets. Amortization is computed over the estimated useful life of the underlying patents, which has historically ranged from 1 to 20 years. Purchased intangible assets acquired in business combinations, other than goodwill, are amortized over their estimated useful lives unless these lives are determined to be indefinite. Intangibles are assessed for recoverability considering the contract life and the period of time over which the intangible will contribute to future cash flow. The unamortized cost of intangible assets, where cash flows are independent and identifiable from other assets, is evaluated periodically and adjusted, if necessary, if events and circumstances indicate that a decline in value below the carrying amount has occurred. Intangible asset impairments recorded during the year ended December 31, 2020, 2019 and 2018 are further discussed in Note 6 "Restructuring and Impairments". Amortization expense related to developed technology and patent and license rights which have been acquired in a business combination is included in cost of sales. Amortization of trademarks, customer base and non-compete agreements which have been acquired in a business combination is recorded in operating expense under the caption 'acquisition-related intangible amortization'. Amortization expenses of intangible assets not acquired in a business combination are recorded within either the cost of sales, research and development or sales and marketing line items based on the use of the asset. We dispose the gross carrying amount and accumulated amortization of fully amortized intangible assets from historic business combinations once they are considered fully integrated into our business. The fair value of in-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when any event or circumstance indicates that the fair value may be below the carrying value. If and when research and development is complete, the associated asset is amortized over the estimated useful life. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired arising from business combinations. Goodwill is subject to impairment tests annually or earlier if indicators of potential impairment exist, using a fair-value-based approach. We have elected to perform our annual test for indications of impairment as of October 1 st
Investments	Non-Marketable Investments We have investments in non-marketable equity securities issued by privately held companies. These investments are included in other long-term assets in the accompanying consolidated balance sheets. Non-marketable investments through which we exercise significant influence but do not have control are accounted for using the equity method. We monitor for changes in circumstances that may require a reassessment of the level of influence. Following the adoption of ASU 2016-01 on January 1, 2018, our non-marketable equity securities not accounted for under the equity method are either carried at fair value or under the measurement alternative. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Investments are evaluated periodically, or when impairment indicators are noted, to determine if declines in value are other-than-temporary. In making that determination, we consider all available evidence relating to the realizable value of a security. This evidence includes, but is not limited to, the following: • adverse financial conditions of a specific issuer, segment, industry, region or other variables; • the length of time and the extent to which the fair value has been less than cost; and • the financial condition and near-term prospects of the issuer. We consider whether the fair values of any of our non-marketable investments have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If any such decline is considered to be other than temporary (based on various factors, including historical financial results, product development activities and the overall health of the affiliate’s industry), then a write-down of the investment would be recorded in operating expense to its estimated fair value. Investment impairments recorded during the year ended December 31, 2020 are discussed in Note 10 "Investments."
Variable Interest Entities	Variable Interest Entities We evaluate at the inception of each arrangement whether we have made an investment in an entity that is considered a variable interest entity (VIE) or if we hold other variable interests in an arrangement that is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE as an investment in a non-marketable investment or in accordance with other applicable GAAP.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. We consider, amongst other indicators, a history of operating losses or a change in expected sales levels to be indicators of potential impairment. Assets are grouped and evaluated for impairment at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying amount of the asset exceeds fair value which is determined by applicable market prices, when available. When market prices are not available, we generally measure fair value by discounting projected future cash flows of the asset. Considerable judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could differ from such estimates.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
Accounting Policies [Abstract]
Exchange Rates of Key Currencies	The exchange rates of key currencies were as follows: Closing rate at December 31, Annual average rate (US$ equivalent for one) 2020 2019 2020 2019 2018 Euro (EUR) 1.2271 1.1234 1.1411 1.1196 1.1813 Pound Sterling (GBP) 1.3649 1.3204 1.2836 1.2768 1.3356 Swiss Franc (CHF) 1.1360 1.0350 1.0659 1.0062 1.0228 Australian Dollar (AUD) 0.7720 0.7023 0.6905 0.6954 0.7478 Canadian Dollar (CAD) 0.7849 0.7696 0.7463 0.7535 0.7719 Japanese Yen (JPY) 0.0097 0.0092 0.0094 0.0092 0.0091 Chinese Yuan (CNY) 0.1530 0.1437 0.1450 0.1448 0.1514
Cash and Cash Equivalents	(in thousands) 2020 2019 Cash at bank and on hand $ 245,373 $ 189,569 Short-term bank deposits 352,611 434,078 Cash and cash equivalents $ 597,984 $ 623,647
Changes in the Allowance for Credit Losses on Accounts Receivable	The changes in the allowance for credit losses on accounts receivable for the year ended December 31, 2020 and in the allowance for doubtful accounts for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2020 2019 2018 Balance at beginning of year $ 12,115 $ 9,270 $ 8,008 ASC 326 adoption impact 8,089 — — Additions charged to expense 16,439 8,701 4,448 Deductions from allowance (9,868) (5,777) (2,827) Currency translation adjustments and other 277 (79) (359) Balance at end of year $ 27,052 $ 12,115 $ 9,270
Inventories	Inventories consisted of the following as of December 31, 2020 and 2019: (in thousands) 2020 2019 Raw materials $ 65,449 $ 26,077 Work in process 74,398 45,729 Finished goods 151,334 98,898 Total inventories, net $ 291,181 $ 170,704

Revenue (Tables)

Revenue (Tables)	12 Months Ended
Revenue (Tables)	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue based on Product Categories and Customer Class	We disaggregate our revenue based on product type and customer class as shown in the tables below for the years ended December 31, 2020, 2019 and 2018: (in thousands) 2020 2019 2018 Consumables and related revenues $ 774,234 $ 665,866 $ 649,602 Instruments 129,742 71,266 82,197 Molecular Diagnostics 903,976 737,132 731,799 Consumables and related revenues 841,201 688,281 665,857 Instruments 125,169 101,011 104,192 Life Sciences 966,370 789,292 770,049 Total $ 1,870,346 $ 1,526,424 $ 1,501,848 Additionally, we disaggregate our revenue based on product category as shown in the tables below for the years ended December 31, 2020, 2019 and 2018: (in thousands) 2020 2019 2018 Sample technologies $ 803,867 $ 548,365 $ 546,636 Diagnostic solutions 460,757 465,503 461,064 PCR / Nucleic acid amplification 363,552 224,685 236,952 Genomics / NGS 165,570 183,768 163,383 Other 76,600 104,103 93,813 Total $ 1,870,346 $ 1,526,424 $ 1,501,848

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
Acquisitions and Divestitures (Tables)	Dec. 31, 2020
Asset Acquisitions, Business Combinations And Divestitures [Abstract]
Purchase Price Allocation	The preliminary purchase price allocation for NeuMoDx as of December 31, 2020 and the difference to September 30, 2020 is as follows: (in thousands) As of December 31, 2020 As of September 30, 2020 Difference Purchase Price: Cash consideration $ 251,730 $ 251,730 $ — Fair value of minority interest 52,727 52,727 — $ 304,457 $ 304,457 $ — Preliminary Allocation: Cash and cash equivalents $ 12,291 $ 12,291 $ — Accounts receivable 5,691 5,691 — Inventories 20,666 18,866 1,800 Prepaid expenses and other current assets 5,961 5,943 18 Accounts payable (12,450) (11,168) (1,282) Accruals and other current liabilities (18,929) (18,770) (159) Other long-term liabilities (4,101) (4,101) — Fixed and other long-term assets 7,076 6,698 378 Developed technology 101,000 119,100 (18,100) In-process research and development 55,000 64,800 (9,800) Patents and license rights 770 770 — Customer backlog 400 900 (500) Goodwill 157,627 149,877 7,750 Deferred tax asset 12,457 — 12,457 Deferred tax liability on fair value of identifiable intangible assets acquired (39,002) (46,440) 7,438 Total $ 304,457 $ 304,457 $ —

Restructuring and Impairments (

Restructuring and Impairments (Tables)	12 Months Ended
Restructuring and Impairments (Tables)	Dec. 31, 2020
Restructuring and Related Activities [Abstract]
Costs Related to the Restructuring Program	Cumulative costs for this program were as follows: (in thousands) Personnel Related Contract and Other Costs Inventory Write-offs & Asset Impairments Total Cost of sales $ — $ — $ 3,039 $ 3,039 Restructuring, acquisition, integration and other, net 6,174 4,583 — 10,757 Total 2017 costs 6,174 4,583 3,039 13,796 Cost of sales 424 1,193 — 1,617 Restructuring, acquisition, integration and other, net 4,207 4,232 1,610 10,049 Total 2018 costs 4,631 5,425 1,610 11,666 Restructuring, acquisition, integration and other, net (1,100) — — (1,100) Total 2019 releases (1,100) — — (1,100) Total cumulative costs $ 9,705 $ 10,008 $ 4,649 $ 24,362
Summary of Cash Components of Restructuring Activity	The following is a summary of the charges recorded in the consolidated statements of income (loss) during the years ended December 31, 2020 and 2019 and total program charges through December 31, 2020. Classification and Type of Charge (in thousands) Note 2020 2019 Total program charges through 2020 Restructuring, acquisition, integration and other, net Personnel related (1) (22) $ 904 $ 70,578 $ 71,482 Contract termination expense (1) 682 42,099 42,781 Consulting fees 1,153 10,150 11,303 Accounts receivable (2) (622) 10,825 10,203 Inventories 1,014 12,336 13,350 Prepaid expenses and other assets (2) 127 17,012 17,139 3,258 163,000 166,258 Long-lived asset impairments Property, plant and equipment (9) 1,034 98,472 99,506 Intangible assets (11) — 40,301 40,301 1,034 138,773 139,807 Other income, net Equity method investment impairment (10) — 4,799 4,799 Total $ 4,292 $ 306,572 $ 310,864 (1) During the year ended December 31, 2019, personnel related and contract termination costs include $2,956 and $15,676, respectively, due to related parties. (2) During the year ended December 31, 2019, accounts receivable and prepaid expenses and other assets includes $5,984 and $2,270, respectively due from related parties. Of the total costs incurred, $11.2 million and $60.2 million are accrued as of December 31, 2020 and 2019, respectively, in accrued and other current liabilities in the accompanying consolidated balance sheets as summarized in the following table that includes the cash components of the restructuring activity. (in thousands) Personnel Related Contract Termination Consulting Fees Total Costs incurred in 2019 $ 44,640 $ 42,099 $ 10,150 $ 96,889 Payments (17,272) (18,294) (2,162) (37,728) Foreign currency translation adjustment 631 493 (53) 1,071 Liability at December 31, 2019 27,999 24,298 7,935 60,232 Additional costs incurred in 2020 4,542 1,639 1,661 7,842 Release of excess accrual (3,638) (957) (508) (5,103) Payments (24,355) (18,319) (9,028) (51,702) Foreign currency translation adjustment 139 (230) (12) (103) Liability at December 31, 2020 $ 4,687 $ 6,431 $ 48 $ 11,166

Short-Term Investments (Tables)

Short-Term Investments (Tables)	12 Months Ended
Short-Term Investments (Tables)	Dec. 31, 2020
Short-term Investments [Abstract]
Summary of Short-Term Investments	As of December 31, 2020 and 2019, short-term investments consisted of the following: (in thousands) 2020 2019 Marketable equity securities $ 117,249 $ — Money market deposits — 87,468 Commercial paper — 22,459 Loans receivable — 19,659 Total $ 117,249 $ 129,586

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2020
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are summarized as follows as of December 31, 2020 and 2019: (in thousands) Note 2020 2019 Prepaid expenses $ 61,159 $ 39,930 Cash collateral (14) 56,100 2,683 Other receivables 32,901 29,486 Value added tax 31,128 20,347 Loan receivables 17,094 7,539 Contract assets (4) 8,539 5,479 Total prepaid expenses and other current assets $ 206,921 $ 105,464

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Including Equipment Under Capital Lease Obligations	Property, plant and equipment of December 31, 2020 and 2019 were as follows: (in thousands) Estimated useful life (in years) 2020 2019 Land — $ 18,903 $ 17,684 Buildings and improvements 5-40 362,902 341,032 Machinery and equipment 3-10 322,379 292,294 Computer software 3-7 260,730 301,604 Furniture and office equipment 3-10 108,339 102,901 Construction in progress — 116,562 98,858 1,189,815 1,154,373 Less: Accumulated depreciation and amortization (630,443) (699,130) Property, plant and equipment, net $ 559,372 $ 455,243
Asset Impairment Charges	sset impairment charges for the years ended December 31, 2020, 2019 and 2018 were as follows: (in thousands) 2020 2019 2018 Machinery and equipment $ 77 $ 9,177 $ — Computer software — 44,649 2,911 Furniture and office equipment 315 4,030 — Construction in progress 642 41,870 4,979 Total impairment in property, plant and equipment $ 1,034 $ 99,726 $ 7,890

Investments (Tables)

Investments (Tables)	12 Months Ended
Investments (Tables)	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Summary of Investments in Marketable Equity Securities with Readily Determinable Fair Values	Short-Term Long-Term (in thousands, except shares held) Invitae Corporation OncoCyte Oncimmune Holdings plc HTG Molecular Diagnostics, Inc Shares held 2,769,189 88,101 560,416 55,556 Cost basis $ — $ — $ — $ 2,000 Fair value $ 115,780 $ 211 $ 1,258 $ 266 Total cumulative unrealized gain (loss) $ 115,780 $ 211 $ 1,258 $ (1,734) Long-Term (in thousands, except shares held) Oncimmune HTGM Shares held 560,416 833,333 Cost basis $ — $ 2,000 Fair value $ 285 $ 585 Total cumulative unrealized gain (loss) $ 285 $ (1,415)
Summary of Equity Method Investments Included in Other Assets	A summary of our non-marketable investments accounted for as equity method investments is as follows: Ownership Equity investments Share of income (loss) ($ in thousands) 2020 2019 2020 2019 2018 PreAnalytiX GmbH 50.00 % $ 4,761 $ 5,452 $ 3,070 $ 3,971 $ 4,062 Suzhou Fuda Business Management and Consulting Partnership 33.67 % 3,301 3,100 — — — Apis Assay Technologies Ltd 19.00 % 1,940 719 1,221 (51) — TVM Life Science Ventures III 3.10 % 1,545 1,219 630 (330) — Hombrechtikon Systems Engineering AG 19.00 % (530) (761) 97 (1,124) (668) MAQGEN Biotechnology Co., Ltd 40.00 % — — — (383) (579) Biotype Innovation GmbH 0.00 % — — — — (123) Pyrobett 0.00 % — — — — (100) $ 11,017 $ 9,729 $ 5,018 $ 2,083 $ 2,592
Changes in Non-Marketable Investments Not Accounted for Under the Equity Method	The changes in these investments which are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 70,849 $ 59,484 Full acquisition of equity securities (41,001) — Sale of equity securities (23,812) — Loss on sale of equity securities (2,250) — Impairments (398) — Cash investments in equity securities, net 173 3,619 Net increases due to observable price changes — 7,760 Foreign currency translation adjustments 581 (14) Balance at end of year $ 4,142 $ 70,849

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
Goodwill and Intangible Assets (Tables)	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Intangible Assets	The following sets forth the intangible assets by major asset class as of December 31, 2020 and 2019: Weighted Average Life 2020 2019 (in thousands) Gross Carrying Amount Accumulated Gross Carrying Accumulated Amortized Intangible Assets: Patent and license rights 10.50 $ 298,395 $ (197,038) $ 320,406 $ (216,554) Developed technology 10.74 860,129 (378,705) 766,966 (346,085) Customer base, trademarks, and non-compete agreements 12.02 314,876 (233,981) 314,638 (213,881) 10.86 $ 1,473,400 $ (809,724) $ 1,402,010 $ (776,520) Unamortized Intangible Assets: In-process research and development $ 62,518 $ 6,944 Goodwill 2,364,031 2,140,503 $ 2,426,549 $ 2,147,447 The changes in intangible assets for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 632,434 $ 475,043 Additions 24,007 286,159 Additions from acquisitions 157,170 36,458 Amortization (103,230) (122,560) Disposals (537) — Impairments — (40,301) Foreign currency translation adjustments 16,350 (2,365) Balance at end of year $ 726,194 $ 632,434 The changes in goodwill for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 2,140,503 $ 2,108,536 Business combinations 157,627 34,807 Purchase adjustments 3,382 (236) Disposals — (225) Foreign currency translation adjustments 62,519 (2,379) Balance at end of year $ 2,364,031 $ 2,140,503
Amortization of Intangibles for the Next Five Years	Amortization of intangibles for the next five years is expected to be approximately: Years ended December 31, (in thousands) 2021 $ 103,485 2022 $ 89,734 2023 $ 87,355 2024 $ 83,520 2025 $ 71,130

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2020
Leases [Abstract]
Supplemental Balance Sheet and Other Information	Supplemental balance sheet and other information related to operating leases as of December 31, 2020 and 2019 are as follows: (in thousands, except lease term and discount rate) Location in balance sheet 2020 2019 Operating lease right-of-use assets Other long-term assets $ 102,522 $ 57,305 Current operating lease liabilities Accrued and other current liabilities $ 23,450 $ 18,739 Long-term operating lease liabilities Other long-term liabilities $ 85,585 $ 39,631 Weighted average remaining lease term 7.04 years 3.71 years Weighted average discount rate 1.89 % 2.39 %
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to operating leases for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Cash paid for operating leases included in operating cash flows $ 24,193 $ 26,113 Operating lease right-of-use assets obtained in exchange for lease obligations $ 58,992 $ 24,670
Maturities of Lease Liabilities	aturities of operating lease liabilities as of December 31, 2020 are as follows: Years ending December 31, (in thousands) 2021 $ 25,353 2022 20,993 2023 16,280 2024 10,790 2025 6,707 Thereafter 36,878 Total lease payments 117,001 Less: imputed interest (7,966) Total $ 109,035

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	12 Months Ended
Accrued and Other Current Liabilities (Tables)	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Accrued and Other Current Liabilities	Accrued and other current liabilities at December 31, 2020 and 2019 consist of the following: (in thousands) Note 2020 2019 Payroll and related accruals $ 99,085 $ 66,866 Other liabilities 67,244 54,241 Deferred revenue (4) 57,066 48,525 Accrued expenses 51,026 38,963 Accrued contingent consideration and milestone payments (15) 23,593 142,604 Operating lease liabilities (12) 23,450 18,739 Restructuring (6) 11,599 62,227 Accrued royalties (20) 7,427 5,481 Accrued interest on long-term debt (16) 4,575 5,257 Cash collateral (14) 600 1,400 Total accrued and other current liabilities $ 345,665 $ 444,303

Derivatives and Hedging (Tables

Derivatives and Hedging (Tables)	12 Months Ended
Derivatives and Hedging (Tables)	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Value Amounts of Derivative Instruments	The following table summarizes the fair value amounts of derivative instruments reported in the consolidated balance sheets as of December 31, 2020 and 2019: 2020 2019 (in thousands) Current Asset Long-Term Asset Current Asset Long-Term Asset Assets: Derivative instruments designated as hedges Interest rate contracts - fair value hedge (1) $ — $ 5,042 $ — $ 2,474 Total derivative instruments designated as hedges $ — $ 5,042 $ — $ 2,474 Undesignated derivative instruments Equity options $ 2,415 $ 374,038 $ 101,179 $ 189,792 Foreign exchange forwards and options 11,712 — 6,689 — Total undesignated derivative instruments $ 14,127 $ 374,038 $ 107,868 $ 189,792 Total Derivative Assets $ 14,127 $ 379,080 $ 107,868 $ 192,266 2020 2019 (in thousands) Current Liability Long-Term Liability Current Liability Long-Term Liability Liabilities: Derivative instruments designated as hedges Interest rate contracts - cash flow hedge (1) $ — $ (17,409) $ — $ (6,027) Total derivative instruments designated as hedges $ — $ (17,409) $ — $ (6,027) Undesignated derivative instruments Equity options $ (5,966) $ (376,046) $ (101,361) $ (190,902) Foreign exchange forwards and options (45,498) — (1,814) — Total undesignated derivative instruments $ (51,464) $ (376,046) $ (103,175) $ (190,902) Total Derivative Liabilities $ (51,464) $ (393,455) $ (103,175) $ (196,929) _________________ (1) The fair value amounts for the interest rate contracts do not include accrued interest.
Summary of the Classification of Gains and Losses on Derivative Instruments and Balance Sheet Line Items in Which the Hedged Item is Included	The following tables summarize the gains and losses on derivative instruments for the years ended December 31, 2020, 2019 and 2018: 2020 2019 2018 (in thousands) Other income, net Other income, net Other income, net Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded $ 114,326 $ 432 $ 5,598 Gains (Losses) on Derivatives in Cash Flow Hedges Interest rate contracts Amount of gain (loss) reclassified from accumulated other comprehensive loss $ 18,666 $ (3,888) $ (9,774) Amounts excluded from effectiveness testing — — — Gains (Losses) on Derivatives in Fair Value Hedges Interest rate contracts Hedged item (2,568) (3,668) 2,051 Derivatives designated as hedging instruments 2,568 3,668 (2,051) Gains (Losses) Derivatives Not Designated as Hedging Instruments Embedded conversion option — (349) 131 Equity options 322,580 (104,125) 74,682 Cash convertible notes embedded cash conversion option (321,213) 106,998 (76,500) Foreign exchange forwards and options (12,429) 1,835 (19,857) Total gains (losses) $ 7,604 $ 471 $ (31,318) The following tables summarizes the balance sheet line items in which the hedged item is included as of December 31, 2020 and 2019: Carrying Amount of the Hedged Assets (Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities) (in thousands) 2020 2019 2020 2019 Long-term debt $ (131,923) $ (129,290) $ 5,042 $ 2,474

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
Financial Instruments and Fair Value Measurements (Tables)	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on a Recurring Basis	The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019: 2020 2019 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ — $ — $ — $ — $ 129,586 $ — $ 129,586 Marketable equity securities 117,515 — — 117,515 870 — — 870 Non-marketable equity securities — — 4,142 4,142 — — 70,849 70,849 Equity options — 376,453 — 376,453 — 290,971 — 290,971 Foreign exchange forwards and options — 11,712 — 11,712 — 6,689 — 6,689 Interest rate contracts — 5,042 — 5,042 — 2,474 — 2,474 $ 117,515 $ 393,207 $ 4,142 $ 514,864 $ 870 $ 429,720 $ 70,849 $ 501,439 Liabilities: Foreign exchange forwards and options $ — $ (45,498) $ — $ (45,498) $ — $ (1,814) $ — $ (1,814) Interest rate contracts — (17,409) — (17,409) — (6,027) — (6,027) Equity options — (382,012) — (382,012) — (292,263) — (292,263) Contingent consideration — — (23,593) (23,593) — — (162,160) (162,160) $ — $ (444,919) $ (23,593) $ (468,512) $ — $ (300,104) $ (162,160) $ (462,264)
Summary of Activity for Liabilities with Level 3 Inputs	For contingent consideration liabilities with Level 3 inputs, the following table summarizes the activity for the years ended December 31, 2020 and 2019: (in thousands) 2020 2019 Balance at beginning of year $ (162,160) $ (48,971) Additions from acquisitions (3,223) (132,422) Payments 141,790 11,800 Gain included in earnings — 7,433 Balance at end of year $ (23,593) $ (162,160)
Carrying Values and Estimated Fair Values of Long-Term Debt	The table below presents the carrying values and the estimated fair values of financial instruments not presented in the tables above as of December 31, 2020 and 2019. 2020 2019 (in thousands) Carrying Amount Level 1 Level 2 Carrying Amount Level 1 Level 2 Long-term debt including current portion: Cash convertible notes $ 791,000 $ 1,167,201 $ — $ 1,046,511 $ 1,296,334 $ — Convertible notes 442,481 510,930 — — — — U.S. Private placement 331,717 — 337,747 328,984 — 329,157 German private placement 357,551 — 361,957 330,857 — 334,371 $ 1,922,749 $ 1,678,131 $ 699,704 $ 1,706,352 $ 1,296,334 $ 663,528

Debt (Tables)

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2020
Debt Instruments [Abstract]
Total Long-Term Debt, Net of Debt Issuance Costs	At December 31, 2020 and 2019, total current long-term debt, net of debt issuance costs of $10.7 million and $10.8 million, respectively, consists of the following: (in thousands) 2020 2019 0.875% Senior Unsecured Cash Convertible Notes due 2021 $ 200 $ 285,244 0.500% Senior Unsecured Cash Convertible Notes due 2023 361,304 347,995 1.000% Senior Unsecured Cash Convertible Notes due 2024 429,496 413,272 0.000% Senior Unsecured Convertible Notes due 2027 442,481 — 3.75% Series B Senior Notes due October 16, 2022 304,761 302,040 3.90% Series C Senior Notes due October 16, 2024 26,956 26,944 German Private Placement (Schuldschein) 357,551 330,857 Total long-term debt 1,922,749 1,706,352 Less current portion 42,539 285,244 Long-term portion $ 1,880,210 $ 1,421,108
Future Maturities of Long-Term Debt	Future maturities (stated at the carrying values) of long-term debt as of December 31, 2020, are as follows: Years ending December 31, (in thousands) 2021 $ 42,539 2022 485,795 2023 361,304 2024 572,870 2025 — thereafter 460,241 $ 1,922,749
Interest Rate, Corresponding Maturities, and Contingent Conversion Periods of Cash Convertible Notes	The interest rate and corresponding maturity of each Note are summarized in the table below. The Cash Convertible Notes are solely convertible into cash in whole, but not in part, at the option of noteholders under the circumstances described below and during the contingent conversion periods as shown in the table below. Cash Convertible Notes Annual Interest Rate Date of Interest Payments Maturity Date Contingent Conversion Period Conversion Rate per $200,000 Principal Amount 2021 Notes 0.875% March 19 and September 19 March 19, 2021 From April 29, 2014 to September 18, 2020 7,063.1647 2023 Notes 0.500% March 13 and September 13 September 13, 2023 From October 24, 2017 to March 13, 2023 4,829.7279 2024 Notes 1.000% May 13 and November 13 November 13, 2024 From December 24, 2018 to August 2, 2024 4,360.3098
Interest Expense Related to the Cash Convertible Notes	Interest expense for the years ended December 31, 2020 and 2019 related to the 2027 Notes and the Cash Convertible Notes was comprised of the following: (in thousands) 2020 2019 Coupon interest $ 9,025 $ 9,954 Amortization of original issuance discount 38,229 36,966 Amortization of debt issuance costs 2,942 3,014 Total interest expense $ 50,196 $ 49,934
Summary of German Private Placement Tranches	A summary of the tranches is as follows: Carrying Value (in thousands) as of Currency Notional Amount Interest Rate Maturity December 31, 2020 December 31, 2019 EUR €11.5 million Fixed 0.4% March 2021 $ 14,115 $ 12,905 EUR €23.0 million Floating EURIBOR + 0.4% March 2021 28,224 25,811 EUR €21.5 million Fixed 0.68% October 2022 26,361 24,112 EUR €64.5 million Floating EURIBOR + 0.5% October 2022 79,083 72,335 USD $45.0 million Floating LIBOR + 1.2% October 2022 44,948 44,919 EUR €25.0 million Floating EURIBOR + 0.5% October 2022 30,642 28,026 EUR €64.0 million Fixed 1.09% June 2024 78,429 71,747 EUR €31.0 million Floating EURIBOR + 0.7% June 2024 37,989 34,753 EUR €14.5 million Fixed 1.61% June 2027 17,760 16,249 $ 357,551 $ 330,857

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Before Income Taxes	Income (loss) before income taxes for the years ended December 31, 2020, 2019 and 2018 consisted of: (in thousands) 2020 2019 2018 Pretax (loss) income in The Netherlands $ (16,640) $ 17,455 $ (1,675) Pretax income (loss) from foreign operations 456,112 (95,231) 227,412 $ 439,472 $ (77,776) $ 225,737
Provision for Income Taxes	Income tax expense (benefit) for the years ended December 31, 2020, 2019 and 2018 are as follows: (in thousands) 2020 2019 2018 Current—The Netherlands $ 270 $ 5,670 $ 5,794 —Foreign 86,720 13,371 52,835 86,990 19,041 58,629 Deferred—The Netherlands (6,921) 4,177 2,551 —Foreign 215 (59,539) (25,823) (6,706) (55,362) (23,272) Total income tax expense (benefit) $ 80,284 $ (36,321) $ 35,357
Difference Between Income Taxes Computed at Statutory Rate and Reported Income Taxes and Effective Tax Rate	The principal items comprising the differences between income taxes computed at The Netherlands statutory rate and our effective tax rate for the years ended December 31, 2020, 2019 and 2018 are as follows: 2020 2019 2018 Income taxes at The Netherlands statutory rate 25.0 % 25.0 % 25.0 % Unrecognized tax benefits (1) 8.2 (14.1) 6.0 Valuation allowance (2) (8.1) (26.9) 1.5 Taxation of foreign operations, net (3) (2.1) 33.1 (15.1) Prior year taxes (1.6) (1.4) 0.2 Tax impact from intangible property transfer (0.8) 27.2 — Tax impact from (deductible) nondeductible items (0.8) (10.3) 1.3 Excess tax benefit related to share-based compensation (0.6) 5.1 (2.1) Government incentives and other deductions (4) (0.6) 9.7 (1.2) Changes in tax laws and rates (0.3) (0.4) 0.8 Other items, net 0.0 (0.3) (0.7) Effective tax rate 18.3 % 46.7 % 15.7 % ____________________ (1) During 2020, we analyzed accruals for tax contingencies, primarily related to the potential nondeductibility of the $95.0 million expense reimbursement paid in connection with the unsuccessful acquisition attempt by Thermo Fisher and ongoing income tax audits. (2) Due to increased taxable income and deferred tax liability position in 2020, we released a net $35.6 million valuation allowance primarily related to U.S. disallowed interest. (3) Our effective tax rate reflects the benefit of our global operations where certain income or loss is taxed at rates higher or lower than The Netherlands’ statutory rate of 25% as well as the benefit of some income being partially exempt from income taxes due to various intercompany operating and financing activities. These foreign tax benefits are due to a combination of favorable tax laws, regulations and exemptions in these jurisdictions. Partial tax exemptions exist on foreign income primarily derived from operations in Germany, The Netherlands and Singapore. Further, we have intercompany financing arrangements in which the intercompany income is nontaxable or partially exempt or subject to lower statutory tax rates. During 2020, we had intercompany arrangements through Dubai, and in 2018 through mid-2019 had arrangements through Luxembourg and Ireland. (4) Government incentives include favorable tax regulations in the U.S. relating to research and development expense and other government incentives.
Changes in Amounts of Unrecognized Tax Benefits	Changes in the amount of unrecognized tax benefits for the years ended December 31, 2020, 2019, and 2018 are as follows: (in thousands) 2020 2019 2018 Balance at beginning of year $ 58,002 $ 55,780 $ 44,033 Additions based on tax positions related to the current year 31,758 5,770 3,359 Additions for tax positions of prior years 3,560 14,532 11,984 Decrease for tax position of prior years (57) (9,073) — Decrease related to settlements — (7,605) — Decrease due to lapse of statute of limitations (520) (409) (1,238) Increase (decrease) from currency translation 7,349 (993) (2,358) Balance at end of year $ 100,092 $ 58,002 $ 55,780
Components of Net Deferred Tax Assets and Liabilities	The components of the net deferred tax asset and liability at December 31, 2020 and 2019 are as follows: 2020 2019 (in thousands) Deferred Deferred Deferred Deferred Net operating loss and tax credit carryforward $ 67,856 $ — $ 50,274 $ — Accrued and other liabilities 22,926 — 17,977 — Inventories 3,872 (2,269) 4,726 (1,439) Unrealized gain (loss) on investments — (25,779) — (4,973) Property, plant and equipment 6,099 (23,376) 5,297 (20,332) Intangible assets 2,817 (55,999) 1,078 (26,294) Share-based compensation 18,377 — 13,787 — Disallowed interest carryforwards 42,090 — 73,690 — Convertible notes 6,512 (13,513) 7,104 — Other 9,428 (6,046) 5,998 (6,174) 179,977 (126,982) 179,931 (59,212) Valuation allowance (37,332) — (87,619) — $ 142,645 $ (126,982) $ 92,312 $ (59,212) Net deferred tax assets $ 15,663 $ 33,100

Equity (Tables)

Equity (Tables)	12 Months Ended
Equity (Tables)	Dec. 31, 2020
Equity [Abstract]
Issuance of Warrants	Cash convertible notes Issued on Number of share warrants issued Exercise price per share Proceeds from issuance of warrants, net of issuance costs (in millions) Warrants expire over a period of 50 trading days beginning on 2019 March 19, 2014 15.2 $32.0560 $40.6 December 27, 2018 2021 March 19, 2014 10.6 $32.0560 $28.3 December 29, 2020 2023 September 13, 2017 9.7 $50.9664 $45.3 June 26, 2023 2024 November 13, 2018 10.9 $52.1639 $72.4 August 27, 2024
Accumulated Other Comprehensive Income (Loss)	The following table is a summary of the components of accumulated other comprehensive loss as of December 31, 2020 and 2019: (in thousands) 2020 2019 Net unrealized loss on hedging contracts, net of tax $ (23,268) $ (2,289) Net unrealized loss on pension, net of tax (599) (561) Foreign currency effects from intercompany long-term investment transactions, net of tax of $10.7 million and $9.7 million in 2020 and 2019, respectively (25,717) (22,587) Foreign currency translation adjustments (194,238) (284,182) Accumulated other comprehensive loss $ (243,822) $ (309,619)

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	12 Months Ended
Earnings per Common Share (Tables)	Dec. 31, 2020
Earnings Per Share [Abstract]
Summary of the Computation of Earnings per Common Share	The following schedule summarizes the information used to compute earnings per common share for the years ended December 31, 2020, 2019 and 2018: (in thousands, except per share data) 2020 2019 2018 Net income (loss) $ 359,188 $ (41,455) $ 190,380 Weighted average number of common shares used to compute basic net income per common share 228,427 226,777 226,640 Dilutive effect of stock options and restrictive stock units 3,350 — 4,613 Dilutive effect of outstanding warrants 2,437 — 2,203 Weighted average number of common shares used to compute diluted net income per common share 234,214 226,777 233,456 Outstanding options and awards having no dilutive effect, not included in above calculation 11 107 272 Outstanding warrants having no dilutive effect, not included in above calculation 26,438 32,938 35,939 Basic earnings (loss) per common share $ 1.57 $ (0.18) $ 0.84 Diluted earnings (loss) per common share $ 1.53 $ (0.18) $ 0.82

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments to Purchase Goods or Services and for Future License and Royalty Payments	At December 31, 2020, we had commitments to purchase goods or services, and for future license and royalty payments. They are as follows: Years ending December 31, (in thousands) Purchase License & Royalty 2021 $ 199,843 $ 10,003 2022 42,628 7,217 2023 5,364 4,483 2024 3,000 2,623 2025 — 2,349 Thereafter — 3,364 $ 250,835 $ 30,039
Contingent Consideration Commitments	Pursuant to the purchase agreements for certain acquisitions and other contractual arrangements, we could be required to make additional contingent cash payments totaling up to $26.6 million based on the achievement of certain revenue and operating results milestones as follows: Years ending December 31, (in thousands) 2021 $ 8,850 2022 17,700 $ 26,550
Changes in the Carrying Amount of Warranty Liability	In the ordinary course of business, we provide a warranty to customers that our products are free of defects and will conform to published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. We provide for estimated warranty costs at the time of the product sale. The changes in the carrying amount of warranty obligations for the years ended December 31, 2020 and 2019 are as follows: (in thousands) 2020 2019 Balance at beginning of year $ 3,141 $ 2,848 Provision charged to cost of sales 5,645 3,229 Usage (3,978) (2,921) Adjustments to previously provided warranties, net (125) (1) Currency translation 130 (14) Balance at end of year $ 4,813 $ 3,141

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
Segment Information (Tables)	Dec. 31, 2020
Segment Reporting Information, Additional Information [Abstract]
Net Sales	Our country of domicile is The Netherlands, which reported net sales of $17.8 million, $15.8 million and $15.9 million for the years ended 2020, 2019 and 2018, respectively, and these amounts are included in the line item Europe, Middle East and Africa as shown in the table below. Net sales (in thousands) 2020 2019 2018 Americas: United States $ 728,577 $ 663,869 $ 632,660 Other Americas 96,880 58,121 60,359 Total Americas 825,457 721,990 693,019 Europe, Middle East and Africa 682,289 487,476 490,301 Asia Pacific, Japan and Rest of World 362,600 316,958 318,528 Total $ 1,870,346 $ 1,526,424 $ 1,501,848
Long-Lived Assets	Long-lived assets (in thousands) 2020 2019 Americas: United States $ 154,843 $ 147,027 Other Americas 2,436 3,507 Total Americas 157,279 150,534 Europe, Middle East and Africa: Germany 304,571 229,225 Other Europe, Middle East and Africa 71,444 49,004 Total Europe, Middle East and Africa 376,015 278,229 Asia Pacific and Japan 26,078 26,480 Total $ 559,372 $ 455,243

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
Share-Based Compensation (Tables)	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Summary of the Status of Employee Stock Options	A summary of the status of employee stock options as of December 31, 2020 and changes during the year then ended is presented below: All Employee Options Number of Shares (in thousands) Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding at January 1, 2020 792 $ 20.06 Exercised (365) $ 20.97 Outstanding at December 31, 2020 427 $ 19.28 1.25 $ 14,338 Vested at December 31, 2020 427 $ 19.28 1.25 $ 14,338 Vested and expected to vest at December 31, 2020 427 $ 19.28 1.25 $ 14,338
Summary of Stock Units	A summary of stock units as of December 31, 2020 and changes during the year are presented below: Stock Units Stock Units Weighted Average Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2020 5,183 Granted 1,035 Vested (720) Forfeited (365) Outstanding at December 31, 2020 5,133 2.25 $ 261,458 Vested and expected to vest at December 31, 2020 3,881 2.02 $ 205,097
Compensation Expense	Share-based compensation expense before taxes for the years ended December 31, 2020, 2019 and 2018 totaled approximately $40.9 million, $65.9 million and $40.1 million, respectively, as shown in the table below. (in thousands) 2020 2019 2018 Cost of sales $ 2,897 $ 2,493 $ 2,879 Research and development 7,014 5,810 6,457 Sales and marketing 15,889 7,947 9,372 General and administrative 15,136 23,705 21,405 Restructuring, acquisition, integration and other, net — 25,938 — Share-based compensation expense 40,936 65,893 40,113 Less: income tax benefit (1) 9,552 12,153 8,277 Net share-based compensation expense $ 31,384 $ 53,740 $ 31,836 (1) Does not include the excess tax benefit realized for the tax deductions of the share-based payment arrangements which totaled $2.5 million, $4.0 million and $4.7 million, respectively, for the years ended December 31, 2020, 2019 and 2018.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2020
Related Party Transactions [Abstract]
Summary of Related Party Transactions	From time to time, we have transactions with other companies in which we hold an interest, all of which are individually and in the aggregate immaterial, as summarized in the table below. Net sales to related parties for the years ended December 31, 2020, 2019, and 2018 are as follows: (in thousands) 2020 2019 2018 Net sales $ 6,025 $ 20,002 $ 23,358 (in thousands) 2020 2019 Accounts receivable $ 3,961 $ 7,589 Prepaid expenses and other current assets $ 25,429 $ 13,697 Other long-term assets $ 9,594 $ 16,830 Accounts payable $ 4,050 $ 1,775 Accrued and other current liabilities $ 1,380 $ 15,404

Corporate Information and Bas_2

Corporate Information and Basis of Presentation (Details) customer in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2019business	Dec. 31, 2020USD ($)employeecountrycustomer	Dec. 31, 2019business	Aug. 13, 2020	Jul. 16, 2020€ / shares	Jul. 16, 2020USD ($)	Mar. 03, 2020€ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of customers \| customer		0.5
Number of employees \| employee		5,600
Number of countries with employees in direct subsidiaries (at least) \| country		35
QIAGEN N.V. \| Thermo Fischer Sceintific
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Expense reimbursement payable						$ 95
Payments for expense reimbursement		$ 95
QIAGEN N.V. \| Thermo Fischer Sceintific
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Cash consideration per share (in USD per share) \| € / shares					€ 43		€ 39
Minimum acceptance threshold				66.67%		66.67%	75.00%
Acquisition-related expenses recorded within restructuring, acquisition, integration and other expenses		$ 125.5
Immaterial Acquisitions
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Number of companies acquired \| business	2		3

Effects of New Accounting Pro_2

Effects of New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Jan. 01, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity		$ 2,797,839		$ 2,536,591		$ 2,634,970		$ 2,540,996
Operating lease liabilities		109,035
Long-term debt		1,922,749		1,706,352
0.000% Senior Unsecured Convertible Notes due 2027 \| Senior Unsecured Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt		442,481		0
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity		$ 1,323,091		1,178,457		1,379,624		1,247,945
Retained Earnings \| ASU 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity							$ (900)
Retained Earnings \| ASU 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity							(16,100)
Impact of Change in Accounting Policy, Pre-Tax \| ASU 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity							(1,100)
Impact of Change in Accounting Policy, Pre-Tax \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity			$ 19,600
Impact of Change in Accounting Policy
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity				(15,074)		(316)
Operating lease liabilities					$ 57,700
Operating lease right-of-use assets					57,400
Impact of Change in Accounting Policy \| Forecast
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt	$ 54,100
Impact of Change in Accounting Policy \| ASU 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity								(1,306)
Impact of Change in Accounting Policy \| ASU 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity								0
Impact of Change in Accounting Policy \| ASU 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity								(16,096)
Impact of Change in Accounting Policy \| 0.000% Senior Unsecured Convertible Notes due 2027 \| Senior Unsecured Notes \| Forecast
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity	$ (54,100)
Impact of Change in Accounting Policy \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity			$ 15,100	$ (15,074)	$ (300)	$ (316)
Impact of Change in Accounting Policy \| Retained Earnings \| ASU 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity							$ (1,300)	(1,306)
Impact of Change in Accounting Policy \| Retained Earnings \| ASU 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity								(942)
Impact of Change in Accounting Policy \| Retained Earnings \| ASU 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity								$ (16,096)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)segmentreportingUnit	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2020USD ($)
Significant Accounting Policies [Line Items]
Net gain (loss) on foreign currency transactions	$ (4,100)	$ (5,700)	$ (12,300)
Number of operating segments \| segment	1
Number of reporting units \| reportingUnit	1
Standard product warranty term	1 year
Cost of sales	$ 637,631	521,162	500,888
Advertising costs	9,500	8,100	8,100
Restricted cash	0	5,743
Provisions for doubtful accounts	$ 16,439	8,701	4,448
Impact of Change in Accounting Policy
Significant Accounting Policies [Line Items]
Allowances for credit losses for other receivables				$ 10,200
Allowances for credit losses for loans receivable				$ 1,300
Minimum
Significant Accounting Policies [Line Items]
Estimated useful life of assets	3 years
Maximum
Significant Accounting Policies [Line Items]
Estimated useful life of assets	40 years
Patents \| Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives finite intangible assets	1 year
Patents \| Maximum
Significant Accounting Policies [Line Items]
Estimated useful lives finite intangible assets	20 years
Prepaid Expenses and Other Current Assets
Significant Accounting Policies [Line Items]
Allowances for credit losses for other receivables	$ 7,900
Other Long-Term Assets
Significant Accounting Policies [Line Items]
Allowances for credit losses for loans receivable	1,200
COVID-19
Significant Accounting Policies [Line Items]
Provisions for doubtful accounts	16,400
Shipping and Handling \| Sales and Marketing Expense
Significant Accounting Policies [Line Items]
Cost of sales	$ 32,100	$ 27,900	$ 28,400

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Exchange Rates of Key Currencies (Details)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Euro (EUR)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.2271	1.1234
Annual average rate	1.1411	1.1196	1.1813
Pound Sterling (GBP)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.3649	1.3204
Annual average rate	1.2836	1.2768	1.3356
Swiss Franc (CHF)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.1360	1.0350
Annual average rate	1.0659	1.0062	1.0228
Australian Dollar (AUD)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.7720	0.7023
Annual average rate	0.6905	0.6954	0.7478
Canadian Dollar (CAD)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.7849	0.7696
Annual average rate	0.7463	0.7535	0.7719
Japanese Yen (JPY)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.0097	0.0092
Annual average rate	0.0094	0.0092	0.0091
Chinese Yuan (CNY)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.1530	0.1437
Annual average rate	0.1450	0.1448	0.1514

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash at bank and on hand	$ 245,373	$ 189,569
Short-term bank deposits	352,611	434,078
Cash and cash equivalents	$ 597,984	$ 623,647

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Changes in the Allowance for Credit Losses on Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of year	$ 12,115	$ 9,270	$ 8,008
Additions charged to expense	16,439	8,701	4,448
Deductions from allowance	(9,868)	(5,777)	(2,827)
Currency translation adjustments and other	277	(79)	(359)
Balance at end of year	27,052	12,115	$ 9,270
Impact of Change in Accounting Policy
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of year	$ 8,089
Balance at end of year		$ 8,089

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Raw materials	$ 65,449	$ 26,077
Work in process	74,398	45,729
Finished goods	151,334	98,898
Total inventories, net	$ 291,181	$ 170,704

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended		36 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Contract assets	$ 8,539	$ 5,479	$ 8,539
Contract liabilities	68,900	56,200	68,900
Contract liabilities, current	57,066	48,525	57,066
Revenue recognized related to advance customer payments previously received	48,100	48,300
Accrued and Other Current Liabilities
Disaggregation of Revenue [Line Items]
Contract liabilities, current	57,100	48,500	57,100
Other Long-Term Liabilities
Disaggregation of Revenue [Line Items]
Contract liabilities, noncurrent	$ 11,800	$ 7,700	$ 11,800
Sales Revenue, Net \| Product Concentration Risk \| Consumable Products \| Minimum
Disaggregation of Revenue [Line Items]
Concentration risk			78.00%
Sales Revenue, Net \| Product Concentration Risk \| Consumable Products \| Maximum
Disaggregation of Revenue [Line Items]
Concentration risk			80.00%
Sales Revenue, Net \| Product Concentration Risk \| Related Revenue \| Minimum
Disaggregation of Revenue [Line Items]
Percentage of net sales			6.00%
Sales Revenue, Net \| Product Concentration Risk \| Related Revenue \| Maximum
Disaggregation of Revenue [Line Items]
Percentage of net sales			10.00%
Sales Revenue, Net \| Product Concentration Risk \| Instruments \| Minimum
Disaggregation of Revenue [Line Items]
Percentage of net sales			11.00%
Sales Revenue, Net \| Product Concentration Risk \| Instruments \| Maximum
Disaggregation of Revenue [Line Items]
Percentage of net sales			14.00%

Revenue - Performance Obligatio

Revenue - Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 $ in Millions	Dec. 31, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Remaining performance obligations	$ 23.7
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected recognition period	12 months
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected recognition period	18 months

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue based on Product Categories and Customer Class (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 1,870,346	$ 1,526,424	$ 1,501,848
Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenue	903,976	737,132	731,799
Molecular Diagnostics \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	774,234	665,866	649,602
Molecular Diagnostics \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	129,742	71,266	82,197
Life Sciences
Disaggregation of Revenue [Line Items]
Revenue	966,370	789,292	770,049
Life Sciences \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	841,201	688,281	665,857
Life Sciences \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	$ 125,169	$ 101,011	$ 104,192

Revenue - Disaggregation of R_2

Revenue - Disaggregation of Revenue Based on Product Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 1,870,346	$ 1,526,424	$ 1,501,848
Sample technologies
Disaggregation of Revenue [Line Items]
Revenue	803,867	548,365	546,636
Diagnostic solutions
Disaggregation of Revenue [Line Items]
Revenue	460,757	465,503	461,064
PCR / Nucleic acid amplification
Disaggregation of Revenue [Line Items]
Revenue	363,552	224,685	236,952
Genomics / NGS
Disaggregation of Revenue [Line Items]
Revenue	165,570	183,768	163,383
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 76,600	$ 104,103	$ 93,813

Acquisitions and Divestitures -

Acquisitions and Divestitures - Business Combinations, Narrative (Details) $ / shares in Units, $ in Thousands	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Jan. 31, 2019USD ($)	Apr. 30, 2018USD ($)	Sep. 30, 2019USD ($)business	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)business$ / shares	Dec. 31, 2018USD ($)
Business Acquisition [Line Items]
Carrying value of equity investments	$ 11,017						$ 11,017	$ 9,729
Cash consideration, net of cash acquired							$ 239,572	68,058	$ 172,832
Weighted average amortization period for intangible assets			10 years				10 years 10 months 9 days
Developed Technology
Business Acquisition [Line Items]
Weighted average amortization period for intangible assets							10 years 8 months 26 days
NeuMoDx
Business Acquisition [Line Items]
Carrying value of equity investments		$ 41,000	$ 41,000
NeuMoDx
Business Acquisition [Line Items]
Percentage of shares acquired		80.10%	80.10%
Percent of shares held prior to acquisition		19.90%	19.90%
Cash consideration, net of cash acquired			$ 239,400
Amount retained in escrow account	8,500						$ 8,500
Fair value of minority interest	52,727	$ 52,727	52,700
Gain on revaluation in connection with acquisition of remaining minority interest			11,700
Acquisition related costs		2,500	$ 2,500
Acquisition related costs expensed							1,800
Pro forma net sales							1,900,000	1,530,000
Pro forma net income (loss)							$ 347,000	$ (69,100)
Pro forma diluted net loss per common share (in USD per share) \| $ / shares							$ 1.48	$ (0.30)
Cash consideration paid	$ 251,730	$ 251,730
NeuMoDx \| Control Premium
Business Acquisition [Line Items]
Minority interest investment, measurement input		0.20	0.20
NeuMoDx \| Developed Technology
Business Acquisition [Line Items]
Expected completion term			3 years
N-of-One, Inc.
Business Acquisition [Line Items]
Cash consideration, net of cash acquired				$ 24,500
Additional Acquisitions
Business Acquisition [Line Items]
Cash consideration, net of cash acquired						$ 43,500
Number of companies acquired \| business						2		3
Other 2018 Acquisition
Business Acquisition [Line Items]
Gain on revaluation in connection with acquisition of remaining minority interest					$ 4,800

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Purchase Price Allocation
Goodwill	$ 2,364,031			$ 2,364,031	$ 2,364,031	$ 2,140,503	$ 2,108,536
Difference
Goodwill					3,382	$ (236)
NeuMoDx
Purchase Price Allocation
Cash consideration	251,730	$ 251,730
Fair value of minority interest	52,727	52,727	$ 52,700
Purchase price	304,457	304,457
Cash and cash equivalents	12,291	12,291	12,291	12,291	12,291
Accounts receivable	5,691	5,691	5,691	5,691	5,691
Inventories	20,666	18,866	18,866	20,666	20,666
Prepaid expenses and other current assets	5,961	5,943	5,943	5,961	5,961
Accounts payable	(12,450)	(11,168)	(11,168)	(12,450)	(12,450)
Accruals and other current liabilities	(18,929)	(18,770)	(18,770)	(18,929)	(18,929)
Other long-term liabilities	(4,101)	(4,101)	(4,101)	(4,101)	(4,101)
Fixed and other long-term assets	7,076	6,698	6,698	7,076	7,076
Goodwill	157,627	149,877	149,877	157,627	157,627
Deferred tax asset	12,457	0	0	12,457	12,457
Deferred tax liability on fair value of identifiable intangible assets acquired	(39,002)	(46,440)	(46,440)	(39,002)	(39,002)
Total	304,457	304,457	304,457	304,457	304,457
Difference
Cash consideration				0
Fair value of minority interest				0
Purchase price				0
Cash and cash equivalents				0
Accounts receivable				0
Inventories				1,800
Prepaid expenses and other current assets				18
Accounts payable				(1,282)
Accruals and other current liabilities				(159)
Other long-term liabilities				0
Fixed and other long-term assets				378
Goodwill				7,750
Deferred tax asset				12,457
Deferred tax liability on fair value of identifiable intangible assets acquired				7,438
Total				0
NeuMoDx \| Developed technology
Purchase Price Allocation
Intangible assets	101,000	119,100	119,100	101,000	101,000
Difference
Intangible assets				(18,100)
NeuMoDx \| In-process research and development
Purchase Price Allocation
Intangible assets	55,000	64,800	64,800	55,000	55,000
Difference
Intangible assets				(9,800)
NeuMoDx \| Patent and license rights
Purchase Price Allocation
Intangible assets	770	770	770	770	770
Difference
Intangible assets				0
NeuMoDx \| Customer backlog
Purchase Price Allocation
Intangible assets	$ 400	$ 900	$ 900	400	$ 400
Difference
Intangible assets				$ (500)

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Asset Acquisitions, Narrative (Details) - Formulatrix, Inc. - USD ($) $ in Millions	Jan. 31, 2019	Dec. 31, 2020
Asset Acquisition [Line Items]
Payments for digital PCR asset	$ 125
Milestone payments		$ 135.9

Acquisitions and Divestitures_4

Acquisitions and Divestitures - Divestitures, Narrative (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018EUR (€)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 1,845		$ 1,000	$ 16,394
Disposed of By Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Portfolio sale price			$ 1,000	18,500		€ 15.1
Proceeds from divestiture	$ 1,800	€ 1.7		16,400	€ 13.4
Gain on divestiture				$ 8,000

Restructuring and Impairments -

Restructuring and Impairments - Summary of Charges Recorded (Details) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Long-lived asset impairments
Property, plant and equipment	$ 1,034	$ 99,726	$ 7,890
Intangible assets	0	40,301
Other income, net
Personnel related (due to related parties)		2,956
Contract termination costs (due to related parties)		15,676
Accounts receivable (due from related parties)		5,984
Prepaid expenses and other assets (due from related parties)		2,270
2019 Restructuring
Restructuring, acquisition, integration and other, net
Personnel related	904	70,578		$ 71,482
Contract termination expense	682	42,099		42,781
Consulting fees	1,153	10,150		11,303
Accounts receivable	(622)	10,825		10,203
Inventories	1,014	12,336		13,350
Prepaid expenses and other assets	127	17,012		17,139
Restructuring, acquisition, integration and other, net	3,258	163,000		166,258
Long-lived asset impairments
Property, plant and equipment	1,034	98,472		99,506
Intangible assets	0	40,301		40,301
Long-lived asset impairments	1,034	138,773		139,807
Other income, net
Equity method investment impairment	0	4,799		4,799
Total	$ 4,292	$ 306,572		$ 310,864

Restructuring and Impairments_2

Restructuring and Impairments - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended				24 Months Ended	36 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring liability	$ 11,599	$ 62,227			$ 11,599	$ 62,227
Impairment in property, plant and equipment	1,034	99,726	$ 7,890
Intangible asset impairment charges	0	40,301
Restructuring costs incurred						24,400
2019 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring liability	11,166	60,232			11,166	60,232
Impairment in property, plant and equipment	1,034	98,472			99,506
Intangible asset impairment charges	0	40,301			40,301
Restructuring costs incurred	7,842	96,889
Restructuring, acquisition, integration and other, net	3,258	163,000			166,258
Cash payments for restructuring	51,702	37,728
Release of excess accrual	5,103
Equity method investment impairment	0	4,799			4,799
2019 Restructuring \| Minimum
Restructuring Cost and Reserve [Line Items]
Future pre-tax costs expected to be incurred	5,000				5,000
2019 Restructuring \| Maximum
Restructuring Cost and Reserve [Line Items]
Future pre-tax costs expected to be incurred	10,000				10,000
2019 Restructuring \| Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring liability	$ 11,200	60,200			$ 11,200	60,200
2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		(1,100)	11,666	$ 13,796		24,362
2017 Restructuring \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		(1,100)	10,049	10,757
2017 Restructuring \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net			1,617	3,039
2017 Restructuring \| Inventory Write-offs & Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		0	1,610	3,039		$ 4,649
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		$ 0	1,610	0
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net			$ 0	$ 3,039

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Cash Components of Restructuring Activity (Details) - USD ($) $ in Thousands	12 Months Ended		36 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2019
Restructuring Reserve [Roll Forward]
Beginning balance	$ 62,227
Costs incurred			$ 24,400
Ending balance	11,599	$ 62,227	62,227
2019 Restructuring
Restructuring Reserve [Roll Forward]
Beginning balance	60,232
Costs incurred	7,842	96,889
Release of excess accrual	(5,103)
Payments	(51,702)	(37,728)
Foreign currency translation adjustment	(103)	1,071
Ending balance	11,166	60,232	60,232
2019 Restructuring \| Personnel Related
Restructuring Reserve [Roll Forward]
Beginning balance	27,999
Costs incurred	4,542	44,640
Release of excess accrual	(3,638)
Payments	(24,355)	(17,272)
Foreign currency translation adjustment	139	631
Ending balance	4,687	27,999	27,999
2019 Restructuring \| Contract Termination
Restructuring Reserve [Roll Forward]
Beginning balance	24,298
Costs incurred	1,639	42,099
Release of excess accrual	(957)
Payments	(18,319)	(18,294)
Foreign currency translation adjustment	(230)	493
Ending balance	6,431	24,298	24,298
2019 Restructuring \| Consulting Fees
Restructuring Reserve [Roll Forward]
Beginning balance	7,935
Costs incurred	1,661	10,150
Release of excess accrual	(508)
Payments	(9,028)	(2,162)
Foreign currency translation adjustment	(12)	(53)
Ending balance	$ 48	$ 7,935	$ 7,935

Restructuring and Impairments_4

Restructuring and Impairments - Costs Related to the Restructuring Program (Details) - 2017 Restructuring - USD ($) $ in Thousands	12 Months Ended			36 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	$ (1,100)	$ 11,666	$ 13,796	$ 24,362
Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		1,617	3,039
Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100)	10,049	10,757
Personnel Related
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100)	4,631	6,174	9,705
Personnel Related \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		424	0
Personnel Related \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100)	4,207	6,174
Contract and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	5,425	4,583	10,008
Contract and Other Costs \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		1,193	0
Contract and Other Costs \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	4,232	4,583
Inventory Write-offs & Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	1,610	3,039	$ 4,649
Inventory Write-offs & Asset Impairments \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		0	3,039
Inventory Write-offs & Asset Impairments \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	$ 0	$ 1,610	$ 0

Short-Term Investments - Summar

Short-Term Investments - Summary of Short-Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of Investments [Line Items]
Short-term investments	$ 117,249	$ 129,586
Money market deposits
Schedule of Investments [Line Items]
Short-term investments	0	87,468
Commercial paper
Schedule of Investments [Line Items]
Short-term investments	0	22,459
Loans receivable
Schedule of Investments [Line Items]
Short-term investments	0	19,659
Marketable equity securities
Schedule of Investments [Line Items]
Short-term investments	$ 117,249	$ 0

Short-Term Investments - Narrat

Short-Term Investments - Narrative (Details) $ in Thousands, € in Millions	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)
Schedule of Investments [Line Items]
Short-term investments	$ 117,249	$ 129,586
USD Denominated
Schedule of Investments [Line Items]
Short-term investments		$ 65,000
EUR Denominated
Schedule of Investments [Line Items]
Short-term investments \| €			€ 57.5

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets [Abstract]
Prepaid expenses	$ 61,159	$ 39,930
Other receivables	32,901	29,486
Value added tax	31,128	20,347
Loan receivables	17,094	7,539
Contract assets	8,539	5,479
Cash collateral	56,100	2,683
Total prepaid expenses and other current assets	$ 206,921	$ 105,464

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment, Including Equipment Under Capital Lease Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,189,815	$ 1,154,373
Less: Accumulated depreciation and amortization	(630,443)	(699,130)
Property, plant and equipment, net	$ 559,372	455,243
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 18,903	17,684
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 362,902	341,032
Buildings and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Buildings and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 322,379	292,294
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Computer software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 260,730	301,604
Computer software \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer software \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 108,339	102,901
Furniture and office equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and office equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 116,562	$ 98,858

Property, Plant and Equipment_2

Property, Plant and Equipment - Asset Impairment Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	$ 1,034	$ 99,726	$ 7,890
Machinery and equipment
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	77	9,177	0
Computer software
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	0	44,649	2,911
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	315	4,030	0
Construction in progress
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	$ 642	$ 41,870	$ 4,979

Property, Plant and Equipment_3

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	$ 1,034	$ 99,726	$ 7,890
Long-lived asset impairments	1,432	144,830	17,020
Depreciation and amortization	78,600	86,000	87,900
Amortization expense related to computer software costs	7,400	18,300	17,200
Unamortized balance of computer software to be sold, leased or marketed	50,500	36,600		$ 50,500
Repairs and maintenance expense	13,800	10,700	12,100
Other Identified Impairment
Property, Plant and Equipment [Line Items]
Long-lived asset impairments		1,200
Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	0	44,649	2,911
Long-lived asset impairments			7,900
Computer Software to be Sold, Leased or Marketed
Property, Plant and Equipment [Line Items]
Long-lived asset impairments		65,900
Strategic Shifts \| Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments			6,300
2019 Restructuring
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	$ 1,034	$ 98,472		$ 99,506
2017 Restructuring \| Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments			$ 1,600

Investments - Narrative (Detail

Investments - Narrative (Details) $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Feb. 28, 2021USD ($)shares	Dec. 31, 2020USD ($)variableInterestEntityshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)
Schedule of Investments [Line Items]
Fair value		$ 117,500
Total realized gain (loss) during the period		(5,700)	$ (2,100)	$ (100)
Cumulative upward adjustments for price changes for non-marketable investments not accounted for under the equity method		700
Carrying value of equity investments		11,017	9,729
Non-marketable investments		4,142	70,849	59,484
Gain (loss) on sale of equity securities		2,250	0
Impairment		398	0
VIE
Schedule of Investments [Line Items]
Carrying value of equity investments		$ 3,000	1,200
Number of variable interest entities \| variableInterestEntity		3
Other Income, Net
Schedule of Investments [Line Items]
Equity method investment impairment			4,800	$ 6,100
Short-Term Investments
Schedule of Investments [Line Items]
Total realized gain (loss) during the period		$ (5,400)
Long-Term Investments
Schedule of Investments [Line Items]
Total realized gain (loss) during the period		(300)
Short-Term Investments
Schedule of Investments [Line Items]
Fair value		117,200
Other Long-Term Assets
Schedule of Investments [Line Items]
Fair value		300
Carrying value of equity investments		11,500
Other Long-Term Assets \| VIE
Schedule of Investments [Line Items]
Carrying value of equity investments		3,500	1,900
Other Long-Term Liabilities
Schedule of Investments [Line Items]
Carrying value of equity investments		(500)
Other Long-Term Liabilities \| VIE
Schedule of Investments [Line Items]
Carrying value of equity investments		$ 500	800
HTGM
Schedule of Investments [Line Items]
Reverse stock split conversion ratio		0.0667
Invitae
Schedule of Investments [Line Items]
Shares received in initial consideration (in shares) \| shares		2.4
Shares received in earn-out (in shares) \| shares		0.4
Shares receivable subject to milestone achievement (in shares) \| shares		1.7
Invitae \| Subsequent Event
Schedule of Investments [Line Items]
Shares sold (in shares) \| shares	2.4
Proceeds from sale of equity securities	$ 101,500
Invitae \| Short-Term Investments
Schedule of Investments [Line Items]
Fair value		$ 115,780
OncoCyte
Schedule of Investments [Line Items]
Fair value			$ 700
Shares received (in shares) \| shares		0.1	0.6
OncoCyte \| Short-Term Investments
Schedule of Investments [Line Items]
Fair value		$ 211
Oncimmune \| Short-Term Investments
Schedule of Investments [Line Items]
Fair value		1,258
Oncimmune \| Long-Term Investments
Schedule of Investments [Line Items]
Fair value			$ 285
TVM Life Science Ventures III
Schedule of Investments [Line Items]
Carrying value of equity investments		$ 1,545	$ 1,219
Ownership percentage		3.10%
ArcherDX
Schedule of Investments [Line Items]
Ownership percentage		8.00%
Proceeds from sale of non-marketable investments		$ 21,100
ArcherDX \| Other Income, Net
Schedule of Investments [Line Items]
Gain (loss) on sale of equity securities		123,300
Investment Sold in Period
Schedule of Investments [Line Items]
Non-marketable investments		2,500
Proceeds from sale of non-marketable investments		300
Investment Sold in Period \| Other Income, Net
Schedule of Investments [Line Items]
Gain (loss) on sale of equity securities		(2,300)
Investment Sold in Period
Schedule of Investments [Line Items]
Proceeds from sale of non-marketable investments		3,700
Investment Fully Impaired in Period \| Other Income, Net
Schedule of Investments [Line Items]
Impairment		$ 400

Investments - Summary of Invest

Investments - Summary of Investments in Marketable Equity Securities with Readily Determinable Fair Values (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt and Equity Securities, FV-NI [Line Items]
Fair value	$ 117,500
Invitae Corporation (Invitae) \| Short-Term
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	2,769,189
Cost basis	$ 0
Fair value	115,780
Total cumulative unrealized gain (loss)	$ 115,780
OncoCyte Corporation (OncoCyte)
Debt and Equity Securities, FV-NI [Line Items]
Fair value		$ 700
OncoCyte Corporation (OncoCyte) \| Short-Term
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	88,101
Cost basis	$ 0
Fair value	211
Total cumulative unrealized gain (loss)	$ 211
HTG Molecular Diagnostics, Inc (HTGM) \| Long-Term
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	55,556	833,333
Cost basis	$ 2,000	$ 2,000
Fair value	266	585
Total cumulative unrealized gain (loss)	$ (1,734)	$ (1,415)
Oncimmune Holdings plc (Oncimmune) \| Short-Term
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	560,416
Cost basis	$ 0
Fair value	1,258
Total cumulative unrealized gain (loss)	$ 1,258
Oncimmune Holdings plc (Oncimmune) \| Long-Term
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)		560,416
Cost basis		$ 0
Fair value		285
Total cumulative unrealized gain (loss)		$ 285

Investments - Summary of Equity

Investments - Summary of Equity Method Investments Included in Other Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of Investments [Line Items]
Equity investments	$ 11,017	$ 9,729
Share of income (loss) for the year	$ 5,018	2,083	$ 2,592
PreAnalytiX GmbH
Schedule of Investments [Line Items]
Ownership percentage	50.00%
Equity investments	$ 4,761	5,452
Share of income (loss) for the year	$ 3,070	3,971	4,062
Suzhou Fuda Business Management and Consulting Partnership
Schedule of Investments [Line Items]
Ownership percentage	33.67%
Equity investments	$ 3,301	3,100
Share of income (loss) for the year	$ 0	0	0
Apis Assay Technologies Ltd
Schedule of Investments [Line Items]
Ownership percentage	19.00%
Equity investments	$ 1,940	719
Share of income (loss) for the year	$ 1,221	(51)	0
TVM Life Science Ventures III
Schedule of Investments [Line Items]
Ownership percentage	3.10%
Equity investments	$ 1,545	1,219
Share of income (loss) for the year	$ 630	(330)	0
Hombrechtikon Systems Engineering AG
Schedule of Investments [Line Items]
Ownership percentage	19.00%
Equity investments	$ (530)	(761)
Share of income (loss) for the year	$ 97	(1,124)	(668)
MAQGEN Biotechnology Co., Ltd
Schedule of Investments [Line Items]
Ownership percentage	40.00%
Equity investments	$ 0	0
Share of income (loss) for the year	$ 0	(383)	(579)
Biotype Innovation GmbH
Schedule of Investments [Line Items]
Ownership percentage	0.00%
Equity investments	$ 0	0
Share of income (loss) for the year	$ 0	0	(123)
Pyrobett
Schedule of Investments [Line Items]
Ownership percentage	0.00%
Equity investments	$ 0	0
Share of income (loss) for the year	$ 0	$ 0	$ (100)

Investments - Changes in Non-Ma

Investments - Changes in Non-Marketable Investments Not Accounted for Under the Equity Method (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity Securities Without Readily Determinable Fair Value [Roll Forward]
Balance at beginning of year	$ 70,849	$ 59,484
Full acquisition of equity securities	(41,001)	0
Sale of equity securities	(23,812)	0
Loss on sale of equity securities	2,250	0
Impairments	(398)	0
Cash investments in equity securities, net	173	3,619
Net increases due to observable price changes	0	7,760
Foreign currency translation adjustments	581	(14)
Balance at end of year	$ 4,142	$ 70,849

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Intangible Assets by Major Asset Class (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years	10 years 10 months 9 days
Gross Carrying Amount		$ 1,473,400	$ 1,402,010
Accumulated Amortization		(809,724)	(776,520)
Goodwill		2,364,031	2,140,503	$ 2,108,536
Intangible assets		2,426,549	2,147,447
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 62,518	6,944
Patent and license rights
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)		10 years 6 months
Gross Carrying Amount		$ 298,395	320,406
Accumulated Amortization		$ (197,038)	(216,554)
Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)		10 years 8 months 26 days
Gross Carrying Amount		$ 860,129	766,966
Accumulated Amortization		$ (378,705)	(346,085)
Customer base, trademarks, and non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)		12 years 7 days
Gross Carrying Amount		$ 314,876	314,638
Accumulated Amortization		$ (233,981)	$ (213,881)

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	$ 171,450	$ 156,934	$ 40,990
Cash paid for purchases of intangible assets accrued in prior years	146,100
Intangible assets additions	24,007	286,159
Amortization of intangible assets	103,230	122,560	$ 118,600
Intangible asset impairment charges	0	40,301
Other Long-term Assets
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	1,400	500
Current Assets
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets		144,900
Accruals
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets		137,800
Prepayments
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets		3,500
Licenses
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	24,000	$ 11,500
Patent and License Rights
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	$ 28,100
Developed Technology
Finite-Lived Intangible Assets [Line Items]
Amortization period	10 years
Intangible asset impairment charges	$ 12,100

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Changes in Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Intangible Assets [Roll Forward]
Balance at beginning of year	$ 632,434	$ 475,043		$ 475,043
Additions	24,007	286,159
Additions from acquisitions	157,170	36,458
Amortization	(103,230)	(122,560)	$ (118,600)
Disposals	(537)	0
Impairments	0	(40,301)
Foreign currency translation adjustments	16,350	(2,365)
Balance at end of year	726,194	632,434	475,043	726,194
Goodwill [Roll Forward]
Balance at beginning of year	2,140,503	2,108,536		2,108,536
Business combinations	157,627	34,807
Purchase adjustments	3,382	(236)
Disposals	0	(225)
Foreign currency translation adjustments	62,519	(2,379)
Balance at end of year	$ 2,364,031	$ 2,140,503	$ 2,108,536	$ 2,364,031

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization of Intangibles for the Next Five Years (Details) $ in Thousands	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 103,485
2022	89,734
2023	87,355
2024	83,520
2025	$ 71,130

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Lease cost	$ 25	$ 24.4
Minimum
Lessee, Lease, Description [Line Items]
Lease terms	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease terms	15 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet and Other Information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	$ 23,450	$ 18,739
Weighted average remaining lease term - operating leases	7 years 14 days	3 years 8 months 15 days
Weighted average discount rate	1.89%	2.39%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:AccruedLiabilitiesCurrent	us-gaap:AccruedLiabilitiesCurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent	us-gaap:OtherLiabilitiesNoncurrent
Other long-term assets
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 102,522	$ 57,305
Accrued and other current liabilities
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	23,450	18,739
Other long-term liabilities
Lessee, Lease, Description [Line Items]
Long-term operating lease liabilities	$ 85,585	$ 39,631

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Cash paid for operating leases included in operating cash flows	$ 24,193	$ 26,113
Operating lease right-of-use assets obtained in exchange for lease obligations	$ 58,992	$ 24,670

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 25,353
2022	20,993
2023	16,280
2024	10,790
2025	6,707
Thereafter	36,878
Total lease payments	117,001
Less: imputed interest	(7,966)
Total	$ 109,035

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Payroll and related accruals	$ 99,085	$ 66,866
Other liabilities	67,244	54,241
Deferred revenue	57,066	48,525
Accrued expenses	51,026	38,963
Accrued contingent consideration and milestone payments	23,593	142,604
Operating lease liabilities	23,450	18,739
Restructuring	11,599	62,227
Accrued royalties	7,427	5,481
Accrued interest on long-term debt	4,575	5,257
Cash collateral	600	1,400
Total accrued and other current liabilities	$ 345,665	$ 444,303

Derivatives and Hedging - Narra

Derivatives and Hedging - Narrative (Details)	12 Months Ended
Derivatives and Hedging - Narrative (Details)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2015EUR (€)derivative
Derivative [Line Items]
Derivative gains (losses) included in accumulated other comprehensive income expected to be reclassified within twelve months	$ 3,600,000
Notes Receivable from Related Party \| Publicly Listed Company Considered a Related Party \| Convertible Note Receivable Purchased in 2017
Derivative [Line Items]
Loans to related parties			$ 3,000,000
Proceeds from the collection of notes receivable	3,200,000
German Private Placement (Schuldschein) \| Private Placement Bond
Derivative [Line Items]
Face amount of debt instrument			$ 331,100,000
German Private Placement (Schuldschein) \| Private Placement Bond \| Designated as Hedging Instrument
Derivative [Line Items]
Face amount of debt instrument \| €				€ 255,000,000
Unrealized gain (loss) recorded in equity	(26,900,000)	$ (400,000)
Accrued Liabilities
Derivative [Line Items]
Derivative liability fair value	(600,000)	(1,400,000)
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative asset fair value	56,100,000	2,700,000
Prepaid Expenses and Other Current Assets \| Notes Receivable from Related Party \| Publicly Listed Company Considered a Related Party
Derivative [Line Items]
Loans to related parties	17,100,000
Interest Rate Swap
Derivative [Line Items]
Number of derivative instruments \| derivative					5
Interest Rate Swap \| Derivative Contracts 2015
Derivative [Line Items]
Derivative asset notional amount \| €					€ 180,000,000
Interest Rate Swap \| Derivative Contracts 2015 \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Interest receivable	1,100,000	1,500,000
Interest Rate Swap \| Derivative Contracts 2014 \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Interest receivable		100,000
Interest Rate Swap \| Derivative Contracts 2014 \| Accrued and Other Current Liabilities
Derivative [Line Items]
Interest receivable	600,000
Foreign Exchange Contracts \| Undesignated Derivative Instruments
Derivative [Line Items]
Notional amount	$ 1,300,000,000	$ 701,400,000

Derivatives and Hedging - Summa

Derivatives and Hedging - Summary of Fair Value Amounts of Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative [Line Items]
Current Asset	$ 14,127	$ 107,868
Long-Term Asset	379,080	192,266
Current Liability	(51,464)	(103,175)
Long-Term Liability	(393,455)	(196,929)
Derivative instruments designated as hedges
Derivative [Line Items]
Current Asset	0	0
Long-Term Asset	5,042	2,474
Current Liability	0	0
Long-Term Liability	(17,409)	(6,027)
Derivative instruments designated as hedges \| Interest rate contracts \| Cash Flow Hedge
Derivative [Line Items]
Current Liability	0	0
Long-Term Liability	(17,409)	(6,027)
Derivative instruments designated as hedges \| Interest rate contracts \| Fair Value Hedge
Derivative [Line Items]
Current Asset	0	0
Long-Term Asset	5,042	2,474
Undesignated derivative instruments
Derivative [Line Items]
Current Asset	14,127	107,868
Long-Term Asset	374,038	189,792
Current Liability	(51,464)	(103,175)
Long-Term Liability	(376,046)	(190,902)
Undesignated derivative instruments \| Equity options
Derivative [Line Items]
Current Asset	2,415	101,179
Long-Term Asset	374,038	189,792
Current Liability	(5,966)	(101,361)
Long-Term Liability	(376,046)	(190,902)
Undesignated derivative instruments \| Foreign exchange forwards and options
Derivative [Line Items]
Current Asset	11,712	6,689
Long-Term Asset	0	0
Current Liability	(45,498)	(1,814)
Long-Term Liability	$ 0	$ 0

Derivatives and Hedging - Sum_2

Derivatives and Hedging - Summary of the Classification of Gains and Losses on Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded	$ 114,326	$ 432	$ 5,598
Gains (Losses) on Derivatives in Cash Flow Hedges
Amount of gain (loss) reclassified from accumulated other comprehensive loss	(13,999)	3,888	7,331
Other income, net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Total gains (losses)	7,604	471	(31,318)
Derivative instruments designated as hedges \| Other income, net
Gains (Losses) on Derivatives in Cash Flow Hedges
Amount of gain (loss) reclassified from accumulated other comprehensive loss	18,666	(3,888)	(9,774)
Amounts excluded from effectiveness testing	0	0	0
Derivative instruments designated as hedges \| Interest rate contracts \| Other income, net
Gains (Losses) on Derivatives in Fair Value Hedges
Hedged item	(2,568)	(3,668)	2,051
Derivatives designated as hedging instruments	2,568	3,668	(2,051)
Undesignated derivative instruments \| Embedded conversion option \| Other income, net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	0	(349)	131
Undesignated derivative instruments \| Equity options \| Other income, net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	322,580	(104,125)	74,682
Undesignated derivative instruments \| Cash convertible notes embedded cash conversion option \| Other income, net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	(321,213)	106,998	(76,500)
Undesignated derivative instruments \| Foreign exchange forwards and options \| Other income, net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	$ (12,429)	$ 1,835	$ (19,857)

Derivatives and Hedging - Sum_3

Derivatives and Hedging - Summary of the Balance Sheet Line Items in Which the Hedged Item is Included (Details) - Long-term debt - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative [Line Items]
Carrying Amount of the Hedged Assets (Liabilities)	$ (131,923)	$ (129,290)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities)	$ 5,042	$ 2,474

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 26,600
Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	23,593	$ 162,160
Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	23,593	162,160
Contingent Consideration \| Restructuring, acquisition, integration and other, net
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain included in earnings		7,400
Contingent Consideration \| Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Additions from acquisitions	3,223	132,422
Contingent Consideration \| Level 3 \| Recurring Basis \| Formulatrix, Inc.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Additions from acquisitions		132,400
Contingent Consideration \| Level 3 \| Restructuring, acquisition, integration and other, net \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain included in earnings	$ 0	$ 7,433
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Rate of achievement of milestones rate	0.00%
Discount rate used for analysis of future milestones	6.50%
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Rate of achievement of milestones rate	100.00%
Discount rate used for analysis of future milestones	6.90%

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Liabilities:
Contingent consideration	$ (26,600)
Recurring Basis
Assets:
Foreign exchange forwards and options	11,712	$ 6,689
Total assets	514,864	501,439
Liabilities:
Foreign exchange forwards and options	(45,498)	(1,814)
Contingent consideration	(23,593)	(162,160)
Total liabilities	(468,512)	(462,264)
Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	129,586
Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	117,515	870
Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	4,142	70,849
Recurring Basis \| Equity options
Assets:
Derivative assets	376,453	290,971
Liabilities:
Derivative liabilities	(382,012)	(292,263)
Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	5,042	2,474
Liabilities:
Derivative liabilities	(17,409)	(6,027)
Level 1 \| Recurring Basis
Assets:
Foreign exchange forwards and options	0	0
Total assets	117,515	870
Liabilities:
Foreign exchange forwards and options	0	0
Contingent consideration	0	0
Total liabilities	0	0
Level 1 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	0
Level 1 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	117,515	870
Level 1 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	0	0
Level 1 \| Recurring Basis \| Equity options
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	0	0
Level 1 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	0	0
Level 2 \| Recurring Basis
Assets:
Foreign exchange forwards and options	11,712	6,689
Total assets	393,207	429,720
Liabilities:
Foreign exchange forwards and options	(45,498)	(1,814)
Contingent consideration	0	0
Total liabilities	(444,919)	(300,104)
Level 2 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	129,586
Level 2 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	0	0
Level 2 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	0	0
Level 2 \| Recurring Basis \| Equity options
Assets:
Derivative assets	376,453	290,971
Liabilities:
Derivative liabilities	(382,012)	(292,263)
Level 2 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	5,042	2,474
Liabilities:
Derivative liabilities	(17,409)	(6,027)
Level 3 \| Recurring Basis
Assets:
Foreign exchange forwards and options	0	0
Total assets	4,142	70,849
Liabilities:
Foreign exchange forwards and options	0	0
Contingent consideration	(23,593)	(162,160)
Total liabilities	(23,593)	(162,160)
Level 3 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	0
Level 3 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	0	0
Level 3 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	4,142	70,849
Level 3 \| Recurring Basis \| Equity options
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	0	0
Level 3 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	$ 0	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Summary of Activity for Liabilities with Level 3 Inputs (Details) - Contingent consideration - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Level 3 \| Recurring Basis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ (162,160)	$ (48,971)
Additions from acquisitions	(3,223)	(132,422)
Payments	141,790	11,800
Balance	(23,593)	(162,160)
Restructuring, acquisition, integration and other, net
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain included in earnings		7,400
Restructuring, acquisition, integration and other, net \| Level 3 \| Recurring Basis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain included in earnings	$ 0	$ 7,433

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements - Carrying Values and Estimated Fair Values of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	$ 1,922,749	$ 1,706,352
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	1,678,131	1,296,334
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	699,704	663,528
Cash convertible notes \| Senior unsecured notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	791,000	1,046,511
Cash convertible notes \| Senior unsecured notes \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	1,167,201	1,296,334
Cash convertible notes \| Senior unsecured notes \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
Convertible notes \| Senior unsecured notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	442,481	0
Convertible notes \| Senior unsecured notes \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	510,930	0
Convertible notes \| Senior unsecured notes \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
U.S. Private placement \| Private placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	331,717	328,984
U.S. Private placement \| Private placement \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
U.S. Private placement \| Private placement \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	337,747	329,157
German private placement \| Private placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	357,551	330,857
German private placement \| Private placement \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
German private placement \| Private placement \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 361,957	$ 334,371

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Debt - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Deferred finance costs	$ 10,700	$ 10,700	$ 10,800
Interest expense on long-term debt		63,500	68,000	$ 61,200
Repayment of long-term debt		296,400	506,400	0
Long-term debt	1,922,749	1,922,749	1,706,352
Cash paid for the intrinsic value of the embedded cash conversion option		237,438	133,763	$ 0
Cash Convertible Notes \| 2021 Notes
Debt Instrument [Line Items]
Repayment of long-term debt			3,400
Cash paid for the intrinsic value of the embedded cash conversion option	237,400
Cash Convertible Notes \| 2019 Notes
Debt Instrument [Line Items]
Repayment of long-term debt			430,000
Senior Unsecured Notes \| 2021 Notes
Debt Instrument [Line Items]
Repayment of long-term debt		296,400
Long-term debt	$ 200	$ 200	285,244
Senior Unsecured Notes \| U.S Private Placement
Debt Instrument [Line Items]
Repayment of long-term debt			$ 73,000

Debt - Total Long-Term Debt, Ne

Debt - Total Long-Term Debt, Net of Debt Issuance Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 17, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total long-term debt	$ 1,922,749		$ 1,706,352
Less current portion	42,539		285,244
Long-term debt, net of current portion	1,880,210		1,421,108
Senior Unsecured Notes \| 0.875% Senior Unsecured Cash Convertible Notes due 2021
Debt Instrument [Line Items]
Total long-term debt	$ 200		285,244
Stated interest rate	0.875%
Senior Unsecured Notes \| 0.500% Senior Unsecured Cash Convertible Notes due 2023
Debt Instrument [Line Items]
Total long-term debt	$ 361,304		347,995
Stated interest rate	0.50%
Senior Unsecured Notes \| 1.000% Senior Unsecured Cash Convertible Notes due 2024
Debt Instrument [Line Items]
Total long-term debt	$ 429,496		413,272
Stated interest rate	1.00%
Senior Unsecured Notes \| 0.000% Senior Unsecured Convertible Notes due 2027
Debt Instrument [Line Items]
Total long-term debt	$ 442,481		0
Stated interest rate	0.00%	0.00%
Senior Unsecured Notes \| 3.75% Series B Senior Notes due October 16, 2022
Debt Instrument [Line Items]
Total long-term debt	$ 304,761		302,040
Stated interest rate	3.75%
Senior Unsecured Notes \| 3.90% Series C Senior Notes due October 16, 2024
Debt Instrument [Line Items]
Total long-term debt	$ 26,956		26,944
Stated interest rate	3.90%
Private Placement \| German Private Placement (Schuldschein)
Debt Instrument [Line Items]
Total long-term debt	$ 357,551		$ 330,857

Debt - Future Maturities of Lon

Debt - Future Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instruments [Abstract]
2021	$ 42,539
2022	485,795
2023	361,304
2024	572,870
2025	0
thereafter	460,241
Total long-term debt	$ 1,922,749	$ 1,706,352

Debt - Zero Coupon Convertible

Debt - Zero Coupon Convertible Notes due 2027 (Details) $ / shares in Units, equityInstrument in Millions, $ in Millions	Dec. 17, 2020USD ($)tradingDayequityInstrument$ / shares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Debt issuance costs accrued		$ 10.7	$ 10.8
0.000% Senior Unsecured Convertible Notes due 2027 \| Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate	0.00%	0.00%
Face amount of debt instrument	$ 500
Net proceeds from the issuance of convertible debt	497.6
Payments of debt issuance costs	3.7
Debt issuance costs accrued		$ 1.3
Liability component of convertible debt	445.9
Equity component of convertible debt	$ 54.1
Effective interest rate	1.65%
Issuance costs attributable to the liability component	$ 3.3
Issuance costs attributable to the equity component	$ 0.5
Conversion rate	0.01238825
Conversion price (in USD per share) \| $ / shares	$ 80.7218
Shares underlying conversion (in shares) \| equityInstrument	6.2
Threshold trading days \| tradingDay	20
Consecutive trading days \| tradingDay	30
Threshold percentage of stock price trigger	130.00%
Threshold days for parity event or trading price unavailability event	10 days
Threshold percentage of of average daily volume-weighted average trading price of common stock	25.00%

Debt - Cash Convertible Notes d

Debt - Cash Convertible Notes due 2019, 2021, 2023 and 2024 (Details)	Nov. 13, 2018USD ($)	Sep. 13, 2017USD ($)	Mar. 19, 2014USD ($)	Dec. 31, 2020USD ($)tradingDay	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Nov. 30, 2020USD ($)	Dec. 31, 2017	Dec. 31, 2014
Debt Instrument [Line Items]
Repayment of long-term debt				$ 296,400,000	$ 506,400,000	$ 0
Long-term debt				1,922,749,000	1,706,352,000
Proceeds from long-term debt, net of issuance costs				$ 497,646,000	0	$ 0
Cash Convertible Notes
Debt Instrument [Line Items]
Threshold trading days \| tradingDay				20
Consecutive trading days \| tradingDay				30
Threshold percentage of stock price trigger				130.00%
Redemption price percentage				100.00%
Percentage of principal amount outstanding				20.00%
2019, 2021, 2023 and 2024 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Consecutive trading days \| tradingDay				20
Threshold percentage of of average daily volume-weighted average trading price of common stock				25.00%
Cash settlement amount period				50 days
2019 and 2021 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Convertible debt			$ 730,000,000
Proceeds from issuance of debt			680,700,000
Consecutive trading days \| tradingDay				10
Threshold percentage of stock price trigger				98.00%
Threshold business period				5 days
Debt issuance cost			13,100,000
2019 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Convertible debt			$ 430,000,000
Repayment of long-term debt					430,000,000
Term of debt instrument			5 years
Effective interest rate									2.937%
2019 Notes \| Cash Convertible Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value			$ 51,200,000
2021 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Convertible debt			$ 300,000,000	$ 200,000
Repayment of long-term debt					3,400,000
Amount converted				177,000,000			$ 119,400,000
Term of debt instrument			7 years
Effective interest rate									3.809%
2021 Notes \| Cash Convertible Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value			$ 54,000,000
2021 Notes \| Senior Unsecured Notes
Debt Instrument [Line Items]
Repayment of long-term debt				296,400,000
Long-term debt				$ 200,000	285,244,000
2023 and 2024 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Threshold business period				10 days
2023 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Convertible debt		$ 400,000,000
Proceeds from long-term debt, net of issuance costs		$ 365,600,000
Term of debt instrument		6 years
Effective interest rate								3.997%
Debt issuance cost		$ 6,200,000
2023 Notes \| Cash Convertible Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value		$ 74,500,000
2023 Notes \| Senior Unsecured Notes
Debt Instrument [Line Items]
Long-term debt				$ 361,304,000	347,995,000
2024 Notes \| Cash Convertible Notes
Debt Instrument [Line Items]
Convertible debt	$ 500,000,000
Proceeds from issuance of debt	$ 468,900,000
Term of debt instrument	6 years
Effective interest rate						4.782%
Debt issuance cost	$ 5,700,000
2024 Notes \| Cash Convertible Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value	$ 98,500,000
2024 Notes \| Senior Unsecured Notes
Debt Instrument [Line Items]
Long-term debt				$ 429,496,000	$ 413,272,000

Debt - Interest Rate, Correspon

Debt - Interest Rate, Corresponding Maturities, and Contingent Conversion Periods of Cash Convertible Notes (Details) - Cash Convertible Notes	12 Months Ended
	Dec. 31, 2020
2021 Notes
Debt Instrument [Line Items]
Annual interest rate	0.875%
Conversion rate	0.0353158235
2023 Notes
Debt Instrument [Line Items]
Annual interest rate	0.50%
Conversion rate	0.0241486395
2024 Notes
Debt Instrument [Line Items]
Annual interest rate	1.00%
Conversion rate	0.021801549

Debt - Interest Expense Related

Debt - Interest Expense Related to the Cash Convertible Notes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 42,318	$ 40,763	$ 35,537
Cash Convertible Notes
Debt Instrument [Line Items]
Coupon interest	9,025	9,954
Amortization of original issuance discount	38,229	36,966
Amortization of debt issuance costs	2,942	3,014
Total interest expense	$ 50,196	$ 49,934

Debt - Cash Convertible Notes C

Debt - Cash Convertible Notes Call Spread Overlay (Details) - USD ($)	Nov. 13, 2018	Mar. 19, 2014	Dec. 31, 2020	Nov. 30, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2014	Nov. 30, 2020	Sep. 13, 2017
Debt Instrument [Line Items]
Payments for call options					$ 0	$ 0	$ 97,277,000
Proceeds from issuance of warrants, net of issuance costs					0	0	72,406,000
Cash received upon the exercise of call options					239,836,000	134,737,000	0
Cash paid for the intrinsic value of the embedded cash conversion option					237,438,000	133,763,000	$ 0
Cash Convertible Notes \| 2019 and 2021 Notes
Debt Instrument [Line Items]
Warrant issuance costs paid								$ 400,000
Convertible debt		$ 730,000,000
Cash Convertible Notes \| 2019 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs		40,600,000
Convertible debt		430,000,000
Cash Convertible Notes \| 2021 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs		28,300,000
Cash paid for the intrinsic value of the embedded cash conversion option			$ 237,400,000
Gain on exercise of call options and payment of embedded cash conversion option			239,800,000
Amount converted			177,000,000		177,000,000					$ 119,400,000
Convertible debt		$ 300,000,000	$ 200,000		200,000
Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs								45,300,000
Convertible debt											$ 400,000,000
Cash Convertible Notes \| 2024 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs	$ 72,400,000			$ 72,400,000
Warrant issuance costs paid				900,000
Convertible debt	$ 500,000,000
Call Spread Overlay
Debt Instrument [Line Items]
Proceeds from issuance of warrants									$ 69,400,000
Net cash outlay for call spread overlay				24,900,000				28,300,000	35,800,000
Call Spread Overlay \| Cash Convertible Notes \| 2019 and 2021 Notes
Debt Instrument [Line Items]
Payments for call options									$ 105,200,000
Call Spread Overlay \| Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Payments for call options								73,700,000
Call Options \| 2019 Notes
Debt Instrument [Line Items]
Cash received upon the exercise of call options						133,200,000
Cash paid for the intrinsic value of the embedded cash conversion option						132,700,000
Gain on exercise of call options and payment of embedded cash conversion option						500,000
Call Options \| 2021 Notes
Debt Instrument [Line Items]
Cash paid for the intrinsic value of the embedded cash conversion option						1,100,000
Gain on exercise of call options and payment of embedded cash conversion option					$ 2,400,000	400,000
Cash received for the intrinsic value of the embedded cash conversion option						$ 1,500,000
Call Options \| Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Payments for call options								$ 73,700,000
Call Options \| Cash Convertible Notes \| 2024 Notes
Debt Instrument [Line Items]
Payments for call options				$ 97,300,000

Debt - Private Placement and Ge

Debt - Private Placement and German Private Placement (Schuldschein) (Details)	1 Months Ended	12 Months Ended
	Oct. 31, 2012USD ($)series	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Number of series of notes issued \| series	3
Repayment of long-term debt		$ 296,400,000	$ 506,400,000	$ 0
Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		$ 699,704,000	663,528,000
Senior Unsecured Notes \| Series A, Series B and Series C Private Placement Notes
Debt Instrument [Line Items]
Face amount of debt instrument	$ 400,000,000
Weighted average interest rate of long-term debt	3.66%
Debt issuance cost	$ 2,100,000
Senior Unsecured Notes \| Series A Private Placement Notes
Debt Instrument [Line Items]
Face amount of debt instrument	$ 73,000,000
Term of debt instrument	7 years
Stated interest rate	3.19%
Repayment of long-term debt			73,000,000
Senior Unsecured Notes \| Series B Private Placement Notes
Debt Instrument [Line Items]
Stated interest rate		3.75%
Senior Unsecured Notes \| Series C Private Placement Notes
Debt Instrument [Line Items]
Stated interest rate		3.90%
Senior Notes \| Designated as Hedging Instrument
Debt Instrument [Line Items]
Face amount of debt instrument			127,000,000				$ 200,000,000
Senior Notes \| Series A, Series B and Series C Private Placement Notes \| Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		$ 337,700,000	329,200,000
Senior Notes \| Series A Private Placement Notes
Debt Instrument [Line Items]
Repayment of long-term debt			73,000,000
Senior Notes \| Series B Private Placement Notes
Debt Instrument [Line Items]
Face amount of debt instrument	$ 300,000,000
Term of debt instrument	10 years
Stated interest rate	3.75%
Senior Notes \| Series C Private Placement Notes
Debt Instrument [Line Items]
Face amount of debt instrument	$ 27,000,000
Term of debt instrument	12 years
Stated interest rate	3.90%
Private Placement Bond \| German Private Placement (Schuldschein)
Debt Instrument [Line Items]
Face amount of debt instrument					$ 331,100,000
Debt issuance cost					$ 1,200,000
Private Placement Bond \| German Private Placement (Schuldschein) \| Designated as Hedging Instrument
Debt Instrument [Line Items]
Face amount of debt instrument \| €						€ 255,000,000
Unrealized gain (loss) recorded in equity		(26,900,000)	(400,000)
Private Placement Bond \| German Private Placement (Schuldschein) \| Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		$ 361,957,000	$ 334,371,000

Debt - Summary of German Privat

Debt - Summary of German Private Placement Tranches (Details) - Designated as Hedging Instrument $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2020EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Carrying Value		$ 357,551	$ 330,857
March 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 11.5
Interest Rate		0.40%
Carrying Value		$ 14,115	12,905
March 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 23
Carrying Value		$ 28,224	25,811
March 2021 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.40%	0.40%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 21.5
Interest Rate		0.68%
Carrying Value		$ 26,361	24,112
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 64.5
Carrying Value		$ 79,083	72,335
October 2022 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.50%	0.50%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount		$ 45,000
Carrying Value		$ 44,948	44,919
October 2022 \| LIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	1.20%	1.20%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 25
Carrying Value		$ 30,642	28,026
October 2022 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.50%	0.50%
June 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 64
Interest Rate		1.09%
Carrying Value		$ 78,429	71,747
June 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 31
Carrying Value		$ 37,989	34,753
June 2024 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.70%	0.70%
June 2027
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 14.5
Interest Rate		1.61%
Carrying Value		$ 17,760	$ 16,249

Debt - Revolving Credit Facilit

Debt - Revolving Credit Facility (Details) - 12 months ended Dec. 31, 2020 $ in Millions	USD ($)lineOfCredit	EUR (€)	USD ($)
Debt Instrument [Line Items]
Credit facilities available and undrawn		€ 427,000,000	$ 524
Amounts utilized under credit facilities			0
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility
Debt Instrument [Line Items]
Credit facilities available and undrawn			$ 400
Commitment fee calculation basis on applicable margin, percent	35.00%
Commitment fee paid	$ 0.9
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility \| Interest Rate Period 1
Debt Instrument [Line Items]
Interest period length	1 month
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility \| Interest Rate Period 2
Debt Instrument [Line Items]
Interest period length	3 months
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility \| Interest Rate Period 3
Debt Instrument [Line Items]
Interest period length	6 months
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility \| EURIBOR \| Minimum
Debt Instrument [Line Items]
Interest rate	0.525%
Revolving Credit Facility \| ESG-Linked Revolving Credit Facility \| EURIBOR \| Maximum
Debt Instrument [Line Items]
Interest rate	1.525%
Line of Credit
Debt Instrument [Line Items]
Credit facilities available and undrawn \| €		€ 27,000,000
Number of lines of credit \| lineOfCredit	3

Income Taxes - Income Before In

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Pretax (loss) income in The Netherlands	$ (16,640)	$ 17,455	$ (1,675)
Pretax income (loss) from foreign operations	456,112	(95,231)	227,412
Income (loss) before income tax (benefit) expense	$ 439,472	$ (77,776)	$ 225,737

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Current—The Netherlands	$ 270	$ 5,670	$ 5,794
—Foreign	86,720	13,371	52,835
Provision for income tax current, total	86,990	19,041	58,629
Deferred—The Netherlands	(6,921)	4,177	2,551
—Foreign	215	(59,539)	(25,823)
Provision for income tax deferred, total	(6,706)	(55,362)	(23,272)
Total income tax expense (benefit)	$ 80,284	$ (36,321)	$ 35,357

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
The Netherlands statutory income tax rate	25.00%	25.00%	25.00%
Unrecognized tax benefit, net	$ 100,100	$ 58,000
Unrecognized tax benefits which may be realized	38,000
Recognized interest (income) expense	1,900	1,600	$ 1,100
Accrued interest included in accrued and other liabilities	4,400	2,500
Deferred tax assets	15,663	33,100
Deferred tax liabilities		33,100
Total foreign net operating losses	686,300
Disallowed interest carryforwards	158,800
Tax credits	3,000
Deferred tax asset valuation allowance	37,332	87,619
Changes in the valuation allowance charged to income tax expense	36,800	19,000	$ 800
Changes in the valuation allowance charged to additional paid-in capital	13,500
Earnings retained by subsidiaries and equity accounted investments	538,300
Undistributed earnings not permanently reinvested	28,100
Deferred tax liabilities on unremitted earnings of certain subsidiary	1,600	$ 1,500
Interest Carryforward
Operating Loss Carryforwards [Line Items]
Changes in the valuation allowance charged to income tax expense	(35,600)
Germany
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	318,600
U.S.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	176,400
Netherlands
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	68,500
Spain
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	49,800
Other Foreign Tax Authorities
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	73,000
Operating loss carryforwards not set to expire	$ 25,300

Income Taxes - Difference Betwe

Income Taxes - Difference Between Income Taxes Computed at Statutory Rate and Reported Income Taxes and Effective Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Percent
Income taxes at The Netherlands statutory rate	25.00%	25.00%	25.00%
Unrecognized tax benefits	8.20%	(14.10%)	6.00%
Valuation allowance	(8.10%)	(26.90%)	1.50%
Taxation of foreign operations, net	(2.10%)	33.10%	(15.10%)
Prior year taxes	(1.60%)	(1.40%)	0.20%
Tax impact from intangible property transfer	(0.80%)	27.20%	0.00%
Tax impact from (deductible) nondeductible items	(0.80%)	(10.30%)	1.30%
Excess tax benefit related to share-based compensation	(0.60%)	5.10%	(2.10%)
Government incentives and other deductions	(0.60%)	9.70%	(1.20%)
Changes in tax laws and rates	(0.30%)	(0.40%)	0.80%
Other items, net	0.00%	(0.30%)	(0.70%)
Effective tax rate	18.30%	46.70%	15.70%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 36.8	$ 19	$ 0.8
Interest Carryforward
Percent
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(35.6)
Thermo Fischer Sceintific \| QIAGEN N.V.
Percent
Payments for expense reimbursement	$ 95

Income Taxes - Changes in Amoun

Income Taxes - Changes in Amounts of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 58,002	$ 55,780	$ 44,033
Additions based on tax positions related to the current year	31,758	5,770	3,359
Additions for tax positions of prior years	3,560	14,532	11,984
Decrease for tax position of prior years	(57)	(9,073)	0
Decrease related to settlements	0	(7,605)	0
Decrease due to lapse of statute of limitations	(520)	(409)	(1,238)
Increase (decrease) from currency translation	7,349	(993)	(2,358)
Balance at end of year	$ 100,092	$ 58,002	$ 55,780

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Asset
Net operating loss and tax credit carryforward	$ 67,856	$ 50,274
Accrued and other liabilities	22,926	17,977
Inventories	3,872	4,726
Unrealized gain (loss) on investments	0	0
Property, plant and equipment	6,099	5,297
Intangible assets	2,817	1,078
Share-based compensation	18,377	13,787
Disallowed interest carryforwards	42,090	73,690
Convertible notes	6,512	7,104
Other	9,428	5,998
Deferred tax assets, gross	179,977	179,931
Valuation allowance	(37,332)	(87,619)
Deferred tax assets, total	142,645	92,312
Deferred Tax Liability
Net operating loss and tax credit carryforward	0	0
Accrued and other liabilities	0	0
Inventories	(2,269)	(1,439)
Unrealized gain (loss) on investments	(25,779)	(4,973)
Property, plant and equipment	(23,376)	(20,332)
Intangible assets	(55,999)	(26,294)
Share-based compensation	0	0
Disallowed interest carryforwards	0	0
Convertible notes	(13,513)	0
Other	(6,046)	(6,174)
Deferred tax liabilities, total	(126,982)	(59,212)
Net deferred tax assets	$ 15,663	$ 33,100

Equity - Shares (Details)

Equity - Shares (Details) - € / shares	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Common shares, shares authorized (in shares)	410,000,000	410,000,000
Preference shares, shares authorized (in shares)	450,000,000	450,000,000
Financing preference shares, shares authorized (in shares)	40,000,000	40,000,000
Common shares, par value (in EUR per share)	€ 0.01	€ 0.01
Preference shares, par value (in EUR per share)	0.01	0.01
Financing preference shares, par value (in EUR per share)	€ 0.01	€ 0.01
Financing preference shares, shares issued (in shares)	0	0
Preference shares, shares issued (in shares)	0	0

Equity - Issuance and Conversio

Equity - Issuance and Conversion of Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Nov. 13, 2018	Mar. 19, 2014	Nov. 30, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 13, 2017
Class of Stock [Line Items]
Number of share warrants (in shares)				4.2	15.2
Proceeds from issuance of warrants, net of issuance costs				$ 0	$ 0	$ 72,406
2019 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)		15.2
Exercise price per share (in USD per share)		$ 32.0560
Proceeds from issuance of warrants, net of issuance costs		$ 40,600
2021 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)		10.6
Exercise price per share (in USD per share)		$ 32.0560
Proceeds from issuance of warrants, net of issuance costs		$ 28,300
2023 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)								9.7
Exercise price per share (in USD per share)								$ 50.9664
Proceeds from issuance of warrants, net of issuance costs							$ 45,300
2024 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)	10.9
Exercise price per share (in USD per share)	$ 52.1639
Proceeds from issuance of warrants, net of issuance costs	$ 72,400		$ 72,400

Equity - Issuance and Convers_2

Equity - Issuance and Conversion of Warrants, Narrative (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 19, 2014
Class of Warrant or Right [Line Items]
Common shares issued in connection with the conversion of warrants (in shares)	800	2,100
Number of warrants converted (in shares)	4,200	15,200
Impact due to conversion of warrants	$ 0	$ (4)
Warrants terminated (in shares)	6,300
Payment for termination of warrants	$ 174,627	0	$ 0
Termination of warrants	174,626
Cash payment for fractional shares		4
Treasury Shares
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	$ 30,272	$ 68,761
Conversion of warrants (in shares)	807	2,056
Additional Paid-In Capital
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	$ (7,547)	$ (31,067)
Termination of warrants	30,289
Retained Earnings
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	(22,725)	$ (37,698)
Termination of warrants	$ 144,337
2019 Notes \| Cash Convertible Notes
Class of Warrant or Right [Line Items]
Number of warrants converted (in shares)				15,200

Equity - Share Repurchase Progr

Equity - Share Repurchase Program (Details) - USD ($) shares in Thousands	12 Months Ended			23 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	May 06, 2019	Jan. 31, 2018
Equity, Class of Treasury Stock [Line Items]
Treasury shares repurchased (in shares)	1,300
Treasury shares repurchased	$ 63,995,000	$ 74,450,000	$ 104,685,000
Treasury Shares
Equity, Class of Treasury Stock [Line Items]
Treasury shares repurchased (in shares)	1,346	1,987	2,871
Treasury shares repurchased	$ 63,995,000	$ 74,450,000	$ 104,685,000
Sixth Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Amount authorized to repurchase shares					$ 100,000,000
Fifth Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Amount authorized to repurchase shares						$ 200,000,000
Treasury shares repurchased (in shares)		2,000	2,900	4,900
Treasury shares repurchased		$ 74,500,000	$ 104,700,000	$ 179,100,000

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	$ 2,797,839	$ 2,536,591	$ 2,634,970	$ 2,540,996
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(243,822)	(309,619)	$ (310,644)	$ (220,759)
Net unrealized loss on hedging contracts, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(25,717)	(22,587)
Foreign currency effects from intercompany long-term investment transactions, tax	10,700	9,700
Net unrealized loss on pension, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(23,268)	(2,289)
Foreign currency effects from intercompany long-term investment transactions, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(599)	(561)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	$ (194,238)	$ (284,182)

Earnings per Common Share - (De

Earnings per Common Share - (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	$ 359,188	$ (41,455)	$ 190,380
Weighted average number of common shares used to compute basic net income per common share (in shares)	228,427	226,777	226,640
Dilutive effect of stock options and restrictive stock units (in shares)	3,350	0	4,613
Dilutive effect of outstanding warrant (in shares)	2,437	0	2,203
Weighted average number of common shares used to compute diluted net income per common share (in shares)	234,214	226,777	233,456
Basic earnings per common share attributable to the owners of QIAGEN N.V. (in USD per share)	$ 1.57	$ (0.18)	$ 0.84
Diluted earnings per common share attributable to the owners of QIAGEN N.V. (in USD per share)	$ 1.53	$ (0.18)	$ 0.82
Stock Options and Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding securities having no dilutive effect, not included in above calculation (in shares)	11	107	272
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding securities having no dilutive effect, not included in above calculation (in shares)	26,438	32,938	35,939

Earnings per Common Share - Nar

Earnings per Common Share - Narrative (Details) shares in Millions	12 Months Ended
	Dec. 31, 2019shares
Stock Options and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from the computation of diluted net loss (in shares)	3.9
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from the computation of diluted net loss (in shares)	1.7

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Percentage of royalty on net product sales range, minimum	0.45%
Percentage of royalty on net product sales range, maximum	25.00%
Accrued royalties	$ 7,427	$ 5,481
Royalty expense related to agreements	12,200	13,500	$ 14,000
Potential contingent consideration commitments	26,550
Contingent obligation	26,600
Commitment under employment contract agreements	21,200
Litigation
Loss Contingencies [Line Items]
Legal settlements accrued	5,200	800
Payment of legal settlement	300
Recurring Basis
Loss Contingencies [Line Items]
Contingent obligation	23,593	162,160
Recurring Basis \| Level 3
Loss Contingencies [Line Items]
Contingent obligation	23,593	$ 162,160
Minimum \| Litigation
Loss Contingencies [Line Items]
Estimated possible litigation loss	4,700
Maximum \| Litigation
Loss Contingencies [Line Items]
Estimated possible litigation loss	16,300
Purchase Obligations \| Companies in Which the Company Holds an Interest
Loss Contingencies [Line Items]
Purchase commitments with companies considered related parties	$ 28,400

Commitments and Contingencies_2

Commitments and Contingencies - Commitments to Purchase Goods or Services and for Future License and Royalty Payments (Details) $ in Thousands	Dec. 31, 2020USD ($)
Purchase Commitments
2021	$ 199,843
2022	42,628
2023	5,364
2024	3,000
2025	0
Thereafter	0
Total	250,835
License & Royalty Commitments
2021	10,003
2022	7,217
2023	4,483
2024	2,623
2025	2,349
Thereafter	3,364
Total	$ 30,039

Commitments and Contingencies_3

Commitments and Contingencies - Contingent Consideration Commitments (Details) $ in Thousands	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 8,850
2022	17,700
Total potential contingent consideration commitments	$ 26,550

Commitments and Contingencies_4

Commitments and Contingencies - Changes in the Carrying Amount of Warranty Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Changes in the Carrying Amount of Warranty Obligations
Balance at beginning of year	$ 3,141	$ 2,848
Provision charged to cost of sales	5,645	3,229
Usage	(3,978)	(2,921)
Adjustments to previously provided warranties, net	(125)	(1)
Currency translation	130	(14)
Balance at end of year	$ 4,813	$ 3,141

Segment Information - Narrative

Segment Information - Narrative (Details) $ in Thousands	12 Months Ended
Segment Information - Narrative (Details) $ in Thousands	Dec. 31, 2020USD ($)segmentcustomer	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments \| segment	1
Number of business segments \| segment	1
Number of customers representing more than ten percent of net sales \| customer	0
Net sales	$ 1,870,346	$ 1,526,424	$ 1,501,848
Long-lived assets	559,372	455,243
Netherlands
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	17,800	15,800	$ 15,900
Long-lived assets	$ 1,500	$ 1,300

Segment Information - Net Sales

Segment Information - Net Sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 1,870,346	$ 1,526,424	$ 1,501,848
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	825,457	721,990	693,019
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	728,577	663,869	632,660
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	96,880	58,121	60,359
Total Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	682,289	487,476	490,301
Asia Pacific, Japan and Rest of World
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 362,600	$ 316,958	$ 318,528

Segment Information - Long-Live

Segment Information - Long-Lived Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 559,372	$ 455,243
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	157,279	150,534
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	154,843	147,027
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	2,436	3,507
Total Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	376,015	278,229
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	304,571	229,225
Other Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	71,444	49,004
Asia Pacific, Japan and Rest of World
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 26,078	$ 26,480

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit for the tax deductions from option exercises	$ 1,300	$ 500	$ 800
Share-based compensation expense	40,936	65,893	40,113
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised	$ 6,500	$ 2,000	$ 5,000
Options excercisable (in shares)	427	800	900
Weighted average exercise price of exercisable options (in USD per share)	$ 19.28	$ 20.06	$ 20.04
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-vesting forfeitures percentage	6.20%
Unrecognized share-based compensation expense related to employee stock option awards	$ 73,100
Unrecognized share-based compensation expense recognized weighted average period, years	2 years 3 months
Weighted-average grant date fair value of restricted stock units granted (in USD per share)	$ 36.92	$ 37.28	$ 35.37
Total fair value of restricted stock units	$ 29,300	$ 123,900	$ 54,300
Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum vesting period	5 years
Restricted Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum vesting period	10 years
The 2005 and 2014 Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved and available for issuance under the plan (in shares)	14,400

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Status of Employee Stock Options (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Outstanding (in shares)	792
Exercised (in shares)	(365)
Outstanding (in shares)	427
Vested (in shares)	427	800	900
Vested and expected to vest (in shares)	427
Weighted Average Exercise Price
Outstanding (in USD per share)	$ 20.06
Exercised (in USD per share)	20.97
Outstanding (in USD per share)	19.28
Vested (in USD per share)	19.28	$ 20.06	$ 20.04
Vested and expected to vest (in USD per share)	$ 19.28
Weighted Average Contractual Term
Outstanding	1 year 3 months
Vested	1 year 3 months
Vested and expected to vest	1 year 3 months
Aggregate Intrinsic Value
Outstanding	$ 14,338
Vested	14,338
Vested and expected to vest	$ 14,338

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options (Details) - Restricted Stock shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)shares
Stock Units
Outstanding (in shares)	5,183
Granted (in shares)	1,035
Vested (in shares)	(720)
Forfeited (in shares)	(365)
Outstanding (in shares)	5,133
Vested and expected to vest (in shares)	3,881
Weighted Average Contractual Term
Outstanding	2 years 3 months
Vested and expected to vest	2 years 7 days
Aggregate Intrinsic Value
Outstanding \| $	$ 261,458
Vested and expected to vest \| $	$ 205,097

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 40,936	$ 65,893	$ 40,113
Less: income tax benefit	9,552	12,153	8,277
Net share-based compensation expense	31,384	53,740	31,836
Excess tax benefit realized for the tax deductions of share-based arrangements	2,500	4,000	4,700
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2,897	2,493	2,879
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	7,014	5,810	6,457
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	15,889	7,947	9,372
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	15,136	23,705	21,405
Restructuring, acquisition, integration and other, net
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 0	$ 25,938	$ 0

Employee Benefits (Details)

Employee Benefits (Details) $ in Millions	12 Months Ended
Employee Benefits (Details) $ in Millions	Dec. 31, 2020USD ($)plan	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Retirement Benefits, Description [Abstract]
Total expense under employee benefit plans	$ 3.6	$ 4	$ 4
Company matching contributions	$ 0.2	0.2	$ 0.2
Number of defined benefit plans \| plan	5
Liability under the defined benefit plans	$ 9.3	$ 8.2

Related Party Transactions - Su

Related Party Transactions - Summary of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Net sales	$ 6,025	$ 20,002	$ 23,358
Accounts receivable	3,961	7,589
Prepaid expenses and other current assets	25,429	13,697
Other long-term assets	9,594	16,830
Accounts payable	4,050	1,775
Accrued and other current liabilities	$ 1,380	$ 15,404

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - Affiliated Entity - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Notes Receivable from Related Party \| Prepaid Expenses and Other Current Assets
Related Party Transaction [Line Items]
Loans to related parties	$ 17.1
Notes Receivable from Related Party \| Other Long-Term Assets
Related Party Transaction [Line Items]
Loans to related parties	$ 9	$ 16.3
Notes Receivable from Related Party \| 8.0% Note Receivable Purchased in 2018
Related Party Transaction [Line Items]
Loans to related parties			$ 15
Interest rate on loans to related parties	8.00%
Notes Receivable from Related Party \| 8.0% Note Receivable Purchased in 2020
Related Party Transaction [Line Items]
Loans to related parties	$ 10
Interest rate on loans to related parties			8.00%
Purchase Commitment Agreement
Related Party Transaction [Line Items]
Purchase commitments due to related parties		$ 12.8

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2020	Jan. 01, 2019	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Equity	$ 2,797,839	$ 2,536,591	$ 2,634,970			$ 2,540,996
Other Long-Term Assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Allowances for credit losses for loans receivable	1,200
Retained Earnings
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Equity	1,323,091	1,178,457	1,379,624			$ 1,247,945
Impact of Change in Accounting Policy
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Equity		(15,074)	(316)
Allowances for credit losses for loans receivable				$ 1,300
Impact of Change in Accounting Policy \| Retained Earnings
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Equity		(15,074)	(316)	15,100	$ (300)
Impact of Change in Accounting Policy, Pre-Tax \| Retained Earnings
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Equity				$ 19,600
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	12,115	9,270	8,008
Charged to Costs and Expense	17,764	8,701	4,448
Deductions	(13,784)	(5,777)	(2,827)
Foreign Exchange and Other	20,089	(79)	(359)
Balance at End of Period	$ 36,184	$ 12,115	$ 9,270